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ABSTRACT 
CTCF is an evolutionary conserved and ubiquitously expressed protein which regulates a 
plethora of cellular functions using different molecular mechanisms. However, the role of 
poly(ADP-ribosyl)ation (PARylation) of CTCF, in particular, two differentially PARylated 
forms of CTCF (termed CTCF130 and CTCF180) in the regulation of cellular processes is not 
well understood. We hypothesize that differentially PARylated isoforms of CTCF control 
different groups of genes (Hypothesis 1) and different functions (Hypothesis 2) in different 
biological situations. To investigate Hypothesis 1, the 226LDM cells, proliferating (expressing 
CTCF130 and CTCF180) and arrested (expressing CTCF180) will be used. The high-throughput 
ChIP-Seq and RNA-Seq assays will be used to obtain and link the CTCF binding and gene 
expression profiles. This study revealed that out of 2051 CTCF binding sites in proliferating 
226LDM cells identified using the polyclonal CTCF antibody (which recognizes both isoforms, 
CTCF130 and CTCF180), 1009 were associated with differentially expressed transcripts. Among 
those, 520 were up-regulated while the remaining 489 were down-regulated. From 64 binding 
sites identified in the arrested cells (CTCF180 only), 26 were associated with genes that were 
differentially expressed; 16 were up-regulated and 10 were down-regulated. There were 8 
common CTCF binding sites between control and treated cells in the up-regulated and 6 in the 
down-regulated group. Overall, binding of CTCF130 and CTCF180 was associated with 
differential gene expression thus confirming Hypothesis 1. To test Hypothesis 2, the role of 
CTCF PARylation in the DNA damage response mechanism was investigated. Following DNA 
damage, translocation of CTCF into the nucleolus and co-localization with PARP1 was 
observed. Ectopic expression of a mutant CTCF deficient for PARylation resulted in nucleolar 
disorganisation and was associated with faster recovery from damage. It also suggests that CTCF 
PARylation is implicated in DNA damage response as well as for nucleolar stability after DNA 
damage thus supporting Hypothesis 2.  
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 Introduction Chapter 1
 CTCF: The CCCTC-binding factor   1.1
The CCCTC-binding factor (CTCF) is a multifunctional and ubiquitously expressed 
protein, which remained highly evolutionarily conserved from Drosophila to man (Ohlsson et 
al., 2001, Phillips and Corces, 2009). 
It was originally identified by Lobanenkov et al. (1990) as a DNA binding protein, 
regulating the expression of the chicken c-myc oncogene. The protein had a binding site 
upstream of the start of the transcription site of c-myc to one of the CCCTC core sequences, 
which gave the protein its name. Since its discovery, studies on CTCF revealed that this protein 
is not only involved in transcriptional control, but that it is a key  regulator of many other cellular 
functions (Holwerda and de Laat, 2013, Ohlsson et al., 2001, Ohlsson et al., 2010, Millau and 
Gaudreau, 2011). 
   CTCF, the gene and the protein 1.2
 The CTCF gene 1.2.1
 The gene encoding CTCF is positioned, in humans, on chromosome 16, on locus 16q22.1 
(Filippova et al., 1998). This genomic locus has been indicated as a hot-spot region for loss of 
chromosomal material linked with cancer, including breast and prostate cancers (Filippova et al., 
1998, Green et al., 2009, Yeh et al., 2002). The intron-exon organization of the chicken CTCF 
gene was determined by Klenova et al. (1998) while that of the human gene was reported later 
(Filippova et al., 2002). These studies showed that there are seven exons in the chicken gene and 
ten in human. The CTCF gene structures were refined in a more recent publication reporting 10 
exons in human, chicken, mouse, zebrafish and frog CTCF, seven of them encode the zinc 
fingers (ZF) which constitute the proteins DNA binding domain (Hore et al., 2008).  
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Figure 1-1 Intron-exon structure of the human CTCF gene and comparison with other 
species 
Top: The structure of the CTCF gene. Bottom: CTCF orthologues from human, mouse, cattle, 
opossum, chicken, green anole and zebrafish. All vertebrate CTCF orthologues possess ten exons 
(adapted from Hore et al. (2008)). 
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 The CTCF protein 1.2.2
Human CTCF is composed of 727 amino acids and structurally highly conserved among 
species (Filippova et al., 1996). The protein can be divided into three main domains; the DNA 
binding domain (DBD) which is comprised of 11 zinc fingers (ZF) (311 amino acids) and the C- 
and N-termini regions flanking the DBD (150 and 250 amino acids respectively) (figure 1-2) 
(Filippova et al., 1996).   
The zinc finger is a versatile supersecondary protein structure, very commonly found in 
eukaryotes mediating the interaction between the protein and a DNA or RNA sequence 
(Matthews and Sunde, 2005). There are different classes of zinc fingers that have different roles 
and can co-exist within a protein. CTCF is such an example protein with 11 zinc fingers out of 
which, 10 belong to the most studied C2H2 class and one in the C2HC class (Klenova et al, 
1993). The CTCF zinc fingers can be employed in different combinations in order for the protein 
to interact with a wide variety of DNA sequences and protein partners; each of the ZFs can be 
important for one interaction and completely unnecessary for another. This feature is indicative 
of the proteins high versatility and it is why it is known as a “multivalent factor” (Filippova et al, 
1996).  
The main ZF domain is flanked by the N- and C-terminus regions, both of which do not 
appear to be implicated in the binding process, however they reportedly can affect the results of 
the interaction (Filippova et al, 1996).  
There are three additional, less significant although not without function, binding motifs 
within the C-terminal region of CTCF. The first is a KRRGRP-type AT-hook that possibly has a 
role in DNA binding and protein-protein interactions in chromatin (Ohlsson et al., 2001, Aravind 
and Landsman, 1998). The second one is a conserved SKKEDSSDSE motif. The third is located 
between the other two and it is an HS3-domain (Ohlsson et al., 2001).  
The molecular weight of CTCF was determined as 82 kDa (Klenova et al., 1993), 
however it migrates at 130 kDa on SDS-PAGE. This abnormality was studied by Klenova et al. 
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(1997) who concluded that this was the results of aberrant mobility on the SDS-PAGE due to 
properties of the C- and N-termini regions. 
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(a) 
Figure 1-2 Schematic representation of the CTCF protein structure 
The main zinc finger domain is flanked by a N-terminus and a C-terminus domain. The zinc 
fingers are employed in different combinations in order to interact with DNA or a target protein 
to take place. Apart from the ZF domain another binding domain located in the C-terminus 
region is the SH3 motif. (Adapted from Ohlsson et al. (2001)). 
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 Biological Functions of CTCF 1.3
Since the discovery of CTCF as a transcriptional repressor, a great variety of functions 
has been attributed to the protein including a role in cell cycle progression and proliferation, 
genomic imprinting, insulation function and chromatin architecture (Holwerda and de Laat, 
2013, Ong and Corces, 2014, Ohlsson et al., 2001).  
The list of very important processes in which the protein is involved in is mainly a result 
of its capacity to engage in multiple protein-protein and DNA-protein interactions and explains 
why the presence of CTCF is crucial for the viability of the eukaryotic cell (Klenova et al, 2002). 
The most important functions of CTCF are discussed in this section. 
 Transcription Regulation 1.3.1
Transcription is a fundamental cellular process, involved in the main pathways of cell 
maintenance, proliferation and death. It is the second step, after DNA replication, in the pathway 
to protein synthesis. Transcription factors (TF) assume a regulatory role in the cell and their 
binding to key DNA positions or, equally important the lack of it, decides the expression status 
of the nearby gene. The balance between over and under-expression of a gene is very delicate 
and requires a tight and fail-proof control system, otherwise both extremes can result in disease 
(Libermann and Zerbini, 2006, Spitz and Furlong, 2012).  
CTCF was originally identified as a transcriptional repressor of the c-myc oncogene in 
chicken and later it was reported to have the same function for the c-myc oncogene in mice as 
well as humans (Filippova et al., 1998, Ohlsson et al., 2001). Other genes that are negatively 
regulated by CTCF include hTERT (Renaud et al., 2005, Renaud et al., 2007, Choi et al., 2010) 
and the lysozyme gene, in conjunction with the thyroid-hormone response element (TRE) (Awad 
et al., 1999). Evidence accumulated highlighting its function as a transcription activator as well. 
CTCF can activate several genes including the amyloid β protein precursor (APP-β), human 
p14ARF and human PIM-1 (Filippova, 2008, Vostrov and Quitschke, 1997). 
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 CTCF transcription regulation studies showed that the flanking regions of the main 
binding domain may also be indirectly involved in the transcription factor activity. Specifically, 
repressor activity is associated with the N-terminal, the C-terminal and the ZF regions, while 
activation activity is localized in the N-terminal region (Klenova et al., 2002). 
 Insulator Function 1.3.2
Insulation is a transcription regulation-related feature of chromatin. Insulator elements 
are either “enhancer blockers”, which prevent the successful communication between the 
enhancer and promoter region, or “chromatin barriers” which prevent the unwanted spread of 
heterochromatin and facilitate the euchromatic state of chromatin, which is more approachable 
for transcription DNA. The exact mechanism that underlies the insulation process remains 
unclear however chromatin loop formation and long-range chromatin interactions frequently 
appear to be involved in the process. Insulator proteins can mediate chromatin architecture 
modulation and three-dimensional looping in order to exert their function (Barkess and West, 
2012, Van Bortle et al., 2014, Schwartz et al., 2012, Kyrchanova et al., 2013, Brasset and Vaury, 
2005).  
CTCF is the only known mammalian protein to be involved in insulation and has been 
implicated in both enhancer blocking and chromatin barrier function (Kim et al., 2007, Xie et al., 
2007, Herold et al., 2012). Bell et al. (1999) first implicated CTCF in insulation function by 
discovering that it binds to the 42 bp insulation element of the chicken β-globin, known to be 
both necessary and sufficient for enhancer blocking activity in human cells (Ohlsson et al., 
2010). Subsequently, more studies emerged highlighting the insulator function of CTCF (Weth 
et al., 2010, Kim et al., 2011, Zielke et al., 2012, Eggeling et al., 2014, Splinter et al., 2006). 
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Figure 1-3 Schematic representation of protein insulation function  
The insulator can block the communication between an enhancer and a promoter thus preventing 
gene expression. This type of insulation is called “enhancer blocker” (a). The second type  can 
promote the expression of a gene by preventing the spread of heterochromatin in the gene 
regional areas (b) (Adapted from Brasset and Vaury (2005)) 
9 
 
 Genomic Imprinting 1.3.3
 The expression of a gene can be restricted to only one of the two parental alleles, commonly 
through methylation or other modifications that lead to the silencing of the other. This conserved 
epigenetic regulation method is employed mostly, but not exclusively, in the case of genes that are 
important during development. To distinguish between the alleles and decide which one will be 
expressed, an epigenetic mark such as DNA methylation can be found at the Imprinting Control Region 
(ICR) (Peters, 2014, Barlow and Bartolomei, 2014) 
CTCF is involved in this epigenetic inheritance phenomenon and the modulation of the Igf2/H19 
genes represents a classic model of genomic imprinting (Lewis and Murrell, 2004, Ideraabdullah et al., 
2014, Singh et al., 2012). The methylation state of the ICR of the two genes differs between the two 
parental alleles and since CTCF binding is sensitive to methylation, it defines whether CTCF will exert its 
activity as an enhancer blocker or not (Bell and Felsenfeld, 2000, Kanduri et al., 2000, Schoenherr et al., 
2003). When the paternal ICR is methylated, CTCF cannot bind to it. In this case the enhancer is free to 
activate Igf2, while in the opposite case, when the ICR is un-methylated, CTCF can bind to it, prevent the 
Igf2 enhancer from acting and thus resulting in the expression of H19 only (figure 1-4) (Reik and Murrell, 
2000, Szabo et al., 2004, Yang et al., 2003). 
Another imprinting regulation phenomenon that CTCF is involved in is the X chromosome 
inactivation. In females, the expression of genes in one of the two X chromosomes is under epigenetic 
silencing control; the choice mechanism is based on the non-coding Xist (inactive x-specific transcript) 
and the antisense Tsix (McCarrey et al., 2002). CTCF was implicated with the X chromosome silencing 
when it was discovered that the promoter of Xist has a CTCF binding site and additionally that the 
binding site of CTCF in the Tsix promoter is under methylation control (Pugacheva et al., 2005, Chao et 
al., 2002, Boumil et al., 2006). More recent studies showed that between Xist and Tsix, at the X 
inactivation center (Xic), another CTCF binding site exists (RS14) and that blocking of this site caused 
aberrant regulation of X chromosome expression (Spencer et al., 2011). 
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Figure 1-4 Genomic imprinting of the Igf2/ H19 locus 
The expression of Igf2 and H19 is under genomic imprinting control exerted by the CTCF 
insulator function. The methylation status of the imprinting control region (ICR) of H19 decides 
whether CTCF can bind to it or not. In the maternal allele, the ICR is not methylated; CTCF can 
bind to it and disallow the communication between the promoter of Igf2 and its enhancer. In this 
case, the H19 gene is expressed and the Igf2 is not. On the other hand, on the paternal 
chromosome the H19 ICR is methylated and CTCF does not bind to it. In this case Igf2 is 
expressed and H19 is not (adapted from Reik and Murrell (2000)). 
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 Chromatin architecture 1.3.4
The development of new techniques which allow high-throughput analysis of the 
organization of chromosomes has offered new insight on CTCF function. Evidence from 
independent studies pinpoints CTCF as an architecture protein able to mediate inter- and intra-
chromosomal interactions between distant sites.  
MacPherson and Sadowski (2010) obtained biochemical evidence that CTCF induces the 
formation of “an unusual DNA structure”. They concluded that CTCF acts as a looping protein 
and the zinc finger domain of the protein is sufficient for the looping function to be exerted. 
Later, Kim et al. (2011) studied the Homeobox gene A locus (HOXA) and discovered that CTCF 
and cohesin act in collaboration to link higher-order chromatin state regulation with transcription 
function. In particular, they found that CTCF keeps heterochromatin off the HOXA locus and 
acts as a docking system for the cohesin complex.  
Sanyal et al. (2012) used the chromosome conformation capture carbon copy (5C) 
technique to show that 79% of long range interactions taking place in the cell need at least one 
CTCF site. This high percentage accentuates the importance of the involvement of CTCF in 
chromatin structure modulation. CTCF can reportedly use the chromatin looping function to 
tether distinct enhancers to their promoters, regulate alternative mRNA splicing and 
transcriptional pausing via RNA polymerase II and to regulate the expression of complex gene 
clusters (Ong and Corces, 2014). In the mammalian brain, the diversity between neurons is 
achieved through alternatively splicing of the protocadherin A (PCDH) gene. The gene cluster is 
composed of over 50 exons, all of which have different promoters. CTCF and cohesin bind to 
most of these as well as the distant enhancer HS5-1. The regulation of the isoform expression 
relies on CTCF binding and facilitating chromatin looping (figure 1-5). 
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 1.4
Figure 1-5 CTCF-mediated chromatin looping is necessary for the transcription regulation 
of the PCDHA gene cluster 
The human protocadherin A (PCDHA) gene cluster contains 15 exons. Each of these 15 variable 
exons has its own promoter. Promoter choice and the formation of an active chromatin hub is 
mediated by CTCF-cohesin DNA looping between the distal HS5-1 enhancer and distinct 
promoters at the PCDHA gene cluster (adapted from Ong and Corces (2014)). 
13 
 
 CTCF binding sites 1.4
Extensive research has been aimed at analyzing CTCF binding sites, however the 
combinatorial use of the CTCF zinc fingers allow it to bind to a wide variety of sequences 
hindering the search for a consensus motif for CTCF binding (Filippova et al., 1996).  
Despite the complexity of CTCF binding, a 20-mer motif has been identified as highly 
conserved in vertebrates (Kim et al., 2007) The wide variety of CTCF binding sites includes 
some which are extensively evolutionarily conserved among different species (Ni et al., 2012), 
while others are unique, not only between species but also between different cell types of the 
same species (Chen et al., 2012).  
Computational methods had revealed more than 13,000 potential binding sites for CTCF 
within the human genome (Kim et al 2007) and with the employment of more recently 
developed next generation sequencing (NGS) techniques the number has risen to over 30,000 
(Chen et al., 2012). Overall more than 15 million binding sites have been discovered in the 
genomes of 15 species including human. The majority of CTCF binding sites are within 1000 bp 
of the transcription start site (TSS) of genes although binding in areas far from any gene has also 
been reported. Although their function is mainly unknown, they could be utilized during 
chromatin looping or other CTCF functions (Chen et al., 2012). 
 Next generation sequencing for the discovery of CTCF binding sites 1.4.1
Transcription factors like CTCF exert their regulatory function mainly through binding to 
DNA. The value of identifying their genome-wide binding sites has become clear especially over 
the last decade and many techniques have been developed aiming at the discovery and functional 
analysis of the binding sites and motifs. 
Genome-wide high-throughput techniques like chromatin immunoprecipitation 
sequencing (ChIP-seq) is used to discover the binding profile of transcription factors and 
histones (Ouyang et al., 2009). Integration of ChIP-seq with RNA-sequencing, which reveals the 
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cellular expression profile, can assist with the elucidation of gene regulatory mechanisms and the 
interplay between genetic and epigenetic regulation (Angelini and Costa, 2014, Gomez-Cabrero 
et al., 2014)  
 CTCF involvement in cellular processes 1.5
CTCF is involved in a wide variety of cellular processes by exerting different functions. 
This is achieved through engaging in protein-DNA or protein-protein interactions (Holwerda and 
de Laat, 2013).  A selection of these functions is discussed in the following subsections. 
 Cell Cycle 1.5.1
Previous studies have concluded that abnormalities in the expression levels of CTCF 
have severe effects on the viability of the cell (Heath et al., 2008). Tissue specific inhibition of 
CTCF expression has a critical result in cell cycle progression, while CTCF knockout mice do 
not survive beyond early embryonic stages (Filippova et al., 2002). On the other hand, ectopic 
expression of CTCF causes growth retardation which has been attributed to CTCF’s ability to 
hinder DNA replication (Rasko et al., 2001). These findings indicate that CTCF is necessary for 
cell cycle progression and survival, but also that its levels have to remain under strict control. 
The interaction of CTCF with proteins known to participate in the regulation of the cell cycle, 
such as p21 and p27 further support the involvement of CTCF in the modulation of the cell cycle 
(Heath et al., 2008, Phillips and Corces, 2009). 
 Apoptosis  1.5.2
Apoptosis is the term used by Gerschenson and Rotello (1992) to describe the 
programmed cell death and comes from the Greek word that means “falling off” (Duque-Parra, 
2005). Studies on CTCF expression levels in breast cancer cell lines, as well as normal and 
cancer tissues, revealed that CTCF is up-regulated in cancer cells (Docquier et al., 2005). 
Surprisingly for a tumour suppressor candidate, this finding suggested that CTCF may have an 
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anti-apoptotic effect in breast cancer cells, which was confirmed by the detection of high levels 
of apoptotic markers following the removal of CTCF from those cells (Docquier et al., 2005). 
 Nucleolar transcription 1.5.3
Guerrero and Maggert (2011) discovered that in Drosophila, CTCF binds to the regulatory 
elements of ribosomal DNA (rDNA) and its absence leads to nucleolar fragmentation and 
decrease of rDNA silencing. In the repeat array of Drosophila rDNA approximately half of the 
genes are active and the other half are inactive. CTCF binding appears to be involved in the 
epigenetic regulation of these genes and modulate ribosomal transcription in the nucleolus. 
Another study using the human HeLa cell line showed that absence of CTCF from the nucleolus 
affects the organization of the nucleolus and results in up-regulated rDNA transcription 
(Hernandez-Hernandez et al., 2012). In addition to this, Torrano et al. (2006) discovered that the 
translocation of CTCF into the nucleolus is associated with growth arrest, apoptosis in MCF-7 
cells and differentiation of the leukemia K562 myeloid cells. All in all, evidence implicating 
CTCF with the architecture and epigenetic regulation of the nucleolus is accumulating. However, 
the exact mechanisms underlying this implication are not yet fully understood.  
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 CTCF and post-translational modifications 1.6
 Many proteins undergo post-translational modifications which sometimes alter their 
biological functions. CTCF can be reportedly subjected to phosphorylation (Klenova et al., 
2001), SUMOylation (MacPherson et al., 2009) or Poly(ADP-ribosyl)ation (PARylation) 
(Docquier et al., 2009). 
 Phosphorylation 1.6.1
 Phosphorylation describes the addition of a phosphate group to a protein and can cause 
the activation or de-activation of the protein. Delgado et al. (1999) first studied CTCF 
phosphorylation during myeloid cell differentiation in leukaemia cell lines. From their 
experiments it was observed that cells induced to differentiate were more highly phosphorylated, 
while cells that are in the proliferation process are under-phosphorylated. Also, they discovered 
that phosphorylation is involved in the modulation of CTCF expression and cell differentiation 
pathways can dictate the levels of phosphorylated CTCF. Klenova et al. (2001) described that the 
majority of the phosphorylation sites of CTCF are located on the C-terminus region and to a 
lesser extent in the ZF domain.  
 SUMOylation 1.6.2
SUMOylation is a relatively newly discovered modification, which includes the covalent 
attachment of small ubiquitin-like modifier (SUMO) proteins in a substrate protein (Alontaga et 
al., 2012). The number of processes that it is implicated in is constantly increasing and includes 
protein localization (Wang et al., 2008, Saito et al., 2010), DNA damage (Cremona et al., 2012, 
Sarangi et al., 2015), senescence (Ivanschitz et al., 2013), and transcription (Sun et al., 2013). 
SUMOylation levels are increased as a result of stressful conditions like hypoxia and this 
increase in SUMOylated proteins is also sometimes followed by cell senescence (Ivanschitz et 
al., 2013).  
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MacPherson et al. (2009) showed that the modification does not interfere with the DNA 
binding capacity of CTCF while their findings also suggested the SUMOylation promotes the 
suppressive role of CTCF on the P2 promoter of myc. Recently, Wang et al. (2012b) discussed 
the de-SUMOylation of CTCF as a means to regulate its activity in hypoxic conditions, based on 
experiments conducted on human corneal epithelial cells   
 Poly(ADP-ribosyl)ation ( PARylation) 1.6.3
PARylation is a phylogenetically ancient mechanism, important for the cellular stability 
mostly by playing an important role in the defense mechanism against threats to the integrity of 
the genome. These threats, such as endogenous or exogenous DNA damage, activate PARylation 
and are at the same time the target of its activity. PARylation is involved in many other cellular 
functions among which are DNA replication, gene expression and cellular differentiation (Golia 
et al., 2015, Robert et al., 2013, Burkle, 2000). 
PARylation has been widely linked to CTCF. The insulator and transcription factor 
functions of CTCF are reportedly by PARylation (Yu et al., 2004a). Docquier et al. (2009) 
showed that PARylation of CTCF results in the formation of the 180kD CTCF isoform 
(CTCF180) which can be detected both in normal and in cancerous conditions. The CTCF130 on 
the other hand is hypo- or non-PARylated and appears in many immortalized cell lines and in 
cancer tissues, including breast tumours. 
The PARylation of CTCF is of particular interest for the present study and this 
modification will be discussed in more detail in the following section. 
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 PARylation and the PARP polymerases 1.7
 PARylation 1.7.1
PARylation utilizes cellular nicotinamide adenine dinoucleotide (NAD
+
) as a substrate 
with a reaction that involves the breakage of the glycosylic link between the nicotinamide and a 
ribose followed by the release of the first along with a proton, and the usage of the ribose as a 
substrate for the formation of ADPR monomers. This is followed by the polymerization of these 
monomers and the attachment of the resulting polymers to a glutamic acid residue of a target 
protein (Figure 1-6) (Kim et al., 2005a). 
PARylation is catalyzed by enzymes called poly(ADP-ribose)polymerases (PARPs). The 
enzyme family contains more than 10 proteins which have common structure and/or functions 
(Nguewa et al., 2005) while the most significant and extensively studied one of the enzymes is 
PARP1 (Kim et al., 2005a, Kim, 2011). PARP family-characteristic functions include the 
addition of the ADPR moieties to target proteins, as well as the elongation of these by creating 
ribosyl-ribosyl bonds. This may result in linear and/or branched polymers of various lengths 
ranging from only a few to more than one hundred residues (Mendoza-Alvarez et al., 2000). The 
variety in the size of the polymers can be attributed to their rapid degradation by the PARG 
enzyme, as well as the nature of the proteins that they are attached to. Not all PARPs can 
catalyze the whole range of the PARP family-characteristic reactions; for example, the non-
hydrolytic cleavage of the protein proximal ADPR moieties is one function restricted to the 
enzyme ADP-ribosyl protein lyase only (Buerkle, 2008, Oka et al., 1984). 
The effect that PARylation exerts on its target proteins can be traced back to the function 
of the polymers. Structurally, they incorporate features found in polynucleotides and/ or 
polysaccharides while they are also significantly negatively charged. As a consequence, they 
affect the structure and the biochemical characteristics of the acceptor protein leading to 
important changes in its function (Buerkle, 2008, Heeres and Hergenrother, 2007). 
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Known PARP targets are involved in many cellular functions such as PCNA, 
topoisomerase I, p53, XRCC1, NF-kβ, CTCF, histone proteins and others (Buerkle, 2008, El-
Khamisy et al., 2003, Wesierska-Gadek et al., 2005, Hegedus and Virag, 2014).The variety in 
the spectrum of targets highlights the importance of this modification for the cellular fate and 
health.  
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Figure 1-6 The metabolism of poly(ADP-ribose) (pADPr) 
PARPs biosynthesize pADPr from NAD
+
 while PARG degrades the polymer to ADP-ribose 
(ADPr). The monomer pADPr can be covalently attached to aspartic acid, glutamic acid, or 
lysine residues of acceptor proteins and the ADPr units of the polymer are connected in a 
linear or branched manner (Tan et al. (2012). 
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 PARP polymerases 1.7.2
 PARP1 1.7.2.1
PARP1 is the most extensively studied enzyme belonging to the PARP family. The gene 
coding for the protein is located on chromosome 1, locus 1q42 and the protein can be found 
mainly throughout the nucleus, as well as the centrosome (Megnin-Chanet et al., 2010). The 
structure of PARP1 includes three distinct domains that play different parts related to its function 
(figure 1-7). The first is a binding domain that infers the polymerase activity and which is 
located on the C-terminal region. It is a highly conserved helix-loop-helix motif, which is 
considered to be the signature domain of the protein and plays the major role in NAD-binding 
and synthesis of the PAR polymers (Megnin-Chanet et al., 2010, Kim et al., 2005a). The N-
terminal DNA binding domain (DBD) contains two zinc fingers and is responsible and necessary 
for DNA binding and the recognition of DNA lesions, in a manner that is not dependant on 
specific DNA sequences (Ko and Ren, 2012). This interaction with DNA results in a 
conformational change in the molecule that increases its catalytic activity greatly. The zinc 
fingers are also involved in the interaction of PARP1 with protein partners and with other 
PARP1 molecules. Between these two domains a central 22kD domain can be found which 
contains the site which is responsible for auto-modification (Ko and Ren, 2012).  
For a long time PARP1 was thought to be the only PARP polymerase, however the 
existence of more members such as PARP2, the tankyrases, ADP-ribosyl protein lyase is now 
well documented. 
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Figure 1-7 . The domain structure of human PARP1 
The structure of human PARP1 contains the DNA-binding, the auto-modification and catalytic 
domains (domains A–F). The PARP signature sequence (in dark blue within the F catalytic 
domain) is the most conserved between the PARPs. (Zn I and Zn II: Zinc-finger motifs - NLS 
nuclear localization signal (adapted from Megnin-Chanet et al. (2010)). 
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 PARP2 1.7.2.2
PARP2 is the second most studied PARP enzyme and, like PARP1, it is involved in the 
detection of DNA damage. Whereas PARP1 detects single, double strand breaks and various 
types of lesions, PARP2 is mostly responsible for recognizing gaps and flap structures (Beck et 
al., 2014). Until recently PARP1 and PARP2 were considered to be the only member of the 
PARP family to be involved in DNA damage repair. However, recent studies have also proved 
that PARP3 can detect double strand DNA breaks (Beck et al., 2014). PARP2 only represents 
10% of the activated PARP activity after DNA damage (Buerkle, 2008). One can therefore infer 
that PARP1 acts as the main contributor in the detection and of the DNA strand breaks and the 
alarm mechanism that is activated against the instability they can cause to the cell.  
PARP2 is a 66kD protein with the coding gene positioned on chromosome 14q11.2. The 
structure of the enzyme resembles that of PARP1 with a catalytic and a DNA binding domain 
found in the C- and N- terminal regions respectively. The auto-modification domain is not 
present and the protein is thought of as a “shorter” version of PARP1. These similarities in 
structure and function led scientists into believing that PARP2 acted as a “back up” enzyme for 
PARP1, however evidence today suggests that the enzymes have unique roles (Beck et al., 
2014). For example, except for the centromeres, PARP2 can be also found at the telomeres 
which is feature not shared with PARP1 (Buerkle, 2008). 
 Tankyrase -1  1.7.2.3
The tankyrase-1 gene is located on the 8q23.1 chromosome and codes for a 142kD 
protein. Tankyrase is another member of the poly(ADP-ribosyl)ation polymerase family carrying 
the characteristic catalytic domain at the C terminal region. It differs from the previously 
described PARPs in that the polymers it creates can only be linear and more importantly, it does 
not contain the N terminal DNA binding domain. Lack of this domain means that the protein 
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does not have the capacity to detect DNA strand breaks and it is therefore not involved in the 
pathway which is activated in response to genotoxic stress. The enzyme can be found on the 
chromosomic telomere region and is involved in the maintenance of telomere length, mainly by 
interacting with the telomeric repeat binding factor (TRF-1) (Chang et al., 2005, Cook et al., 
2002). TRF-1 is part of a nucleoprotein complex that protects telomeres. PARylation by 
tankyrase-1 exposes the telomere and telomerase can then add telomeric repeats (Lehtio et al., 
2008).  
 PARP inhibitors 1.7.3
PARP inhibitors are used as chemosensitizers and cancer therapeutics, based on the 
inefficiency of tumour cells to repair DNA double strand breaks (DSB). The rationale behind this 
strategy is that induction of single strand breaks (SSB) together with blocking of the enzymes 
that are involved in the repair (PARPs) will result in the accumulation of DBS that the tumour 
cells cannot repair and thus eventually in cell death (Underhill et al., 2011).   
Because of the common structural organization of the PARPs, all of the family members 
can be inhibited by 3-ammobenzamide which binds to the nicotinamide region of the NAD 
binding site and prevents the enzyme to bind and use NAD (Buerkle, 2008). Several PARP 
inhibitors are currently in clinical trials including TIQ-A, olaparib and ABT-888. PARP 
inhibitors mainly target PARP1 however a lack of strict target specificity is common between all 
inhibitors (Wahlberg et al., 2012).   
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 Poly(ADP-ribosyl)ation and DNA damage response (DDR) 1.7.4
 PARylation is involved in the response mechanism against DNA damage (Malanga and 
Althaus, 2005, Zhou and Elledge, 2000, Golia et al., 2015, Oliver et al., 1999). Mostly PARP1, 
but also PARP2, can detect single and double strand DNA breaks leading to an increase in the 
catalytic activity of both PARP proteins. Recently, PARP3 also emerged as a part of the DDR 
(Beck et al., 2014). PARP1’s affinity for single DNA ends/ lesions renders it a “nick sensor” in 
the cell (Shall and de Murcia, 2000). When activated, the two PARPs modify themselves and 
then recruit and PARylate other important proteins. A very important part of their role is this 
recruitment of DNA damage checkpoint proteins which will later on coordinate the downstream 
events and decide the fate of the cell. Target proteins of the PARPs all have in common a 
polymer binding domain comprised of 20-26 amino acids (Buerkle, 2008). Interestingly, in many 
cases this domain overlaps with other functional domains of the acceptor proteins and thus 
binding of the polymer causes a disruption of other functions and/or interactions of the target 
PARylated proteins (Buerkle, 2008), perhaps highlighting the high priority of the repair function.  
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 Poly(ADP-ribose) glycohydrolase (PARG) 1.7.5
PARPs catalyze mono(ADP-ribosyl)ation of the acceptor protein substrate, elongation 
and branching of the poly(ADP-ribose) chain. The polymers can vary in length of units and they 
have very short half-life. The polymerization can be reversed by an enzyme called Poly(ADP-
ribose) glycohydrolase (PARG) which can cleave the polymer branches (Bonicalzi et al., 2005). 
There is only a single gene coding for PARG localized on chromosome 10q11.23 and 
three different isoforms of the protein can be detected as a result of alternative splicing of the 
gene transcripts. The gene comprises of 18 exons and 17 introns and from these, the catalytic 
region is found between introns 9 and 14 (Slade et al., 2011, Hassler et al., 2011). The largest 
PARG isoform can be found in the nucleus and has a molecular weight of 111kD. The two splice 
variants are detected in the cytoplasm and lack the first one and two exons resulting in a 102kD 
and a 99kD isoform respectively. The nuclear localization sequence (NLS) is on exon 1 which 
explains why the two splice variants are not localized in the nucleus (Meyer-Ficca et al., 2004).   
The PARG enzyme is activated as a result of increased concentration of poly(ADP) 
ribose and has a balancing effect. It acts by hydrolyzing ribose bonds and releasing free ADP-
ribose residues from both linear and branched forms of poly(ADP)ribose (Slade et al., 2011). 
PARG was discovered during the decade of 1970, it is present in all eukaryotic cells apart from 
yeast and its isoforms are differentially localized in the nucleus (Bonicalzi et al., 2005). Mostly 
due to the fact that PARG is present in small amounts in the cell, studying it has been proven to 
be a difficult task. Experiments on directed mutations of the gene in Drosophila showed that lack 
of it prohibited the larvae from developing into adult flies. The small percentage of flies that did 
progress to adulthood, suffered from neurodegeneration, pointing to the fact that PARylation 
and, equally importantly the regulation of PARylation, is also involved in the normal function of 
the neurons (Bonicalzi et al., 2005). 
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 Project aims 1.8
CTCF has been pinpointed as a key regulator of many important cellular functions, mainly 
through engaging in protein-DNA interactions throughout the genome. However, the role of 
poly(ADP-ribosyl)ation of CTCF in the regulation of cellular processes is not well understood. 
We hypothesize that differentially PARylated isoforms of CTCF (CTCF130 and CTCF180) 
control different groups of genes (Hypothesis 1) and different functions (Hypothesis 2) in 
different biological situations. To investigate Hypothesis 1 the following Objectives will be 
studied as follows: 
I. To identify the binding sites of the CTCF isoforms (CTCF130 and CTCF180) using a 
cell line model, LDM226, proliferating (expressing CTCF130 and CTCF180) and 
arrested (expressing only CTCF180). The high-throughput chromatin 
immunoprecipitation (ChIP-seq) technique will be used to achieve this Objective. 
II. To identify gene expression profiles in the above cell line model by employing the 
high-throughput RNA-Seq technique. 
III. To integrate the ChIP-seq output data with the global mRNA expression profile data 
generated by RNA-sequencing on the same cell model. This integration will provide 
useful information regarding the potential of CTCF180 as a gene expression 
regulator. 
In the second part of our investigation, we will focus on the involvement of CTCF PARylation in 
the DNA damage response mechanism and test Hypothesis 2; to achieve this, Objective IV will 
be studied as follows: 
IV. To investigate the role of CTCF PARylation in the context of DNA damage and 
repair. The cellular expression ratio and localization of CTCF, as well as the effect of 
PARylation inhibition will be studied in response to induced DNA damage. 
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 Materials and Methods Chapter 2
 Cell lines and culture techniques 2.1
All cell culture experiments were performed in laminar flow type II hoods (Thermo Fisher 
Scientific, USA) using sterile plastic and glassware. 10% Virkon (DuPont, USA) solutions and 
70% ethanol were used to ascertain aseptic conditions. All cell lines were maintained at 37
o
C in 
a 5% CO2 (SANYO, USA) incubator. 
 Cell lines 2.1.1
The majority of the experiments conducted in this study utilized the cell line 226LDM 
which derived from normal luminal breast cells. This cell line was immortalized using the viral 
constructs carrying the modified T antigen, TAg(U19dl89-97) (Cotsiki et al., 2005). Selected 
experiments were performed using a panel of cell lines derived from non-transformed cells such 
as the immortalized human Benign Prostatic Hyperplasia (BPH-1) (Hayward et al., 1995) and the 
human foreskin fibroblast cell line Hs27. A panel of cancer cell lines was also employed 
including the human epithelial cervical cancer cell line HeLa (Scherer et al., 1953) and the 
human ductal carcinoma cell line ZR-75.1 (Engel et al., 1978). In addition to these, the human 
embryonic kidney cell line 293T was also utilized (DuBridge et al., 1987).  
 Culture media 2.1.2
For culturing 226LDM cells the growth medium DMEM/F-12 (PAA) was supplemented 
with 5 μg / ml insulin, 1 μg / ml hydrocortisone, 20 ng / ml epidermal growth factor, 20 ng / ml 
cholera toxin (all from Sigma), 10% fetal bovine serum (FBS) (Biosera), and 50 μg / ml 
gentamicin (Life Technologies-Invitrogen). 
The growth medium used for culturing Hs27, HeLa and 293T cells was the DMEM 
(Dulbecco’s Modified Eagles Medium) (PAA-GE Healthcare) supplemented with 10% of FBS 
(Biosera) and 50 μg / ml of gentamicin (Life Technologies-Invitrogen). 
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The ZR-75.1 and BPH-1 cells were maintained in RPMI 1640 medium (PAA-GE 
Healthcare) supplemented with 10% FBS (Biosera) and 50 μg / ml gentamicin (Life 
Technologies-Invitrogen). 
 Cell culture techniques 2.1.3
 Passaging cells 2.1.3.1
All cell lines used in this study grow adherently in a monolayer and require passaging when 
reaching approximately 70-80% confluence. To trypsinize, the spent growth medium was 
aspirated and 2 ml of EDTA (1X) (SIGMA) was used for washing the cells. To detach cells, 1 ml 
of warm 10% trypsin/EDTA (SIGMA) was added and the flasks were incubated for 2-10 min 
incubation at 37
o
C. Especially for the 226LDM cells, due to being strongly adherent to the flask, 
3 ml of trypsin were added instead of 1 ml and the incubation time was raised to 15-20 min. 
After confirming under the microscope that the cells had detached, the trypsin in the flask was 
diluted ten times with warm complete culture medium and then the cells were carefully 
transferred into a centrifuge tube. The cell suspension was centrifuged at 450 g for 5 min and the 
supernatant was aspirated off. The cell pellet was re-suspended in fresh growth medium and one-
tenth of the suspension was transferred in a culture flask for future culture. The remaining cell 
suspension was used according to the requirements of other experiments. 
 Counting and seeding of cells 2.1.3.2
Cells from the final cell suspension as described in 2.1.3.1 were counted using a 
haemocytometer. The concentration of cells per ml was determined by calculating the average of 
cells contained in the four corners of a haemocytometer and multiplying it by 10
4
. Depending on 
the experiment, the cells were diluted to the required concentration using growth medium and 
seeded in 6- or 12-well plates or flasks. 
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 Freezing and defrosting cell stocks 2.1.3.3
Cells were trypsinised as described in 2.1.3.1, counted and 1 ml of cell suspension, 
containing approximately 1 x 10
6
 cells, was mixed with 1 ml of freezing mix composed of 20% 
Dimethyl Sulfoxide-DMSO (SIGMA) and 80% FBS. The suspension was transferred to a 
labelled cryotube wrapped in insulating material to ensure that the drop of temperature will be 
achieved gradually. The tube was stored in -80
o
C and after 2-3 days it was moved to the liquid 
nitrogen storage tank. 
To defrost cells, the cryotubes containing cells were removed from the liquid nitrogen tank 
on dry ice. The following day, the cells were defrosted by placing the vial under warm running 
water. The defrosted suspension was added to warm complete medium and centrifuged at 200 g 
for 3 minutes. The pellet was re-suspended in 9 ml of complete medium and transferred to a 
small flask. The flask was maintained at 37
o
C and 5% CO2 until reaching confluence of 70-80%. 
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 Cell culture treatments 2.2
 Cell cycle arrest treatment with hydroxyurea and nocodazole 2.2.1
Cells approximately 60-70% confluent were stripped off their spent medium and fresh 
culture medium containing 100 mΜ hydroxyurea was added to the flask. The cells were 
incubated for 24 h at 37
o
C and CO2. After the end of the incubation time, the cells were 
incubated in fresh complete medium for 1hr at 37
o
C and CO2. After 1 hr the complete medium 
was aspirated off and fresh medium supplemented with 500 ng / ml nocodazole was added. After 
24 h the detached cells were harvested, counted as described in 2.1.3.2 and used for a variety of 
assays. 
 DNA damage 2.2.2
 DNA damage caused by exposure to hydrogen peroxide (H2O2) 2.2.2.1
Cells were seeded in 12-well plates (commonly 1.5 x 10
5 
/ well) and grown on cover-slips 
until reaching approximately 70% confluence. At that time, the spent medium was aspirated off 
and fresh complete medium containing 200 μM H2O2 was added to the wells. Depending on the 
requirements of the experiment, the treatment was allowed for different time-points varying 
between 5 and 90 min at all times incubated at 37
o
C and CO2. After the completion of the 
treatment, the cells were fixed with 4% paraformaldehyde for immunostaining experiments or 
harvested and lysed if they were used in a western blotting experiment. 
 DNA damage caused by exposure to X-irradiation 2.2.2.2
Cells grown in flasks were trypsinised (as described in 2.1.3.1) and aliquoted to 
microcentrifuge tubes with a concentration of 6 x10
 5 
/ tube. The cells were placed in an iron ice 
box and then irradiated using an X-ray generator from CHF Müller (Germany). The dose to be 
delivered was applied by variation of irradiation time at a fixed dose rate. The irradiation 
parameters were: 70 keV energy, 1.25-mm aluminium filter, and 9.4 mA current.  
32 
 
 
 Treatment with the PARP inhibitor ABT-888 2.2.3
Cells were seeded in 12-well plates and grown on cover-slips. When they reached 70% 
confluence the spent medium was removed and fresh medium was added supplemented with 5-
10 μM ABT-888. The incubation, at 37
o
C and CO2 varied between 2 and 12 h. 
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 Mammalian cell transfection 2.3
Transient transfection is a method of introducing exogenous DNA into the nucleus of 
eukaryotic cells (Scangos and Ruddle, 1981, Scangos et al., 1981). Plasmid DNA carrying a gene 
of interest was transfected into mammalian cells for the purposes of this PhD study. Descriptions 
of the plasmids used in this study are summarized in table 2-1. Two transient transfection 
methods were used; the calcium phosphate method and the SuperFect transfection reagent 
method from Qiagen. 
 DNA transfection using the calcium phosphate method 2.3.1
The calcium phosphate method is based on the formation of micro-precipitates in DNA-
calcium mixtures. These adhere to the surface of cells and enhance the DNA uptake capacity of 
cells (Kingston et al., 2001). 
Cells reaching 60-70% confluence were stripped of their spent medium and supplied with 
growth medium without antibiotic. They were incubated in this medium for 1 h. In the 
meantime, the transfection solutions were prepared. For each well of a 12-well plate a total of 
100 μl of transfection solution was prepared. This composed of 1 μg of plasmid DNA in 50 μl 
TE buffer (10 mM Tris/HCl pH 8.0 / 1 mM EDTA) and 2 M CaCl2. The mix was carefully added 
to 50 μl of HBS buffer (Hepes 50 mM / NaCl 280 mM/ sodium phosphate 1.5 mM). The mixture 
was incubated for 20 min, then transferred drop-wise into the well and incubated for a period of 
48 h.      
 DNA transfection using the SuperFect transfection reagent (Qiagen) 2.3.2
According to the manufacturer, SuperFect consists of activated-dendrimer molecules with 
a defined spherical architecture. These are branched and have charged ends that attract the 
negatively charged DNA. The DNA-dendrimer structures adhere to the cells and they enter the 
cell through non-specific endocytosis. The reagent buffers the pH of the endosome, leading to 
pH inhibition of endosomal nucleases, which ensures stability of SuperFect–DNA complexes. 
34 
 
 
Transfection using the SuperFect transfection reagent from Qiagen was used for enhanced 
transfection efficiency following the manufacturer’s instructions. 
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Table 2-1 Plasmids used in transient DNA transfection experiments 
Plasmid Description Source 
pEGFP-C1 
Enhanced Green Fluorescent 
Protein 
Clontech 
pEGFP-CTCFwt 
CTCF cDNA cloned in 
pEGFR-C1 vector 
(Farrar et al., 2010) 
pEGFP-CTCFmut 
PARylation – deficient 
CTCF cDNA cloned in 
pEGFR-C1 vector 
(Farrar et al., 2011) 
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 General microbiology techniques 2.4
 Bacterial culture 2.4.1
All bacterial culture work was carried out in a specific laminar flow hood designated for 
bacterial work. DH5α, an Escherichia  coli (E. coli) strain, were the competent cells (Invitrogen) 
used for plasmid transformation (Hanahan et al., 1991). The bacterial cells were grown in Luria 
Broth (LB). To prepare 1 liter of LB we used 10 g NaCl, 10 g Bactotryptone and 5 g yeast 
extract supplemented either with 100 μg / ml of ampicillin (SIGMA) or 50 μg / ml kanamycin 
(SIGMA). 
 Amplification of plasmid DNA using bacterial system 2.4.2
 Transformation of competent cells 2.4.2.1
Competent bacterial cells (DH5α) were thawed on ice. 0.5 μg of the plasmid DNA was added to 
50 μl of the competent cells and the mix was incubated on ice for 30 min. The cells were heat 
shocked by placing the tubes in a heat-block at 42
o
C for 20 seconds. Following the heat shock 
the cells were immediately placed on ice. After 2 min, 950 μl of warm LB medium was added to 
the cells. The tube was placed in the Stuart Orbital shaker incubator S150 at 225 rpm and 37
o
C 
for 1 h. From the cell suspension, 100 μl were spread onto an agar plate containing antibiotic. 
The remaining cell suspension was centrifuged at 2500 g for 5 min and the pellet was re-
suspended in 100 μl of LB. a second agar plate was plated and both plates were incubated 
overnight at 37
o
C. Bacterial colonies could be seen in both plates the following day. 
  Inoculation of LB medium for plasmid DNA extraction 2.4.2.2
From one of the plates prepared as described in 2.4.2.1 a single colony was carefully 
picked using a sterile tip. The colony was dropped in a culture tube containing 5 ml of LB 
medium supplemented with antibiotic. The culture was incubated overnight in the Stuart Orbital 
incubator at 37
o
C. The following day, 3 ml of the transformed bacterial cells were harvested by 
centrifugation (5000 g / 3 min) and used for small scale DNA extraction. The remaining 2 ml 
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were stored at 4
o
C. Once enzymatic digestion of the isolated DNA confirmed that the plasmid 
transformation and culture was successful, the stored 2 ml were used for the preparation of 
culture for plasmid isolation at a bigger scale. 
 Plasmid DNA isolation from bacterial cells 2.4.3
 Small scale plasmid DNA isolation  2.4.3.1
Plasmid DNA was isolated from the small scale culture that was prepared as described in 
2.4.2.2. This was achieved using the QIAPrep Spin Miniprep kit (Qiagen) following the 
manufacturer’s instructions. The quality and quantity of the obtained DNA was measured by 
using the Nanodrop ND-1000 spectrophotometer using the manufacturer’s guidelines. 
 Large scale plasmid DNA isolation 2.4.3.2
For isolation of larger quantities of plasmid DNA, the Endotoxin-free Plasmid Maxi prep 
kit (Qiagen) was used according to the manufacturer’s instructions. The Nanodrop 
spectrophotometer was used to assess the quality and quantity of the isolated DNA. 
 
 DNA quantification and quality control 2.4.4
 Isolated DNA quality control using restriction enzymes 2.4.4.1
Enzymatic digestions were done on plasmids prepared as described in 2.4.3. in each case 
a detailed restriction site map was generated using the online software NEB cutter (Vincze et al., 
2003). One microliter of the appropriate restriction enzyme (FastDigest from Thermo Scientific) 
was used to digest 1 μg of plasmid DNA. In the solution the appropriate buffer solution provided 
by the manufacturer was also added. The reaction was incubated for 30 min at 37
o
C before 
running the digested and undigested DNA in agarose gel. 
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 Agarose gel electrophoresis 2.4.4.2
Agarose gel electrophoresis was used to measure the size of the digested DNA (and RNA) 
according to how it migrates in the agarose matrix in response to electric current. Agarose gel 
was prepared by 1 g of agarose powder (for 1% gel) added to 100 ml of 1 x TAE (Tris Acetate 
EDTA) as well as 5 μl of ethidium bromide. The samples, containing a tracking dye (30% 
glycerol / 0.25% bromophenol blue), were added to the wells of the gel and the gel was run in 1 
x TAE (40 mM Tris/ 20 mM acetic acid/ 1 mM EDTA) buffer. Apart from the samples, a DNA 
ladder (GeneRuler™ DNA ladder, Fermentas) of appropriate size range was also loaded in 
parallel to help with the estimation of the unknown samples. The samples could be visualized 
under a UV light system (Alpha Innotech and Fusion Fx7 from Peqlab, Germany) because of the 
ethidium bromide which is contained in the gel and has the capacity to intercalate into DNA 
(LePecq and Paoletti, 1967).   
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 Automated Fluorimetric detection of Alkaline DNA Unwinding (FADU) 2.5
assay 
 
The automated fluorimetric detection of alkaline DNA unwinding (FADU) assay was used 
to measure DNA strand breaks in large populations of cells (Moreno-Villanueva et al., 2011). 
The assay is based on the principles of the original work from Birnboim and Jevcak (1981). The 
automated FADU modified by Moreno-Villanueva et al. (2009) produces less bias by being 
conducted by a liquid handling robot in a controlled environment. The assay has increased 
throughput while requiring smaller number of output cells per assay compared to its predecessor. 
An overview of the steps involved in FADU can be seen in figure 2-1. 
 Cell preparation 2.5.1
Cells (6 x 10
5 
/ well) were seeded in custom-made 96-well plates, treated and allowed 
repair incubation time according to the experiment requirements. After the completion of the 
treatment/ repair protocol, the culture medium was aspirated off the well plate and the plate was 
positioned in the working space of the robotic device and kept in dark at 0
o
C. 
 Lysis 2.5.2
In an automatic manner, dispensing of 70 μl of lysis buffer (9 M urea / 10 mM NaOH / 2.5 
mM cyclohexyl-diamine-tetraacetate / 0.1% sodium dodecyl sulphate / at RT) was completed for 
each well at a rate of 150 μl / s. Incubation with this buffer for 12 min causes the cellular 
membranes to lyse and the contents of the cells to come into solution. 
 DNA unwinding 2.5.3
Following cell lysis, 70 μl of alkaline solution (0.425 parts lysis solution in 0.2 M NaOH, 
pre-cooled to 0°C) was added on top of the cell lysate in such a way as to form a second layer, 
thus avoiding any mixing with the lysate. To achieve this, the robotic pipettes were placed at a 
controlled distance from the well-plates and the dispensing speed was lowered to 10 μl / s. The 
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pH of the cell solution during the 12 min incubation with this buffer reaches 12.5 which causes 
the unwinding of the DNA double helix in the contents of the samples. 
 Neutralization 2.5.4
To stop the DNA unwinding after the 12 min of incubation, 140 μl of neutralization 
solution (14 mM β-mercaptoethanol / 1 M glucose) were added at a rate of 200 μl / s. At this 
point the temperature was shifted to 22°C. 
 SybrGreen® addition and fluorescence detection 2.5.5
156 μl of diluted SybrGreen (1:8,333 in H2O) (from MoBiTec, Germany) were dispensed 
onto the samples and the robotic pipettor mixed the solution by re-suspending. The fluorescence 
emitted from the samples was analysed immediately in a fluorescence plate reader at 492 nm 
excitation / 520 nm emission. As SybrGreen intercalates to double stranded DNA, the level of 
fluorescence was inversely correlated with single stranded DNA representing DNA 
damage.  Statistical significance was evaluated by using t-test. 
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Figure 2-1 Diagrammatic representation of the stapes included in the automated FADU 
assay
42 
 
 
 Total RNA extraction and purification 2.6
For RNA experiments, all work was done under a fume hood using sufficient amounts of 
the RNA decontamination solution RNase-zap (Life Technologies). Total RNA from cell lines 
was extracted using the TRIsure reagent (Bioline) according to the manufacturer’s guidelines.  
 Extraction of total RNA from cell lines 2.6.1
Cells were cultured in a flask until 70-80% confluent. At that point, the medium was 
aspirated off and 2 ml of ice-cold PBS were added to the attached cells. The flask was drained 
again and new PBS was added (1 ml). The cells were scrapped off and collected in a 
microcentrifuge tube. Centrifugation at 300 g for 5 min was done to obtain a cell pellet. The 
supernatant was removed and the white-coloured pellet was re-suspended in 1 ml of PBS. The 
pellet was once again centrifuged and the supernatant removed. 1 ml of TRIsure was added to 
the pellet and following re-suspension, the solution was incubated for 5 min at RT. 200 μl of 
chloroform were added and the tube was shaken with force and incubated for 15 min at RT. At 
this point the solution had separated into three phases, the top aqueous phase, the white phase 
and the oily bottom layer. The solution was centrifuged at 9,500 g for 15 min at 4
o
 and the 
separated top aqueous layer was carefully extracted and transferred into a fresh centrifuge tube. 
The volume of this separated phase was approximately 250 μl. The genetic material was 
precipitated with 625μl of isopropanol and incubated for 20 min on ice. The solution was 
centrifuged under the same conditions as previously, the supernatant was removed and the pellet 
re-suspended in 1 ml of 75% ethanol. The solution was centrifuged for 15 min at 4
o
C at 6000 g. 
The ethanol washing step was repeated twice before removing the supernatant completely and 
air-drying the RNA pellet. The RNA was solubilized in sterile water (40-50 μl) and heated for 10 
min at 55
o
C. The pellet was stored at -80
o
C. 
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 RNA quantification and quality control 2.6.2
 RNA quantification using the Nanodrop ND-1000 2.6.2.1
The Nanodrop ND-1000 was used for the quantification of the RNA samples. The 
manufacturer’s instructions were followed. Nanodrop results are adequate for assessing the 
concentration of RNA samples but not to establish the integrity of the samples and to identify 
DNA contamination. For this reason the Bioanalyzer 2100 by (Agilent) is preferable. 
 RNA quality analysis using the Bioanalyzer 2100 (Agilent) 2.6.2.2
The quality of the RNA samples was assessed using the Bioanalyzer 2100 by Agilent 
according to the manufacturer’s instructions. The assay is based on microfluidics technology and 
it is an efficient method for testing the quality of RNA samples prior to microarrays and 
sequencing techniques. The quality of the RNA was assessed from the electropherograms 
obtained at the end of the analysis. Only RNA of acceptable quality was used for the RNA-
sequencing experiments.  
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 Methods for protein extraction and analysis 2.7
 Preparation of cell extracts for SDS-PAGE 2.7.1
 
Cells were trypsinized and centrifuged for 5 min at 400 g. The obtained pellet, was lysed 
immediately with SDS lysis buffer (0.1 M Tris/HCl pH6.8 / 7 M Urea / 4% SDS, phenol red dye 
and 10% β-mercaptoethanol -added before use) with a ratio of 20 μl of buffer per 1 x 10
5
 cells. 
The lysate was vortexed and heated at 95
o
C for 5 min. The prepared samples could be used 
immediately or stored at -20
o
C.  
 Preparation of acrylamide gel, Sodium Dodecyl Sulphate –Polyacrylamide Gel 2.7.2
Electrophoresis (SDS-PAGE) and Western Blot  
SDS-PAGE is a method commonly used for the separation of proteins by electrophoresis 
based on their molecular weight (Chrambach and Rodbard, 1971).  A porous polyacrylamide gel 
is used as a matrix and sodium dodecyl sulphate (SDS) is used to denature and negatively charge 
the proteins of interest. In SDS-PAGE, proteins migrate on the gel according to their size from 
the negative to the positive pole of the gel tank. Smaller proteins travel faster through the pores 
of the gel, while larger proteins migrate slower. 
 In this study an SDS-PAGE apparatus from Bio Rad was used. The composition of the 
buffers used in these experiments can be seen in table 2-2. The cell lysates were prepared as 
described in 2.7.1 and together with a pre-stained protein marker they were loaded on a 10% 
acrylamide gel (the composition of the gels can be seen in table 2-3). After the electrophoresis in 
running buffer (125 V / 40 mA / 2.5 h) the gel contained all the proteins of the cell lysates 
separated according to size. To detect and visualize a specific protein of interest SDS-PAGE was 
followed by Western Blotting (Towbin et al., 1979).  
Western Blotting is a technique that follows SDS-PAGE and involves the transfer of all 
the proteins resolved in an acrylamide gel onto a membrane. This membrane can then be 
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incubated with a specific antibody which will bind to the protein of interest. This binding can be 
visualized and the protein size can be compared to the pre-stained marker.  
 The resolved proteins and marker were transferred to a polyvinylidene difluoride 
(PVDF) membrane (Millipore, USA). Prior to the transfer, the gel was incubated in running 
buffer 1% methanol for 15 min and the membrane was hydrated in absolute methanol for 10-15 
sec and rinsed with RO H2O. A stack consisting of 10 Whatman papers soaked in transfer buffer, 
in the middle of which the gel and membrane were placed, was put on the surface of the blotting 
apparatus. The semi-dry transfer was set for 2 hours (30 V / 100 mA). 
After the transfer, the membrane containing all the proteins was washed in 20% 
methanol, rinsed with RO H2O2 and incubated overnight in blocking buffer, which prevents 
nonspecific binding. The membrane was then probed with the primary antibody (see table 2-4 for 
concentrations) for 2 h and then washed thrice with washing buffer. The membrane was 
incubated with the secondary antibody (prepared in blocking buffer) for 2 h at RT. The 
membrane was finally washed 3 times for 5 min each in washing buffer. All the secondary 
antibodies used in our study were conjugated with the horse radish peroxidase (HRP) enzyme 
which reacts with the substrate (UptiLight) provided in the Enhanced Chemiluminescence kit 
(ECL) (Interchim). The development of the signal with chemiluminescent peroxidase substrate 
for blotting was performed in a dark room using a red light and the signal was captured on an 
autoradiography film (Kodak, Japan). The signal on the film was visualized using the GBX 
Developer and Fixer (Kodak, Japan). For some of the Western blotting experiments in our study, 
the signal was visualized using the Fusion FX7 gel documentation system from Peqlab 
(Germany). 
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Table 2-2 Composition of buffers used in SDS-PAGE and Western Blotting 
Buffer Composition 
SDS Lysis Buffer 
0.1 M Tris/HCl pH 6.8, 7 M Urea, 4% SDS, phenol red dye 
2 β-mercaptoethanol (just before use) 
Resolving Buffer 2 M Tris/HCl(pH 8.9), 0.2% SDS 
Stacking Buffer 
0.1 M Tris/HCl (pH 6.8), 0.1% SDS, 5%  Acrylamide / Bis-
acrylamide 30% solution 
Running Buffer 0.025 M Tris/HCl, 0.192 M Glycine, 0.1% SDS 
Transfer Buffer 20 mM Na2PO4, 2% Methanol, 0.05% SDS 
Blocking Buffer 
0.1% Tween, 5% dried skimmed milk in powder form, 1x 
PBS 
Washing Buffer 0.1% Tween, 1 x PBS 
 
 
 
Table 2-3 Composition of resolving and stacking gels used in SDS-PAGE 
Composition 
Resolving Gel (10% gel) 
Volume (ml) 
Stacking Gel (4% gel) 
Volume (ml) 
Acrylamide / Bis-
acrylamide 30% 
3.3 - 
Resolving buffer / stacking 
buffer 
5 2 
APS 10% 0.05 0.01 
TEMED 0.02 0.004 
ddH2O 1.7 - 
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 Immunofluorescence (IF) staining on fixed cells 2.7.3
In immunofluorescence staining, which is based on the same principle as 
immunocytochemistry staining, an antibody is used to detect a specific protein. This antibody is 
appropriately tagged with a visible dye such as a fluorescent dye (Ramos-Vara, 2005).  
 IF staining was performed on adherent cells grown on cover slips. The cells were fixed 
with addition of 4% paraformaldehyde (PFA). After three washes with PBS/glycine (0.1 M), 
they were incubated for 15 min in boiling citrate buffer (10 mM citric acid, pH 6.0). After 
incubation for 20 min with permeabilization buffer (0.25% Triton / PBS) the cells were washed 
thrice with 1 x PBS. The coverslips were placed in petri dishes, circled with hydrophobic marker 
on the slides and 90 μl of blocking buffer (0.05% Tween, 2% serum, 1% BSA / 1 x PBS) was 
added. A moist towel was put in the dish to keep the environment humid and the dish was 
covered and left on slow rocking in 4
o
C overnight. A 2 h long incubation with primary 
antibodies in buffer (0.05% Tween, 1% BSA, in 1 x PBS) was followed by three PBS washes. 
Incubation continued in the dark (covered with foil) with secondary antibodies conjugated with 
fluorescent dyes (e.g. FITC, TRITC) for 1hr. After 3 more washes with 1 x PBS, the coverslips 
were left to dry and then they were mounted to microscope slides with DAPI (4’,6-diamidino-2-
phenylindole, dilactate) mounting medium.  
 
 Microscopy 2.7.3.1
The majority of the immunofluorescence staining was observed under the Nikon Ti-
Eclipse wide-field microscope which was used to capture the staining images. Staining from 
selected experiments was observed under the Nikon A1R confocal microscope. The visualisation 
tool used to view the images was Fusion FX viewer from Nikon.    
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Table 2-4 Antibodies used in our study and their applications 
Primary 
Antibody / 
Product Code 
Supplier 
Application 
 Concentration 
Secondary Antibody Supplier 
Rabbit 
polyclonal, 
anti-CTCF 
 
07-729, lot # 
JBC1903613 
Millipore 
WB (1:10,000) 
Goat anti-rabbit horseradish 
peroxidase (1:15,000) 
Abcam 
IF (1:500) 
Goat anti-rabbit 
fluorescein isothiocyanate (FITC) 
(1:500) 
Millipore 
ChIP, IP (1:250) - - 
Mouse 
monoclonal, 
anti-α tubulin 
 
T6074 
SIGMA WB (1:5,000) 
Goat anti-mouse horseradish 
peroxidase (1:10,000) 
Abcam 
Mouse 
monoclonal, 
anti-PARP1 
Provided by 
the Buerkle 
group, 
Konstanz, 
Germany 
IF (1:400) 
Goat anti-mouse 
tetramethylrhodamine (TRITC) 
(1:400) 
Millipore 
Rabbit 
polyclonal,  
anti-γH2AX 
 
H5912 
Millipore IF (1:200) 
Goat anti-rabbit 
fluorescein isothiocyanate (FITC) 
(1:500) 
Millipore 
Mouse 
monoclonal, 
anti-UBF(F-9) 
 
Sc-13125  
Santa Cruz IF (1:300) 
Goat anti-mouse 
tetramethylrhodamine (TRITC) 
(1:400) 
Millipore 
Rabbit 
polyclonal, 
anti-trimethyl-
Histone H3 
(Lys9) 
 
07-523 
Millipore ChIP (1:250) - - 
Mouse 
monoclonal, 
anti-CTCF130 
 
Peovided by 
the Loba-
nenkov 
group, USA 
ChIP (1:50) - - 
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 Individual protein immunoprecipitation (IP) 2.7.4
This method is used to detect and immunoprecipitate a protein of interest out of a solution 
containing thousands of proteins using an antibody that specifically recognizes this protein  
(Kaboord and Perr, 2008). 
Cells cultured on flasks were trypsinised according to protocol (2.1.3.1). After centrifugation, 
the cell pellet was washed twice with 1 x PBS and then lysed by vortexing in BF2 (25 mM 
Tris/Hepes - pH 8.0, 2 mM EDTA, 0.5% Tween20, 0.5 M NaCl, 1:100 Halt Protease Inhibitors). 
The lysate was incubated on ice for 15 min and then equal volume of BF1 (25 mM Tris/Hepes - 
pH 8.0, 2 mM EDTA, 0.5% Tween20, 1:100 Halt Protease Inhibitors) was added.  
For Immunoprecipitation, the cell lysate was pre-cleared by incubating 500 μl of the lysate in 
50 μl of pre-blocked Protein A/Sepharose beads for 30 minutes at 4
o
C on a rotor shaker. The 
sample was then centrifuged at 200 x g for 1 minute at RT and the pre-cleared supernatant was 
transferred into a fresh centrifuge tube. 50 μl of the sepharose beads were added to the pre-
cleared lysate along with the antibody (see table 2-4 for concentrations) and the samples were 
incubated overnight at 4
o
C on a rotating wheel. On the following day, the immune-complexes 
were recovered by centrifugation at low speed for 1 min and the supernatant was removed. The 
pellet was washed three times with immunoprecipitation buffer (BF1+BF2) and each time the 
beads were collected with centrifugation at low speed for 1 minute. The sepharose was then 
lysed in SDS-lysis buffer and analysed by SDS-PAGE and western blot analysis as described in 
2.7.2. 
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 Chromatin Immunoprecipitation (ChIP) 2.9
Chromatin immunoprecipitation is a technique that allows the selection of specific protein-
DNA complexes using an antibody that recognizes the protein of interest (Solomon et al., 1988, 
Collas, 2010). ChIP is commonly used in transcription factor research, especially when coupled 
with massive parallel sequencing (ChIP-seq) (Johnson et al., 2007) 
In this study, chromatin immunoprecipitation was used to identify the genome-wide binding 
sites of the transcription factor CTCF in the 226LDM cell line. Two methods were employed to 
that end, the manual protocol and a specialized kit. 
 Manual Chromatin Immunoprecipitation method 2.9.1
 
 Cell Sample Preparation for ChIP 2.9.1.1
 Medium was drained off of one plate containing roughly 8 x 10
5
 cells and 2 ml of 1 x 
PBS was added. To crosslink DNA and protein 54.7 μl of formaldehyde (37%) was added to the 
plate and left for 10 min in RT on a rocker to incubate. To quench the crosslink reaction 0.125 M 
of glycine was added and the plate was incubated for 5 min. The cells were scraped and 
transferred into two centrifugation tubes. Centrifugation for 5 min at 1000 x g at 4
o
C was done to 
collect the cells as the supernatant was removed. 1 ml of ice cold hypotonic buffer was added in 
each of the microcentrifuge tubes and the samples were re-suspended a few times to make the 
final cell suspension. The samples were incubated on ice for 10 min and then span at 2000 x g 
for 5 min at 4
o
C. The pellets were collected and re-suspended in 300 μl of LB-A buffer (50 mM 
Tris/HCL - pH8, 10 mM EDTA, 1%SDS, 1:100 Halt Protease Inhibitor Cocktail 100x Thermo 
Scientific x10) and incubated for 10 min on ice. Finally the samples were sonicated (3 x 7 min) 
with the Bioruptor from Diagenode to shear the DNA in fragments of 200-1000 bp size. To 
confirm the fragment size, samples were run on 1% agarose gel and observed under UV light as 
described in 2.4.4.2. 
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 Chromatin immunoprecipitation protocol 2.9.1.2
 After obtaining fragments of the desired size the cell suspension was diluted 10 times 
using ChIP dilution buffer (0.01% SDS, 1.1%Triton x-100, 1.2 mM EDTA, 16.7 mM Tris-HCL - 
pH 8.0, 16.7 mM NaCl, 1:100 Protease inhibitors). 10% of the diluted suspension was kept for 
Input, while the rest was used for antibody incubation and negative control. The Agarose beads 
were blocked overnight with BSA1% PBS 1x at 4
o
C with agitation. The next day after washing 
the beads with PBS three times, antibody (see table 2-4 for concentrations) was added in one of 
the tubes at the right concentration and the samples were incubated for 1 hr at 4
o
C on a rotating 
wheel. They were centrifuged briefly at 250 x g and 4
o
C. The supernatant containing the 
unbound DNA was discarded, while the pellet containing the antibody-DNA complexes were 
washed for 3-5 min on a rotating wheel with 1 ml of the following buffers: 2x Low Salt buffer 
(0,1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris/HCl - pH 8.0, 150 mM NaCl), 1x High 
Salt (0.1% SDS, 1.1% Triton X-100, 2 mM EDTA, 20 mM Tris/HCl - pH 8.0, 500 mM NaCl), 
2x ChIP dilution buffer (as described above), 3x TE buffer. All the buffers were kept on ice and 
the samples were centrifuged briefly (250 x g / 1 min / 4
o
C) between each wash. After the last 
wash, DNA was eluted with the addition of 200 μl of freshly prepared Elution buffer (1% SDS/ 
0.1 M NaHCO3) in each tube. In this step, the sample previously kept as “input”, was eluted as 
well. The suspension was incubated for 10 min at 65
o
C and then spun at 13,000 x g. The 
supernatant was carefully transferred to a new tube and the elution step was repeated. After that, 
400 μl of eluates were obtained. In each one of the tubes 18 μl of 5 M NaCl was added and the 
samples were incubated for 4-5 h at 65
o
C to reverse the DNA-protein crosslinks. Following this 
incubation step, 10 μl of 0.5 M EDTA, 20 μl of 1 M Tris/HCl - pH 6.8 and 1.5 μl of 14-22 mg/ml 
Proteinase K were added to the eluates and incubated for 1 hr at 45
o
C. After the incubation step, 
400 μl of phenol/chloroform (Fluka Biochemica) were added to each eluate. After 30 sec of 
vortexing the samples were centrifuged for 5min at 13,000 x g at 4
o
C. 1.5 μl of glycogen and 1 
ml of 100% ethanol were added to the samples and stored in -20
o
C overnight. The following day 
the samples were spun for 20 min at 13,000 x g at 4
o
C. Without disturbing the visible pellet, the 
supernatant was discarded and 1ml of 70% ethanol was added to each tube.  The samples were 
spun again under the same conditions as before and the supernatant was discarded. The samples 
were left to air-dry and then 20 μl of sterile ddH2O was added. The samples diluted in ddH2O 
were stored in -20
o
C.  
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 Chromatin Immunoprecipitation kit method. 2.9.1.3
Several kits are commercially available to assist with the immunoprecipitation of protein-
DNA complexes. The kit used for ChIP in our study was the Zymo Spin® DNA kit from (Zymo 
Research, USA). The samples were prepared, sonicated and handled following the protocol as 
described by the manufacturer. 
 Measurement of ChIP DNA concentration using the NanoDrop 3300 2.9.1.4
fluorospectrophotometer 
The concentration of DNA in ChIP samples was in the pico-scale and a special 
spectrophotometer was used to establish the concentration of DNA in our samples. This was the 
NanoDrop 3300 (Thermo Scientific). The Quant-iT™ PicoGreen® ds DNA assay kit was used 
according to the manufacturer’s instructions. 
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 Next Generation Sequencing (NGS) techniques 2.10
Next generation sequencing (NGS) techniques including ChIP- and RNA-seq, also known 
as high-throughput sequencing, are a rapidly advancing field of genome-wide research, used for 
genome wide gene expression profiling, transcription factor and histone modification research 
(Cullum et al., 2011, Johnson et al., 2007). 
In our study, we performed ChIP and RNA sequencing. The ChIP samples were generated 
with the Zymo Spin kit (Zymo Research) as described in 2.9.1.3 and the RNA samples were 
prepared as described in 2.6.1. 
Samples for both experiments were delivered to the genetics laboratory at University 
College London (UCL), under the supervision of Prof Mike Hubank. The library preparation and 
sequencing using the sequencing platforms from Illumina was performed at UCL and King’s 
College London. 
 Analysis of ChIP and RNA sequencing output data  2.10.1
The raw sequenced data from both ChIP and RNA-seq were received in FASTQ format 
(Cock et al., 2010). The bioinformatics analysis of both datasets was performed using a high 
performance computer (HPC) and the Galaxy bioinformatics tools organizing platform (Giardine 
et al., 2005, Goecks et al., 2010). 
 
 ChIP-sequencing data analysis 2.10.1.1
The raw sequenced data underwent initial quality control with the FASTQ Quality 
Trimmer tool from Galaxy. The Novoalign 3.2 tool was used to align the reads to the genome 
(Ruffalo et al., 2011) and the peak calling was done with the MACS2 algorithm from the Galaxy 
toolbox (Feng et al., 2012). The entries were filtered for p value lower or equal to 0.05, q value 
lower or equal to 0.4 and then the binding sites further form +/- 1000 from known genes were 
discarded.  
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The gene ontology analysis was performed using the Gene Ontology database (Ashburner 
et al., 2000, Harris et al., 2004), the database for annotation, visualization and integrated 
discovery (DAVID) (Huang da et al., 2009b) and the online enrichment analysis tool REViGO 
(Supek et al., 2011). Cytoscape (v3.2.1) was used to visualize and optically manipulate the 
ontology graphs (Shannon et al., 2003). The de novo discovery of binding motifs from the 
datasets was performed with use of the Multiple Em for Motif Elicitation (MEME) algorithm 
(Bailey et al., 2006). The visualization of the binding sites on human chromosomes was achieved 
using MATLAB installed on a workstation with multi-threading enabled (package: 
bioinfotoolbox MATLAB library v.R2012a).   
 RNA-sequencing data analysis 2.10.1.2
The FASTQ Quality Trimmer tool from Galaxy was used to discard the low quality 
reads. The Novoalign 3.2 tool was used to align the reads to the reference genome (human) and 
the raw counts were normalized using the Bam2fpkm tool form Galaxy. To discover the 
differentially expressed genes in our study and prepare the diagnostics plots we used the DESEQ 
toolkit. The ensuing lists of genes were filtered for p value (≤0.05) and q value (≤0.05). Gene 
ontology analysis as well as visualization of the findings on chromosomes was performed as 
described 2.10.1.1. 
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 Genome-wide analysis of CTCF binding in proliferating Chapter 3
and arrested 226LDM cells using ChIP-Seq  
 
 Introduction / Background 3.1
CTCF was initially discovered as a transcriptional repressor of the c-myc gene in chicken 
and mammalian cells (Filippova et al., 1996, Rasko et al., 2001). However, in following research 
studies, it became clear that repression was not the only function that CTCF was involved in. It is 
now known to be a transcriptional repressor, silencer and an activator, the only insulator known 
in mammals, the regulator of imprinting and X-chromosome inactivation, and as an architectural 
protein capable of mediating chromatin structure remodelling (Ohlsson et al., 2001, Holwerda 
and de Laat, 2013, Ong and Corces, 2014, Burcin et al., 1997, Hancock et al., 2007, Qi et al., 
2015).  
 CTCF binding 3.1.1
All functions attributed to CTCF can be exerted through specific, and at the same time 
divergent, DNA binding sites. While most DNA binding proteins have a consensus, a sequence 
they preferably bind to and only very rarely diverge from it, CTCF uses its 11 DNA binding zinc 
fingers in different combinations that allow it to bind to different motifs (Filippova et al., 1996). 
Recent studies of genome-wide CTCF distribution in different cells revealed tens of thousands 
CTCF binding sites in the genomes of these cells (Chen et al., 2012, Xie et al., 2007). Some 
specific motifs and sites are remarkably evolutionarily conserved among species, from 
Drosophila to man (Ni et al., 2012). However, CTCF binding capacity is dynamic resulting in 
thousands of unique binding sites even between cell lines originating from the same species. 
Moreover, it would appear that binding affinity decreases with uniqueness (Chen et al., 2012, 
Plasschaert et al., 2014).  
Mainly, but not exclusively, CTCF binds in the proximity of the transcription start site 
(TSS) of genes. The transcription of thousands of genes is  regulated by CTCF in this fashion, 
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but studies have also shown, or predicted, CTCF binding in non-coding regions, closed 
chromatin and areas far away from any gene (Chen et al., 2012). The mode of CTCF activity on 
the majority of these sites, if such exists, remains unclear. 
The overall number of known and predicted binding sites of CTCF across the genomes of 
15 different species has been estimated in the region of 15 million. Such extraordinary numbers 
lead to the creation of the CTCFBSDB (http://insulatordb.uthsc.edu/); a database designed to 
assist researchers in the field by collecting and making available all the binding sites of CTCF 
with useful information such as the exact location and experiment that led to its discovery 
(Ziebarth et al., 2013).  
The complexity of CTCF binding has been the focus of many studies, gene-by-gene in the 
past and genome-wide in the recent years due to the development of next generation sequencing 
(NGS). Chromatin immunoprecipitation (ChIP) is a method developed to explore DNA binding 
proteins, such as transcription factors and histones by enriching the fragments to which they 
bind. Coupled with massively parallel sequencing of the ensuing fragments (ChIP-seq), it is 
currently leading the way in research aimed to unravel the mechanisms underlying gene 
regulation. 
  ChIP-seq technique 3.1.2
ChIP sequencing can be broken down to three major parts: (1) Chromatin 
immunoprecipitation, (2) sequencing of the isolated fragments and (3) computational analysis of 
the sequenced data (figure 3-1) (Cullum et al., 2011, Nielsen and Mandrup, 2014).  
1. Chromatin Immunoprecipitation: Initially, all protein-DNA binding events are “locked 
in place” by chemical cross-linking, often using paraformaldehyde. The cells are then disrupted 
and sonicated, resulting in fragments of DNA ranging between 200-600bp. The fragments of 
interest – still in complex with the proteins – are immunoprecipitated using a specific ChIP-
grade antibody and finally after reversal of the cross-linking, the proteins are removed and the 
57 
 
 
sample contains the DNA fragments where the protein of interest was binding to at the time of 
cross-linking. 
2. Library preparation and sequencing: Following ChIP, library preparation includes size 
selection and amplification of the DNA fragments in each sample. The sequencing of the isolated 
fragment is performed by a high-throughput sequencing platform; the Mi-seq from Illumina and 
the 454 GS junior from Roche are among the most popular ones. Sequencing platforms have 
been compared in a number of studies, concluding that they essentially provide corresponding 
results (Quail et al., 2012, Loman et al., 2012). 
 3. Bioinformatics: The set of raw sequences corresponding to each fragment are stored in 
FASTQ format files (Cock et al., 2010) and several steps of computational analysis are required 
in order for information of biological value to be obtained from them.  
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Figure 3-1 Diagrammatic presentation of the steps involved in a ChIP-sequencing 
experiment 
The first step in a ChIP-sequencing experiment requires the immunoprecipitation of DNA 
fragments that the protein of interest binds to (1). This is achieved by cross-linking DNA with 
proteins, shearing of the DNA by sonication, selection of the fragments using the antibody of 
interest and then reversal of the cross-linking. At the end of this step, the sample will contain the 
DNA fragments that the protein of interest binds to. After chromatin immunoprecipitation, the 
samples are used to create sequencing libraries and the sequencing takes place in NGS 
platforms (2). The raw sequenced data must then be analyzed with bioinformatics tools and 
algorithms to elicit the biologically relevant information according to the experimental aims (3).  
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 Initially, the sequences (reads) are aligned/ mapped to the reference genome of choice, by 
identifying all the possible locations in the genome that match the reads – allowing only for 1-2 
mismatched base-pairs owing to single nucleotide polymorphisms (SNP) or small errors in the 
sequencing process.  
 After the reads have been mapped, the elimination of background signal is imperative as 
several of the previous steps can introduce artefacts, such as non-uniform DNA shearing during 
sonication or the non-specific binding of proteins other than the one of interest to the antibody 
used for immunoprecipitation. For this reason, control ChIP samples are usually prepared in 
advance. Controls can include sheared input DNA (input control) or a ChIP sample created 
without an antibody (mock control) or by using a non-specific antibody. All the reads found in 
the control sample are removed from the results in the sample of interest. The rationale behind 
this is that all the “background reads” are this way discarded while the remaining “true reads” 
correspond to the specific binding events of interest.  
Peak calling software is subsequently employed to scan across the genome and discover 
the areas where the true reads appear to show enrichment. These enrichment peaks correspond to 
the binding sites that were isolated during ChIP. Each one of the peaks is associated with the 
nearest gene and the ensuing list contains all the binding sites discovered for the protein of 
interest for this experiment. 
After these steps are completed, further analysis can be done depending on the 
experimental design, including comparison between different samples, retrieval of the top-
scoring binding motifs, or a study on the ontology relationships between the discovered genes.  
 Experimental Aims 3.2
Currently, all the existing information regarding the binding characteristics of CTCF has 
been mined from experiments on the main, non-modified CTCF isoform, which has a molecular 
weight of 130 kD (CTCF130). However, a highly PARylated CTCF isoform has also been 
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discovered. The molecular weight of this isoform is 180 kD (CTCF180) and it is the only 
isoform that can be found in healthy breast tissue (Docquier et al., 2009). There is at present no 
information regarding the binding characteristics of this isoform.   
This chapter will be aimed at the identifying the binding sites of CTCF in 226LDM cells, 
with special focus on the binding of CTCF180 and the genes it is implicated with in contrast with 
CTCF130. To achieve this, ChIP-seq experiments will be performed in two separate groups of 
226LDM cells.  
The first group will consist of control, proliferating cells which express both of the 
isoforms, while the second group will be chemically induced to stop proliferating. This 
treatment, with hydroxyurea and nocodazole, causes the depletion of CTCF130 and the 
expression of CTCF180 only. 
Both groups of cells will be used in ChIP experiments using a polyclonal antibody 
recognising all CTCF isoforms as well as a monoclonal antibody recognizing the CTFC130 only. 
Therefore, the 226LDM cell line model provides us with the unique opportunity to study the 
binding of this isoform, whereby overcoming the problem with the absence of a specific 
antibody against the CTCF180. 
Following ChIP, library preparation from the isolated DNA fragments will be performed at 
the University College London (UCL) and the sequencing of the enriched samples will take 
place at Kings College London using the Mi-seq platform from Illumina. The output data will be 
analyzed using the bioinformatics software organizing platform Galaxy among other specialized 
computational tools and algorithms (Giardine et al., 2005).  
The study will then be directed to identify the genes associated with either or both of the 
CTCF isoforms. Special interest will be cast upon CTCF180 binding characteristics as there is 
currently no known information regarding the function and features of this isoform in the 
existing literature. The top-scoring motifs for each isoform will be discovered and a comparison 
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will be run in order to obtain further information regarding the possible differences between the 
isoforms.   
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 Results 3.3
 Cell cycle blocking treatment 3.3.1
226LDM cells in the control condition express both CTCF isoforms, namely CTCF180 
and CTCF130. In order to manipulate the cells into expressing the 180kD CTCF isoform only, 
they were treated with hydroxyurea (HU) and nocodazole (NO), which block the cell cycle on 
the S and G2-M phase respectively.  
 Hydroxyurea is a useful tool for synchronizing asynchronous cell populations to the S 
phase of the mitotic cycle as it completely inhibits DNA replication (Sinclair, 1965, Yarbro, 
1992), while nocodazole, in concentrations on the nano-molar scale, is involved in rearranging 
the dynamics of the mitotic spindle (Jordan et al., 1992, Vasquez et al., 1997).  
Optimization of the effects of HU and NO treatment on the cells was performed by 
adjustments on parameters such as the incubation duration and the concentration of the 
chemicals. 24 and 48 hours of incubation with each and both of the two reagents were tested, 
while the concentrations ranged from 100 to 200 mM for HU and 500 to 1000 ng / ml for NO.  
The CTCF expression profiles of the cells that were attached to the bottom of the flask as 
well as the detached cells were analyzed by western blotting (data not shown). This experiment 
confirmed that the most favourable conditions for this treatment to be effective in the case of 
226LDM cells include a 24 hour-long incubation with 100 mM HU followed by 24 hours of 
incubation with 500 ng / ml of NO as described in materials and methods.  
In these conditions, the detached 226LDM cells (>79% viable according to Countess® 
automated cell counter from Life Sciences, USA) express the CTCF180 isoform while the 
CTCF130 disappears (figure 3-2). This complies with the parameters of the protocol described 
by Docquier et al. (2009). 
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Figure 3-2 Western blotting of the control and nocodazole/hydroxyurea treated 226LDM 
cells 
226LDM cells were cell-cycle arrested by addition of 100 mM hydroxyurea and 500 ng/ml 
nocodazole in their culturing medium. The treatment was administered as follows: After 24 
hours of incubation with hydroxyurea, the cells were incubated with fresh complete culturing 
medium for 1 hour at 37
o
C / 5% CO2. Nocodazole was added for another 24 hours after which 
the detached 226LDM cells were harvested and prepared for western blotting. The treated 
sample, as well a sample prepared from control (untreated) proliferating cells, were used for 
western blotting, probed with a polyclonal anti-CTCF antibody found to recognize both 
CTCF130 and CTCF180. The development of the signal was done with the UptiLight™ 
chemiluminescence substrate. Tubulin was used as a loading control.  
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 Immunoprecipitation of CTCF180 3.3.2
 As there is currently no available antibody specifically recognising CTCF180 and a ChIP 
experiment focusing on this isoform has not been performed before, a series of optimization 
experiments were conducted to assess whether the immunoprecipitation of this protein would be 
possible. Firstly, prior to ChIP, a protein immunoprecipitation (IP) experiment was performed 
using the treated cells. An IP involves the retrieval of a specific protein from a solution using an 
antibody raised against this protein. Both IP and ChIP techniques are based on the capacity of a 
protein to be immunoprecipitated by an antibody and therefore if one of the two experiments is 
successful, this can be an indication regarding the other. 
The polyclonal antibody was used to immunoprecipitate CTCF from lysed 226LDM cells 
(figure 3-3). This experiment revealed that the CTCF180 can be successfully 
immunoprecipitated by the polyclonal antibody. 
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Figure 3-3 Immunoprecipitation of CTCF in 226LDM cells using a polyclonal antibody 
226LDM cells were used in a single protein immunoprecipitation experiment to assess whether 
CTCF180 can be precipitated. The two isoforms are shown on the graph with black arrows. A 
no-antibody sample was used as control for the experiment. The visualization of the signal was 
performed using UptiLight™. 
CTCF       No antibody 
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 ChIP sample preparation and Shearing 3.3.3
The chromatin immunoprecipitation of CTCF from control and treated 226LDM cells was 
initially attempted following the protocol as described by Farrar et al. (2010), however the 
resulting DNA yield was insufficient for sequencing. To obtain the required amount of DNA we 
conducted the ChIP experiments using the Zymo-Spin™ ChIP Kit from Zymo Research (USA), 
following the manufacturer’s protocol. 
According to the experimental design of this study, a total of 16 ChIP samples were 
prepared (see table 3-1). For each of the two conditions, control and treatment, there were 4 ChIP 
samples produced in duplicates: (1) immunoprecipitated with the CTCF polyclonal antibody, (2) 
with the CTCF monoclonal antibody, (3) the histone (closed chromatin) antibody and (4) with 
no-antibody.  
The control (untreated) ChIP samples were obtained from two biological replicates, each 
equally distributed into 4 ChIP samples. For treated samples, due to low yield of cells after each 
treatment, several biological replicates were pooled together into two groups. From each of these 
groups, 4 ChIP samples were produced.  
The ChIP reactions of the 16 samples were completed with two experiments; 8 samples 
were prepared each time, and their duplicates were prepared in the second attempt (from table 
3-1: samples 1, 3, 5, 7, 9, 11, 13 and 15 were included in ChIP experiment #1, while 2, 4, 6, 8, 
10, 12, 14 and 16 in ChIP experiment no.2). 
Prior each of the two immunoprecipitation experiments, the samples were fragmented by 
sonication in order to obtain DNA lengths ranging between 200-400 bp (figure 3-4). 
The concentration of the DNA samples generated by ChIP was measured using the 
NanoDrop™ ND 3300 fluorospectrophotometer (Desjardins and Conklin, 2010) and the Quant-
iT™ PicoGreen® fluorescent dye kit from Invitrogen. 
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Table 3-1 Experimental design of the ChIP-Seq experiments using control and treated 
226LDM cells. The antibodies and their recognition molecules are indicated 
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Figure 3-4 Fragmentation of cross-linked chromatin in control and treated 226LDM 
samples 
Control and treated 226LDM cells were prepared as described previously. After cross-linking and 
prior to chromatin immunoprecipitation, the chromatin from both groups of cells was fragmented 
by sonication using the Bioruptor® from Diagenode. The samples were run on a 1% agarose gel 
to confirm that the lengths were between 200-400 bp. The GeneRuler™ 100 bp ladder from 
Thermo Scientific was used to estimate the size of the DNA fragments.   
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 Library preparation and sequencing 3.3.4
The obtained DNA samples were delivered to UCL for the preparation of the libraries and 
subsequently the sequencing of the enriched DNA fragments was performed at Kings College 
London using the HI-seq platform from Illumina.  
 Computational analysis 3.3.5
The raw sequenced data was acquired from UCL stored in FASTQ format files. The data 
underwent the initial quality control with the FAST Q quality trimmer tool from Galaxy and 
then the Novoalign 3.2 tool was used to align the reads to the human genome (Ruffalo et al., 
2011).  
For this analysis, the values of the ChIP samples for inactive chromatin were used as 
controls to remove the background noise. All reads that were common between the closed 
chromatin samples and the CTCF antibody samples were discarded, aiming to eliminate artefacts 
stemming from the shearing and other processes of the sample preparation, which would be 
common between them.  
After removing the background reads, peak calling was performed with the MACS2 
algorithm (Feng et al., 2012). The ensuing lists of peaks for each sample were filtered to discard 
the non-significant ones (only entries with p value ≤0.05 and q value >0.4 were kept) and the 
binding sites that were within 1000 bp upstream or downstream of a gene were used associated 
with their closest gene. At the end of this process, the genes associated with the binding sites for 
each of the samples in the control and treated cells were discovered and listed in tables. 
 Analysis of CTCF binding sites in 226LDM cells 3.3.6
The binding sites from the ChIP-Seq samples obtained from the control and treated 
226LDM cells using the monoclonal and polyclonal CTCF antibodies were then retrieved and 
analyzed. From the generated tables it was possible to compare the binding events between 
control and treated cells.  
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With the polyclonal antibody, 2051 sites were found in control 226LDM cells and only 64 
in the treated cells. Given the experimental design of this study, we suppose that the binding of 
the polyclonal CTCF in the treated cells can be attributed to CTCF180.  
Out of the 64 binding sites of CTCF180 in treated cells, 41 are common between the 
control and treated cell datasets for this antibody. This means that, judging from the binding of 
the polyclonal antibody, CTCF lost 2002 binding sites in the treated cells, retaining only 41 and 
gaining 23 new sites.  
Presumably, these 41 common sites would be bound by CTCF180 in the control cells as 
well, however further experiments would be required to prove this. The remaining 23 sites 
appear to be uniquely bound by CTCF180 in treated cells, with the exception of two genes 
(RBM15B and FXYD3) which are bound by CTCF130 in control cells.   
To produce a more stringent list of true targets, the false discovery rate (FDR)-adjusted p 
value (Q value) was used. The Q value implies the percentage of significant tests that would give 
a false positive (Benjamini and Hochberg, 1995). A Q value threshold of <0.4 was used. 
In table 3-2 and table 3-3 the transcript and gene IDs associated with each binding event 
discovered with the polyclonal CTCF in control cells are shown in order of declining Q value. 
Next, in table 3-4  the binding sites in treated cells is shown in color-coded format according to 
whether this site is uniquely bound by the polyclonal antibody in treated cells (white entries), or 
if it is also bound by CTCF in control cells (blue entries). 
The samples belonging to each of the colour-coded groups are shown next (table 3-5) 
featuring the description of each gene, when this is available. The descriptions were retrieved 
from the RefSeq project database (Pruitt et al., 2014) and the GeneCards® online database 
(Safran et al., 2010).   
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Table 3-2 Top 50 binding sites of the polyclonal CTCF antibody in control 226LDM cells 
Transcript ID 
Gene 
Symbol 
Chromo 
some 
Strand 
Distance 
from the 
TSS 
Q value 
1. MEAF6:NM_022756 MEAF6 chr1 - 0 0,309780 
2. GRM4:NM_001256809 GRM4 chr6 - 503 0,310226 
3. EGR1:NM_001964 EGR1 chr5 + 116 0,310449 
4. KCNA2:NM_001204269 KCNA2 chr1 - 467 0,311346 
5. EPHA61:NM_001278301 EPHA6 chr3 + 82 0,311496 
6. EPHA6:NM_001080448 EPHA6 chr3 + 82 0,311496 
7. PLEKHG5:NM_001042665 PLEKHG5 chr1 - 0 0,311646 
8. CNOT11:NM_017546 CNOT11 chr2 + 0 0,312022 
9. SIRT5:NM_012241 SIRT5 chr6 + -664 0,312399 
10. STAG2:NM_001042749 STAG2 chrX + 0 0,312475 
11. STAG2:NM_001282418 STAG2 chrX + 0 0,312475 
12. OCRL:NM_000276 OCRL chrX + 0 0,312929 
13. OCRL:NM_001587 OCRL chrX + 0 0,312929 
14. FIBP:NM_004214 FIBP chr11 - 0 0,313308 
15. FIBP:NM_198897 FIBP chr11 - 0 0,313308 
16. SPG11:NM_001160227 SPG11 chr15 - 0 0,313460 
17. SPG11:NM_025137 SPG11 chr15 - 0 0,313460 
18. IDE:NM_004969 IDE chr10 - 0 0,313764 
19. C15orf40:NM_001160113 C15orf40 chr15 - 530 0,314145 
20. C15orf40:NM_001160114 C15orf40 chr15 - 530 0,314145 
21. C15orf40:NM_001160115 C15orf40 chr15 - 530 0,314145 
22. C15orf40:NM_001160116 C15orf40 chr15 - 530 0,314145 
23. C15orf40:NM_144597 C15orf40 chr15 - 530 0,314145 
24. ARL6IP1:NM_015161 ARL6IP1 chr16 - 0 0,314988 
25. CD300LG:NM_001168322 CD300LG chr17 + 0 0,315295 
26. CD300LG:NM_001168323 CD300LG chr17 + 0 0,315295 
27. CD300LG:NM_001168324 CD300LG chr17 + 0 0,315295 
28. CD300LG:NM_145273 CD300LG chr17 + 0 0,315295 
29. ACSS2:NM_001242393 ACSS2 chr20 + 0 0,315680 
30. HOXC5:NM_018953 HOXC5 chr12 + 0 0,315757 
31. FAM83H:NM_198488 FAM83H chr8 - 156 0,315835 
32. ADRA2A:NM_000681 ADRA2A chr10 + 0 0,316221 
33. ZNF398:NM_020781 ZNF398 chr7 + 0 0,316608 
34. ZNF425:NM_001001661 ZNF425 chr7 - 0 0,316608 
35. DDT:NM_001084392 DDT chr22 - 0 0,316686 
36. SAMD5:NM_001030060 SAMD5 chr6 + 802 0,318404 
37. MTUS1:NM_020749 MTUS1 chr8 - -906 0,318561 
38. MYO7A:NM_000260 MYO7A chr11 + 0 0,318718 
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39. MYO7A:NM_001127179 MYO7A chr11 + 0 0,318718 
40. MYO7A:NM_001127180 MYO7A chr11 + 0 0,318718 
41. NUTM1:NM_001284292 NUTM1 chr15 + 0 0,319191 
42. NUTM1:NM_001284293 NUTM1 chr15 + 0 0,319191 
43. NUTM1:NM_175741 NUTM1 chr15 + 0 0,319191 
44. NOP10:NM_018648 NOP10 chr15 - 0 0,319191 
45. LPGAT1:NM_014873 LPGAT1 chr1 - 0 0,320379 
46. MESP1:NM_018670 MESP1 chr15 - 327 0,320538 
47. TBX1:NM_005992 TBX1 chr22 + 0 0,320936 
48. TBX1:NM_080646 TBX1 chr22 + 0 0,320936 
49. TBX1:NM_080647 TBX1 chr22 + 0 0,320936 
50. NARFL:NM_022493 NARFL chr16 - 0 0,321576 
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Table 3-3 Top 50 genes associated with CTCF in control 226LDM cells with descriptions 
Gene Symbol Description 
1. MEAF6 
This gene encodes a nuclear protein involved in transcriptional activation. The 
encoded protein may form a component of several different histone acetyltransferase 
complexes. There is a pseudogene for this gene on chromosome 2. Alternative 
splicing results in multiple transcript variants. 
2. GRM4 
L-glutamate is the major excitatory neurotransmitter in the central nervous system 
and activates both ionotropic and metabotropic glutamate receptors. Glutamatergic 
neurotransmission is involved in most aspects of normal brain function and can be 
perturbed in many neuropathologic conditions. The metabotropic glutamate 
receptors are a family of G protein-coupled receptors, which have been divided into 
3 groups on the basis of sequence homology, putative signal transduction 
mechanisms, and pharmacologic properties. Group I includes GRM1 and GRM5 and 
these receptors have been shown to activate phospholipase C. Group II includes 
GRM2 and GRM3 while Group III includes GRM4, GRM6, GRM7 and GRM8. 
Group II and III receptors are linked to the inhibition of the cyclic AMP cascade but 
differ in their agonist selectivities. Several transcript variants encoding different 
isoforms have been found for this gene.  
3. EGR1 
The protein encoded by this gene belongs to the EGR family of C2H2-type zinc-
finger proteins. It is a nuclear protein and functions as a transcriptional regulator. 
The products of target genes it activates are required for differentiation and 
mitogenesis. Studies suggest this is a cancer suppressor gene. 
4. KCNA2 
Potassium channels represent the most complex class of voltage-gated ion channels 
from both functional and structural standpoints. Their diverse functions include 
regulating neurotransmitter release, heart rate, insulin secretion, neuronal 
excitability, epithelial electrolyte transport, smooth muscle contraction, and cell 
volume. Four sequence-related potassium channel genes - shaker, shaw, shab, and 
shal - have been identified in Drosophila, and each has been shown to have human 
homolog(s). This gene encodes a member of the potassium channel, voltage-gated, 
shaker-related subfamily. This member contains six membrane-spanning domains 
with a shaker-type repeat in the fourth segment. It belongs to the delayed rectifier 
class, members of which allow nerve cells to efficiently repolarize following an 
action potential. The coding region of this gene is intronless, and the gene is 
clustered with genes KCNA3 and KCNA10 on chromosome 1. 
5. EPHA6 
EPHA6 (EPH Receptor A6) is a Protein Coding gene. Among its related pathways 
are EPHA forward signaling and G-protein signaling_RhoA regulation pathway. GO 
annotations related to this gene include ephrin receptor activity. An important 
paralog of this gene is EPHB3. 
6. PLEKHG5 
This gene encodes a protein that activates the nuclear factor kappa B (NFKB1) 
signaling pathway. Mutations in this gene are associated with autosomal recessive 
distal spinal muscular atrophy. Multiple transcript variants encoding different 
isoforms have been found for this gene. 
7. CNOT11 
CNOT11 (CCR4-NOT Transcription Complex, Subunit 11) is a Protein Coding 
gene. Among its related pathways are Gene Expression and Deadenylation-
dependent mRNA decay. 
8. SIRT5 
This gene encodes a member of the sirtuin family of proteins, homologs to the yeast 
Sir2 protein. Members of the sirtuin family are characterized by a sirtuin core 
domain and grouped into four classes. The functions of human sirtuins have not yet 
been determined; however, yeast sirtuin proteins are known to regulate epigenetic 
gene silencing and suppress recombination of rDNA. Studies suggest that the human 
sirtuins may function as intracellular regulatory proteins with mono-ADP-
ribosyltransferase activity. The protein encoded by this gene is included in class III 
of the sirtuin family. Alternative splicing of this gene results in multiple transcript 
variants. 
9. STAG2 
The protein encoded by this gene is a subunit of the cohesin complex, which 
regulates the separation of sister chromatids during cell division. Targeted 
inactivation of this gene results in chromatid cohesion defects and aneuploidy, 
suggesting that genetic disruption of cohesin is a cause of aneuploidy in human 
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cancer. Alternatively spliced transcript variants encoding different isoforms have 
been found for this gene.  
10. OCRL 
This gene encodes a phosphatase enzyme that is involved in actin polymerization 
and is found in the trans-Golgi network. Mutations in this gene cause 
oculocerebrorenal syndrome of Lowe and also Dent disease. 
11. FIBP 
Acidic fibroblast growth factor is mitogenic for a variety of different cell types and 
acts by stimulating mitogenesis or inducing morphological changes and 
differentiation. The FIBP protein is an intracellular protein that binds selectively to 
acidic fibroblast growth factor (aFGF). It is postulated that FIBP may be involved in 
the mitogenic action of aFGF. Two transcript variants encoding different isoforms 
have been found for this gene. 
12. SPG11 
The protein encoded by this gene is a potential transmembrane protein that is 
phosphorylated upon DNA damage. Defects in this gene are a cause of spastic 
paraplegia type 11 (SPG11). Multiple transcript variants encoding different isoforms 
have been found for this gene. 
13. IDE 
This gene encodes a zinc metallopeptidase that degrades intracellular insulin, and 
thereby terminates insulins activity, as well as participating in intercellular peptide 
signalling by degrading diverse peptides such as glucagon, amylin, bradykinin, and 
kallidin. The preferential affinity of this enzyme for insulin results in insulin-
mediated inhibition of the degradation of other peptides such as beta-amyloid. 
Deficiencies in this protein's function are associated with Alzheimer's disease and 
type 2 diabetes mellitus but mutations in this gene have not been shown to be 
causitive for these diseases. This protein localizes primarily to the cytoplasm but in 
some cell types localizes to the extracellular space, cell membrane, peroxisome, and 
mitochondrion. Alternative splicing results in multiple transcript variants encoding 
distinct isoforms. Additional transcript variants have been described but have not 
been experimentally verified. 
14. C15orf40 -No known function- 
15. ARL6IP1 
ARL6IP1 (ADP-Ribosylation Factor-Like 6 Interacting Protein 1) is a Protein 
Coding gene. Diseases associated with ARL6IP1 include spastic paraplegia 61, 
autosomal recessive. Among its related pathways are PAK 
Pathway and Phospholipase-C Pathway.  
16. CD300LG 
Members of the CD300 (see MIM 606786)-like (CD300L) family, such as 
CD300LG, are widely expressed on hematopoietic cells. All CD300L proteins are 
type I cell surface glycoproteins that contain a single immunoglobulin (Ig) V-like 
domain.[supplied by OMIM, Mar 2008] 
17. ACSS2 
This gene encodes a cytosolic enzyme that catalyzes the activation of acetate for use 
in lipid synthesis and energy generation. The protein acts as a monomer and 
produces acetyl-CoA from acetate in a reaction that requires ATP. Expression of this 
gene is regulated by sterol regulatory element-binding proteins, transcription factors 
that activate genes required for the synthesis of cholesterol and unsaturated fatty 
acids. Alternative splicing results in multiple transcript variants. 
18. HOXC5 
This gene belongs to the homeobox family of genes. The homeobox genes encode a 
highly conserved family of transcription factors that play an important role in 
morphogenesis in all multicellular organisms. Mammals possess four similar 
homeobox gene clusters, HOXA, HOXB, HOXC and HOXD, which are located on 
different chromosomes and consist of 9 to 11 genes arranged in tandem. This gene, 
HOXC5, is one of several homeobox HOXC genes located in a cluster on 
chromosome 12. Three genes, HOXC5, HOXC4 and HOXC6, share a 5' non-coding 
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exon. Transcripts may include the shared exon spliced to the gene-specific exons, or 
they may include only the gene-specific exons. Two alternatively spliced variants 
have been described for HOXC5. The transcript variant which includes the shared 
exon apparently doesn't encode a protein. The protein-coding transcript variant 
contains gene-specific exons only. 
19. FAM83H 
The protein encoded by this gene plays an important role in the structural 
development and calcification of tooth enamel. Defects in this gene are a cause of 
amelogenesis imperfecta type 3 (AI3). 
20. ADRA2A 
Alpha-2-adrenergic receptors are members of the G protein-coupled receptor 
superfamily. They include 3 highly homologous subtypes: alpha2A, alpha2B, and 
alpha2C. These receptors have a critical role in regulating neurotransmitter release 
from sympathetic nerves and from adrenergic neurons in the central nervous system. 
Studies in mouse revealed that both the alpha2A and alpha2C subtypes were 
required for normal presynaptic control of transmitter release from sympathetic 
nerves in the heart and from central noradrenergic neurons; the alpha2A subtype 
inhibited transmitter release at high stimulation frequencies, whereas the alpha2C 
subtype modulated neurotransmission at lower levels of nerve activity. This gene 
encodes alpha2A subtype and it contains no introns in either its coding or 
untranslated sequences. 
21. ZNF398 
This gene encodes a member of the Kruppel family of C2H2-type zinc-finger 
transcription factor proteins. The encoded protein acts as a transcriptional activator. 
Two transcript variants encoding distinct isoforms have been identified for this gene. 
Other transcript variants have been described, but their full length sequence has not 
been determined. 
22. ZNF425 
ZNF425 (Zinc Finger Protein 425) is a Protein Coding gene. Among its related 
pathways are Gene Expression and Gene Expression. An important paralog of this 
gene is ZNF786. The encoded protein acts as a transcriptional repressor. 
23. DDT 
D-dopachrome tautomerase converts D-dopachrome into 5,6-dihydroxyindole. The 
DDT gene is related to the migration inhibitory factor (MIF) in terms of sequence, 
enzyme activity, and gene structure. DDT and MIF are closely linked on 
chromosome 22. 
24. SAMD5 -No known function- 
25. MTUS1 
This gene encodes a protein which contains a C-terminal domain able to interact 
with the angiotension II (AT2) receptor and a large coiled-coil region allowing 
dimerization. Multiple alternatively spliced transcript variants encoding different 
isoforms have been found for this gene. One of the transcript variants has been 
shown to encode a mitochondrial protein that acts as a tumor suppressor and 
partcipates in AT2 signaling pathways. Other variants may encode nuclear or 
transmembrane proteins but it has not been determined whether they also participate 
in AT2 signaling pathways. 
26. MYO7A 
This gene is a member of the myosin gene family. Myosins are mechanochemical 
proteins characterized by the presence of a motor domain, an actin-binding domain, 
a neck domain that interacts with other proteins, and a tail domain that serves as an 
anchor. This gene encodes an unconventional myosin with a very short tail. Defects 
in this gene are associated with the mouse shaker-1 phenotype and the human Usher 
syndrome 1B which are characterized by deafness, reduced vestibular function, and 
(in human) retinal degeneration. Alternative splicing results in multiple transcript 
variants. 
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27. NUTM1 
NUTM1 (NUT Midline Carcinoma, Family Member 1) is a Protein Coding gene. 
Among its related pathways are Chromatin Regulation / Acetylation. An important 
paralog of this gene isNUTM2B. 
28. NOP10 
This gene is a member of the H/ACA snoRNPs (small nucleolar ribonucleoproteins) 
gene family. snoRNPs are involved in various aspects of rRNA processing and 
modification and have been classified into two families: C/D and H/ACA. The 
H/ACA snoRNPs also include the DKC1, NOLA1 and NOLA2 proteins. These four 
H/ACA snoRNP proteins localize to the dense fibrillar components of nucleoli and 
to coiled (Cajal) bodies in the nucleus. Both 18S rRNA production and rRNA 
pseudouridylation are impaired if any one of the four proteins is depleted. The four 
H/ACA snoRNP proteins are also components of the telomerase complex. This gene 
encodes a protein related to Saccharomyces cerevisiae Nop10p.  
29. LPGAT1 
Acyl-CoA:lysophosphatidylglycerol (LPG) acyltransferase catalyzes the reacylation 
of LPG to phosphatidylglycerol, a membrane phospholipid that is an important 
precursor for the synthesis of cardiolipin [supplied by OMIM, Mar 2008] 
30. MESP1 
MESP1 (Mesoderm Posterior Basic Helix-Loop-Helix Transcription Factor 1) is a 
Protein Coding gene. Diseases associated with MESP1 include spondylocostal 
dysostosis. Among its related pathways are Cardiac Progenitor Differentiation. GO 
annotations related to this gene include sequence-specific DNA binding transcription 
factor activity and protein dimerization activity. An important paralog of this gene 
is MSGN1. 
31. TBX1 
This gene is a member of a phylogenetically conserved family of genes that share a 
common DNA-binding domain, the T-box. T-box genes encode transcription factors 
involved in the regulation of developmental processes. This gene product shares 
98% amino acid sequence identity with the mouse ortholog. DiGeorge syndrome 
(DGS)/velocardiofacial syndrome (VCFS), a common congenital disorder 
characterized by neural-crest-related developmental defects, has been associated 
with deletions of chromosome 22q11.2, where this gene has been mapped. Studies 
using mouse models of DiGeorge syndrome suggest a major role for this gene in the 
molecular etiology of DGS/VCFS. Several alternatively spliced transcript variants 
encoding different isoforms have been described for this gene. 
32. NARFL 
NARFL (Nuclear Prelamin A Recognition Factor-Like) is a Protein Coding gene. 
Diseases associated with NARFL include pertussis. Among its related pathways 
are Metabolism andCytosolic Iron-sulfur Cluster Assembly. GO annotations related 
to this gene include 4 iron, 4 sulfur cluster binding. An important paralog of this 
gene is NARF. 
33. NTRK2 
This gene encodes a member of the neurotrophic tyrosine receptor kinase (NTRK) 
family. This kinase is a membrane-bound receptor that, upon neurotrophin binding, 
phosphorylates itself and members of the MAPK pathway. Signalling through this 
kinase leads to cell differentiation. Mutations in this gene have been associated with 
obesity and mood disorders. Alternative splicing results in multiple transcript 
variants. 
34. KCTD15 
KCTD15 (Potassium Channel Tetramerization Domain Containing 15) is a Protein 
Coding gene. Among its related pathways are Activation of cAMP-Dependent 
PKA and Activation of cAMP-Dependent PKA. An important paralog of this gene 
is KCTD11. During embryonic development, interferes with neural crest formation 
(By similarity). Inhibits AP2 transcriptional activity by interaction with its activation 
domain. 
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35. SNX19 
SNX19 (Sorting Nexin 19) is a Protein Coding gene. GO annotations related to this 
gene include phosphatidylinositol binding. 
36. MYOM3 
MYOM3 (Myomesin 3) is a Protein Coding gene. GO annotations related to this 
gene include protein homodimerization activity. An important paralog of this gene 
is MYBPC2. 
37. OLFM1 
This gene product shares extensive sequence similarity with the rat neuronal 
olfactomedin-related ER localized protein. While the exact function of the encoded 
protein is not known, its abundant expression in brain suggests that it may have an 
essential role in nerve tissue. Several alternatively spliced transcripts encoding 
different isoforms have been found for this gene. 
38. PVRL1 
This gene encodes an adhesion protein that plays a role in the organization of 
adherens junctions and tight junctions in epithelial and endothelial cells. The protein 
is a calcium(2+)-independent cell-cell adhesion molecule that belongs to the 
immunoglobulin superfamily and has 3 extracellular immunoglobulin-like loops, a 
single transmembrane domain (in some isoforms), and a cytoplasmic region. This 
protein acts as a receptor for glycoprotein D (gD) of herpes simplex viruses 1 and 2 
(HSV-1, HSV-2), and pseudorabies virus (PRV) and mediates viral entry into 
epithelial and neuronal cells. Mutations in this gene cause cleft lip and 
palate/ectodermal dysplasia 1 syndrome (CLPED1) as well as non-syndromic cleft 
lip with or without cleft palate (CL/P). Alternative splicing results in multiple 
transcript variants encoding proteins with distinct C-termini. 
39. CLUL1 -No known function- 
40. GNAI2 
The protein encoded by this gene is an alpha subunit of guanine nucleotide binding 
proteins (G proteins). The encoded protein contains the guanine nucleotide binding 
site and is involved in the hormonal regulation of adenylate cyclase. Several 
transcript variants encoding different isoforms have been found for this gene. 
41. TMTC2 -No known function- 
42. KMT2A 
This gene encodes a transcriptional coactivator that plays an essential role in 
regulating gene expression during early development and hematopoiesis. The 
encoded protein contains multiple conserved functional domains. One of these 
domains, the SET domain, is responsible for its histone H3 lysine 4 (H3K4) 
methyltransferase activity which mediates chromatin modifications associated with 
epigenetic transcriptional activation. This protein is processed by the enzyme 
Taspase 1 into two fragments, MLL-C and MLL-N. These fragments reassociate and 
further assemble into different multiprotein complexes that regulate the transcription 
of specific target genes, including many of the HOX genes. Multiple chromosomal 
translocations involving this gene are the cause of certain acute lymphoid leukemias 
and acute myeloid leukemias. Alternate splicing results in multiple transcript 
variants. 
43. PPIF 
The protein encoded by this gene is a member of the peptidyl-prolyl cis-trans 
isomerase (PPIase) family. PPIases catalyze the cis-trans isomerization of proline 
imidic peptide bonds in oligopeptides and accelerate the folding of proteins. This 
protein is part of the mitochondrial permeability transition pore in the inner 
mitochondrial membrane. Activation of this pore is thought to be involved in the 
induction of apoptotic and necrotic cell death. 
44. PIGO 
This gene encodes a protein that is involved in glycosylphosphatidylinositol (GPI)-
anchor biosynthesis. The GPI-anchor is a glycolipid which contains three mannose 
molecules in its core backbone. The GPI-anchor is found on many blood cells and 
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serves to anchor proteins to the cell surface. This protein is involved in the transfer 
of ethanolaminephosphate (EtNP) to the third mannose in GPI. At least three 
alternatively spliced transcripts encoding two distinct isoforms have been found for 
this gene. 
45. PEX5 
The product of this gene binds to the C-terminal PTS1-type tripeptide peroxisomal 
targeting signal (SKL-type) and plays an essential role in peroxisomal protein 
import. Peroxins (PEXs) are proteins that are essential for the assembly of functional 
peroxisomes. The peroxisome biogenesis disorders (PBDs) are a group of 
genetically heterogeneous autosomal recessive, lethal diseases characterized by 
multiple defects in peroxisome function. The peroxisomal biogenesis disorders are a 
heterogeneous group with at least 14 complementation groups and with more than 1 
phenotype being observed in cases falling into particular complementation groups. 
Although the clinical features of PBD patients vary, cells from all PBD patients 
exhibit a defect in the import of one or more classes of peroxisomal matrix proteins 
into the organelle. Defects in this gene are a cause of neonatal adrenoleukodystrophy 
(NALD), a cause of Zellweger syndrome (ZWS) as well as may be a cause of 
infantile Refsum disease (IRD). Alternatively spliced transcript variants encoding 
different isoforms have been identified. 
46. LRP10 
LRP10 (Low Density Lipoprotein Receptor-Related Protein 10) is a Protein Coding 
gene. Among its related pathways are Signaling by GPCR and Disease. An 
important paralog of this gene is LRP3. 
47. SMIM13 -No known function- 
48. RAB3IP 
RAB3IP (RAB3A Interacting Protein) is a Protein Coding gene. GO annotations 
related to this gene include Rab guanyl-nucleotide exchange factor activity. An 
important paralog of this gene is RAB3IL1. 
49. TTLL12 -No known function- 
50. SEC24B 
The protein encoded by this gene is a member of the SEC24 subfamily of the 
SEC23/SEC24 family, which is involved in vesicle trafficking. The encoded protein 
has similarity to yeast Sec24p component of COPII. COPII is the coat protein 
complex responsible for vesicle budding from the ER. The role of this gene product 
is implicated in the shaping of the vesicle, and also in cargo selection and 
concentration. Two transcript variants encoding different isoforms have been found 
for this gene. 
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Table 3-4 Binding sites of the polyclonal CTCF antibody in treated 226LDM cells: white 
entry, site is uniquely bound by the polyclonal antibody in treated cells; blue entries, the site 
is also bound by CTCF in control cells 
Transcript ID 
Gene 
Symbol 
Chromo 
some 
Strand Distance from the TSS Q value 
S100A13:NM_001024213 S100A13 chr1 - 0 0,382065 
S100A13:NM_001024212 S100A13 chr1 - 0 0,384789 
S100A1:NM_006271 S100A1 chr1 + 0 0,384789 
CISD1:NM_018464 CISD1 chr10 + -615 0,384789 
SGPL1:NM_003901 SGPL1 chr10 + 0 0,386166 
TCTN3:NM_001143973 TCTN3 chr10 - 0 0,393198 
 
Table 3-5 Genes associated uniquely with CTCF180 in treated 226LDM cells and genes 
associated with CTCF180 in treated 226LDM cells but also discovered in control cells; with 
descriptions 
Gene Symbol Description 
CISD1 
This gene encodes a protein with a CDGSH iron-sulfur domain and has been shown to 
bind a redox-active [2Fe-2S] cluster. The encoded protein has been localized to the outer 
membrane of mitochondria and is thought to play a role in regulation of oxidation. Genes 
encoding similar proteins are located on chromosomes 4 and 17, and a pseudogene of this 
gene is located on chromosome 2. 
 
 
S100A13 
The protein encoded by this gene is a member of the S100 family of proteins containing 2 
EF-hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or 
nucleus of a wide range of cells, and involved in the regulation of a number of cellular 
processes such as cell cycle progression and differentiation. S100 genes include at least 13 
members which are located as a cluster on chromosome 1q21. This protein is widely 
expressed in various types of tissues with a high expression level in thyroid gland. In 
smooth muscle cells, this protein co-expresses with other family members in the nucleus 
and in stress fibers, suggesting diverse functions in signal transduction. Multiple 
alternatively spliced transcript variants encoding the same protein have been found for this 
gene. 
S100A1 
The protein encoded by this gene is a member of the S100 family of proteins containing 2 
EF-hand calcium-binding motifs. This protein may function in stimulation of Ca2+-
induced Ca2+ release, inhibition of microtubule assembly, and inhibition of protein kinase 
C-mediated phosphorylation. Reduced expression of this protein has been implicatedin 
cardiomyopathies. 
SGPL1 -No known function- 
TCTN3 
This gene encodes a member of the tectonic gene family which functions in Hedgehog 
signal transduction and development of the neural tube. Mutations in this gene have been 
associated with Orofaciodigital Syndrome IV and Joubert Syndrom 18. Alternatively 
spliced transcript variants encoding multiple isoforms have been observed for this gene. 
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 Gene Ontology analysis 3.3.6.1
To further compare the characteristics of the CTCF occupancies in samples obtained with 
the polyclonal CTCF antibodies (“pan”) in control and treated cells and in order to gain an 
understanding of the biological functions of CTCF in each case, a gene ontology analysis was 
performed.  
Gene Ontology (GO) is based on universal annotation of genes with one or more GO 
terms according to the processes that it is involved. The GO terms can be specific or broad and 
they are structured in a parent-child manner, portraying the relationships between functions 
(Ashburner et al., 2000, Harris et al., 2004, Gene Ontology, 2008). 
Gene Ontology annotations for the binding sites of the polyclonal CTCF in control and 
treated cells were retrieved form the gene ontology project database, the enrichment analysis was 
performed by DAVID functional annotation tool (Huang da et al., 2009b, Huang da et al., 
2009a). Based on this analysis, in control cells the genes bound by CTCF are mostly involved in 
cellular protein localization, intracellular transport, membrane organization and neuron 
differentiation and development. On the other hand, the genes bound in the control cells are 
involved in cell cycle and differentiation (S100A13) and the hedgehog pathway (TCTN3). The 
set of proteins involved in the hedgehog pathway, which is mostly set in motion during 
embryogenesis, have also been linked with cancer and in particular with basal cell carcinomas 
(Rubin and de Sauvage, 2006, Von Hoff et al., 2009).  
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 Motif search 3.3.6.2
One more method of analysing the characteristics of CTCF180 binding involves the 
analysis of the motifs to which it binds. The motifs corresponding to the top scoring peaks from 
the ChIP-seq analysis were entered into the motif finding algorithm MEME (Multiple EM for 
Motif Elicitation) (Bailey et al., 2006). The algorithm identifies shared motifs in a dataset of 
sequences and with statistical modelling it produces visuals of the motifs along with occurrence 
number and e-value. E-value expresses the “expected frequency” of random alignments of the 
same width as our motif that would generate the same or higher entropy score. Similarly with p-
value, a motif scored with a low e-value is predicted more confidently than one with a higher e-
value (Nagarajan et al., 2006).   
A comparison between the lists of top 10 scoring motifs representing the binding events 
taking place within 1000 bp upstream or downstream of gene promoters in control and treated 
cells reveals divergent binding characteristics for CTCF in control and treated cells. 
The most conserved and well documented consensus motif of CTCF is listed first in the 
control cells but fourth in the treated. There are many factors that can affect this list, including 
motif enrichment due to interaction with another protein or complex instead of direct binding to 
DNA. However the change in the list and the introduction of new motifs in it is an additional 
indication that the CTCF180 binding profile can be divergent from that of CTCF130.  
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Figure 3-5 Top 10 binding motifs of CTCF discovered by ChIP with the polyclonal CTCF antibody in control 226LDM cells 
Control 226LDM cells were used to conduct a ChIP-seq experiment using the polyclonal CTCF antibody which recognizes both CTCF130 and 
CTCF180 isoforms. Following bioinformatics analysis the top peaks representing the binding events were entered in the MEME algorithm for de 
novo discovery of binding motifs. The top ten discovered motifs and the frequency of their occurrence in our datasets are listed above in order of 
decreasing e-value. The reverse complement motifs are shown beside each motif.   
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Figure 3-6 Top 10 binding motifs of CTCF discovered by ChIP with the polyclonal CTCF antibody 
in treated 226LDM cells 
226LDM cells treated with hydroxyurea and nocodazole were used to conduct a ChIP-seq experiment 
using the polyclonal CTCF antibody which recognizes both CTCF130 and CTCF180 isoforms. Following 
bioinformatics analysis the top peaks representing the binding events were entered in the MEME 
algorithm for de novo discovery of binding motifs. The top ten discovered motifs and the frequency of 
their occurrence in our datasets are listed above in order of decreasing e-value. The reverse complement 
motifs are shown beside each motif.   
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 Discussion 3.4
The aim of this chapter was to identify and analyze the binding sites of CTCF in 226LDM 
cells, with special focus on the binding of CTCF180. To achieve this, a cell line model was 
generated comprised of two populations of 226LDM cells.  The first consisted of proliferating 
cells (control), which normally express both known CTCF isoforms, namely CTCF130 and 
CTCF180. The second group was exposed to controlled concentrations of hydroxyurea and 
nocodazole leading to a cell-cycle block at the G2-M stage. This treatment causes the 
disappearance of CTCF130 in 226LDM cells, whereas CTCF180 remains. 
In the absence of a specific anti-CTCF180 antibody, this model makes the study of the 
binding for this isoform possible for the first time. Two ChIP-grade CTCF antibodies were at our 
disposal for this experiment; a polyclonal CTCF antibody recognizing both CTCF130 and 
CTCF180 and a monoclonal antibody recognizing CTCF130 only.  
In our initial experiments, CTCF180 was successfully immunoprecipitated with the 
polyclonal antibody, which indicated that this antibody could be used for ChIP assays. The 
ChIP-DNA fragments obtained with this antibody (precipitating CTCF130 and CTCF180) and 
also the monoclonal antibody (precipitating CTCF130) were sequenced by a next generation 
sequencing methods and, subsequently, a bioinformatics analysis was performed using the raw 
output data. The analysis generated lists of the annotated regions associated with the CTCF 
binding sites discovered in each sample.  
Taking into account the design of these experiments, the binding events discovered in the 
treated cells by the polyclonal antibody are presumably attributed to CTCF180. This list, 
although short, is the first evidence of CTCF180 binding and can be a stepping stone to future 
research of the binding profile of this isoform and its characteristics, for example in normal 
breast tissues where it is present as a sole isoform (Docquier et al., 2009). 
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It should be noted that experimental validation of these findings has not been conducted in 
this study due to time limitations. It will be a necessary step in the follow up investigation to 
ensure the accuracy of the data. Such validation would require real-time PCR assays using the 
ChIP materials from the control and treated cells obtained as described in this Chapter to confirm 
specific binding of CTCF180 and CTCF130 to specific targets identified in the ChIP-Seq 
analyses. 
Moreover, for this study the ChIP background-reads were eliminated using the closed 
chromatin reads as control at the peak calling stage of the analysis. At this stage the decision was 
made to limit the discovered data to open chromatin binding sites, however it is known that 
CTCF can bind to chromatin in closed conformation, and therefore analysis including these 
regions should be performed. This could be accomplished using the no-antibody ChIP samples 
as controls. Comparing the outputs from the two pipelines would strengthen the robustness of the 
binding sites in open chromatin and provide new information about the closed chromatin binding 
events.  
Furthermore, one of the most important factors contributing to ChIP-seq efficiency and 
quality is the ChIP-grade antibodies used to immunoprecipitate the protein of interest. In our 
investigation two ChIP-grade antibodies were used, a polyclonal and a monoclonal. The 
difference in the performance of the two antibodies was greater than originally expected; with 
the polyclonal over 2000 binding sites where discovered in the control cells, while with the 
monoclonal the number was lower, at 280. Such great number variation renders the comparison 
between the results from the two antibodies inadequately informative. Another antibody, specific 
for recognizing CTCF130, could solve this issue. Without a doubt, the production of a 
CTCF180-specific antibody would also enhance the current experimental framework. 
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It is worth highlighting that although we hypothesize that the binding sites obtained by the 
polyclonal antibody in treated cells are linked to CTCF180, these may not be the same sites that 
CTCF180 would bind to in control cells. Given the exposure to treatment we anticipate that the 
need for gene regulation changes and therefore the binding sites as well as the motifs would be 
affected accordingly.  
Additionally, another possibility must be considered, that during ChIP some of the 
CTCF180 molecules could lose their PARylation mark. PARylation is known to be a dynamic 
procedure and the circumstances surrounding the switch between isoforms are currently obscure. 
This would account for the small number of binding sites in treated cells discovered by the 
monoclonal CTCF antibody. 
What is more, one of the limitations that come with ChIP experiments is that it is not 
possible to distinguish whether a DNA fragment is immunoprecipitated due to direct contact of 
the protein to the binding site or if the protein of interest is there as part of a complex with 
another protein or proteins. In the latter situation, a binding site would be discovered in the ChIP 
sample of our protein of interest; however it would not be a true binding site for it.  
All these limitations emphasize the argument for data validation; however they do not 
decrease the value of this study as the first attempt in exploring CTCF180 DNA binding.  
The wealth of data that has been generated by this experiment has been vast and many 
more steps could be made to exhaust all avenues of research. Firstly, the discovered binding sites 
could be compared to those retrieved from preceding studies to determine whether any 
previously unknown sites were discovered in our experiments. Similarly, this could be applied to 
the discovered binding motifs as well. The motif search could be expanded to regions outside the 
promoters as well to assess whether these change. This could help to associate specific motifs 
with transcription on regulation or other functions.  
87 
 
 
Finally, the binding of CTCF alone does not provide any information about how or 
whether it regulates a gene. A combination of ChIP-seq with RNA-seq can provide more 
information about whether the binding of CTCF or, equally the loss of binding, affects the 
expression levels of a gene from one condition to the other. 
In the following chapter, the isolation and sequencing of total RNA from control and 
treated 226LDM cells will be discussed and eventually, in chapter 5, an intersection of the two 
experiments will be explored. 
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 Genome-wide gene expression analysis in proliferating Chapter 4
and arrested 226LDM cells using RNA-Seq  
 
 Introduction / Background 4.1
RNA is an important molecule which performs a wide range of molecular functions in 
various biological systems. The full set of RNA transcripts of a cell is composed of, in order of 
contribution, ribosomal (rRNA), transfer (tRNA), messenger (mRNA), as well as intronic and 
non-coding RNA (ncRNA) (Lindberg and Lundeberg, 2010). The field of study focused on the 
exploration of these transcripts and how they change under certain circumstances or 
developmental changes is called transcriptomics (Hine, 2008). 
The fundamental target of transcriptomics is to identify and characterize the RNA contents 
of cells in various developmental stages and physiological/ pathological conditions, and 
ultimately to understand their function.  
More and more evidence of the treasure of information that could be mined from RNA 
transcripts was discovered with the development of experimental techniques such as real-time 
PCR and, subsequently, with the development of gene expression microarrays (Valasek and 
Repa, 2005, Brown and Botstein, 1999).  
However, it was the recent development of massively parallel sequencing platforms that 
admittedly revolutionized the field and became the springboard for unprecedented progress. 
RNA sequencing (RNA-seq) is a Next Generation Sequencing (NGS) method used to study the 
complexity of the transcriptome and it offers a better chance of understanding the role of the its 
constituents as well as their role in development and disease (Wang et al., 2009, Marguerat and 
Bahler, 2010, Mutz et al., 2013). RNA-seq has a clear advantage over its predecessors as it holds 
the benefit of being more practical (inexpensive, rapid, high-throughput) while at the same time 
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offering higher sensitivity, quantitative results and the option of different types of analyses 
(Marioni et al., 2008, Mutz et al., 2013). 
Published reviews give a comprehensive description of the steps that are required in order 
to complete an RNA sequencing experiment (Wang et al., 2009, Mutz et al., 2013). The three 
most important segments include, firstly, the RNA isolation and library preparation; secondly, 
the sequencing of the samples by a specialized platform and, finally, the bioinformatics analysis 
of the output data (figure 4-1). 
Initially for the library preparation, the isolated RNA samples are fragmented and 
converted to cDNA. After ligation to NGS-specific adapters, the samples can be amplified by 
PCR prior to sequencing on a high-throughput platform such as Illumina. The sequencing event 
generates millions of short reads from both ends of each cDNA fragment (for the “paired-end” 
method).  
As discussed by Voelkerding et al. (2009), Liu et al. (2012) and (Fox et al., 2014), the 
main companies that supply NGS platforms presently are Illumina, Roche, PacBio and Life 
Sciences.  Despite engineering differences and variations in the chemical compositions of 
consumables, they follow a comparable paradigm, in that short and clonally amplified DNA is 
sequenced in a massively paralleled manner.  
The datasets that are generated in an RNA-seq experiment are extremely large and 
complex and the choice of the appropriate analysis methods is crucial to correctly interpret the 
data. Although several methods and variations have been devised and a number of software tools 
have been created to accommodate them, the main steps involved in the procedure remain the 
same. 
The raw sequencing data come in the form of FASTQ files that include the nucleotide 
sequence of each short read and quality score for each position. These reads are mapped on the 
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reference transcriptome and using the appropriate tools, the mapped data are counted and 
normalized and the gene expression is measured, leading to a list of genes with associated p-
values and fold changes. The majority of studies using the RNA-seq approach aim to explore the 
differential expression (DE) of genes between wild type and mutant or untreated and treated 
conditions. These lists can then be studied in parallel with ChIP-seq or other proteomics data to 
get a biological insight on the results (Oshlack et al., 2010, Marguerat and Bahler, 2010). 
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 Figure 4-1 Overview of the steps involved in an RNA sequence experiment 
An RNA-seq experiment consists of three major steps. Firstly, the library preparation from 
isolated purified RNA. Then, the sequencing takes place with aid from specialized sequencing 
platforms and lastly, the raw output data is analyzed with bioinformatics tools. The analysis can 
focus on events such as differential expression, non-coding RNA and splicing events. 
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Differential expression between two biological systems has been the main focus of most 
RNA-seq studies as it offers the opportunity to gain further insight on the interconnection 
between the transcriptome and phenotype. However, there is so much more information that   
could be mined from a specially designed RNA-seq experiment, including transcript splicing, 
epigenetic modifications, chromatin structure variation and evolutionary development 
(Voelkerding et al., 2009). RNA-seq has emerged also as a means of detecting molecular 
mutations or mutation patterns that could be responsible for initiating cancer or other diseases 
(Costa et al., 2013, Wei et al., 2014).  
Recent explorations of the genome using modern technologies have advanced our 
knowledge and understanding of non-coding RNA (ncRNA) and its biological role. NcRNA 
includes sequences of transcribed RNA that are not translated into proteins and their function 
remains largely unspecified. These transcripts can be divided in two categories based on an 
arbitrary size threshold (200 nucleotides), with the shorter ones, especially miRNA, capturing 
most of the interest due to its implication in numerous biological processes. However, long non-
coding RNA is also emerging as an important factor in gene expression and more (Huntzinger 
and Izaurralde, 2011, Nagano and Fraser, 2011). 
 Experimental Aims 4.2
The aim of this chapter is to explore the gene expression profile of 226LDM cells and to 
compare the differences in expression between two groups, namely control 226LDM cells and 
cell cycle arrested cells. The primary aim is to obtain a list of the ranked genes whose expression 
is affected by the cell-cycle cessation. The secondary aim of this Chapter is to record the long 
non-coding RNA sequences that are affected by this change and which could be later on 
exploited in further studies.  
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To block cell cycle, the 226LDM cells will be treated as described in chapter 2, with the 
addition of hydroxyurea (Hu) and nocodazole (No). RNA will be then isolated from both groups 
of cells ( i.e. control and treated) and, after the quality control, the  RNA samples in triplicates-
will be sequenced at the University College London (UCL).  
The bioinformatics analysis of the raw data will be conducted using a high performance 
computer (HPC) and the Galaxy server, which is a bioinformatics software management system 
in a click-and-point environment. Following the analysis pipeline, the raw output files will be 
aligned and mapped to the human genome, the read counts will be normalized and the DESEQ 
package will be employed to measure differential expression (DE) (Anders and Huber, 2010). 
From the obtained results, the top up-regulated and down-regulated genes will be identified and 
Gene Ontology analysis on them will be performed. Furthermore, the analysis will be repeated 
focusing on the long non-coding RNA transcripts.  
This DE study is interesting on its own due to the richness of data that comes with it as 
well as the fact that, to our knowledge, 226LDM cells have never been used in RNA-seq 
experiments previously. In the context of the current study, these data will be linked to the ChIP-
seq data described in chapter 3.  
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 Results 4.3
 Cell cycle blocking treatment 4.3.1
In these experiments, 226LDM cells were initially grown in culture flasks and treated with 
100 mM hydroxyurea and 500ng / ml nocodazole, as described in chapter 2. After treatment, the 
detached treated cells as well as control 226LDM cells were harvested for sample preparation. 
Three biological replicates were prepared for each condition to ensure the reliability of the 
results interpretation. The success of the treatment for each replicate was confirmed by western 
blotting where control cells exhibited expression of both CTCF isoforms, while all treated 
samples showed no presence of CTCF130 (figure 4-2). 
 RNA isolation and quality control 4.3.2
The isolation of total RNA from the 6 samples was done following the protocol from 
Trizol®. The samples were run on a 1% agarose gel stained with ethidium bromide (EtBr) in 
order to test the quality of the RNA. Two distinct bands representing the 28S and 18S rRNAs 
were visible indicating that the integrity of the RNA was high (figure 4-3). 
The concentration and purity of the samples were measured with the NanoDrop ND-1000 
spectrophotometer. The 260/280 (RNA/ protein) absorbance ratios varied between 1.86 and 1.96 
while they were between 1.64 and 1.89 for the 260/230 (RNA/ contaminants) (see table 4-1 for 
values). Subsequently, integrity control was performed using the Agilent 2100 Bioanalyzer 
where clear and distinct 18S and 28S bands representing ribosomal RNA were present in all the 
samples (figure 4-4). Upon completion of the quality control the samples were delivered to UCL 
for library preparation and sequencing. 
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Figure 4-2 Western blotting using lysates from 226LDM cells after treatment with 
Hydroxyurea and Nocodazole 
226LDM cells were treated with 100 mM hydroxyurea for 24 hours and then 500 ng /ml 
nocodazole for another 24 hours. Following treatment the detached cells were harvested and 
used to prepare samples for western blotting. A polyclonal antibody recognizing both CTCF 
isoforms was used for the experiment. Each isoform can be seen on the image with arrows. 
The visualization of the signal was done with use of the Fusion FX7 and tubulin was used as a 
loading control. 
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Table 4-1 Concentrations and absorbance ratios of RNA samples measured with the 
NanoDrop ND-1000. 
Sample 
Number 
Concentration 
Provided to UCL 
(in 20μl of H2O) 
260/280 260/230 
1 163.8 ng/μl 1 μg 1.91 1.82 
2 164.7 ng/μl 1 μg 1.96 1.88 
3 117.8 ng/μl 1.5 μg 1.95 1.69 
4 63.4 ng/μl 1 μg 1.86 1.64 
5 173.2 ng/μl 1.5 μg 1.89 1.91 
6 131.6 ng/μl 1.5 μg 1.95 1.82 
 
 
Figure 4-3 Assessment of RNA integrity on samples prepared from 226LDM control and 
treated cells 
Total RNA extracted from control and treated 226LDM cells, both prepared in triplicates, was 
run on an agarose gels stained with ethidium bromide (EtBr) in order to assess its integrity. The 
bands representing the 28S and 18S ribosomal RNAs are shown with arrows.   
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Figure 4-4 Quality control of RNA isolated from control and treated 226LDM cells 
Total RNA was isolated from control and treated 226LDM cells, each group in triplicates. To 
confirm the integrity of the content, the samples were run on a microfluidic chip using the 
Agilent Bioanalyzer 2100. The 28S and 18S ribosomal subunits are represented by peaks on the 
electropherograph and by bands on the gel placed on the right side of each graph.     
28S 
18S 
18S 
28S 
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 Sequencing data analysis 4.3.3
The sequencing of the samples took place at UCL using the Illumina Hiseq platform. The 
raw sequence files were received in FASTQ format which is the most common format used in 
NGS (Cock et al., 2010). It contains the output reads from the sequencer which need to be 
mapped in the reference genome which in this study is the human genome. 
Initially, the FASTQ quality trimmer was used to discard the low quality reads that did 
not pass the quality threshold and then the reads were aligned to the human genome using the 
robust aligning tool Novoalign (Ruffalo et al., 2011) and a high performance computer (HPC). 
The sequence aligning data were stored in BAM file format using SAMtools (Li et al., 2009). 
 The next step of the procedure involved the raw reads count (RPKM) and normalization 
of the reads (FPKM) using the Bam2fpkm tool in galaxy. Multi-dimensional scaling (MDS) 
(Borg and Groenen, 2005) was employed to generate plots from both the raw and normalized 
data in order to assess the level of similarity between samples (figure 4-5). The samples of each 
group appeared clustered together (figure 4.5.A) and the in the normalized data they are grouped 
even closer which fits to the expectation from the experimental design (figure 4.5.B).  
Using the raw count reads, the differential gene expression between the two sample 
groups was investigated using the DESEQ tool kit. With this package, diagnostics plots were 
created to visualize the characteristics of the analysis, such as a histogram portraying the 
distribution of p values (figure 4-6) and two heatmaps; one to show the expression variance of 
the 100 most differentially expressed genes by p value and one portraying the similarities 
between the samples according to Euclidean distance (figure 4-7). Furthermore, a volcano plot 
was generated with MATLAB combining the magnitude of expression change (log2 fold 
change) with the significance (q value) (figure 4-8). 
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The genes whose transcription was affected by the treatment were discovered and 
analysed. From the set of results, the data correlated with a p-value higher than 0.05 were 
discarded as potentially not-significant and the remaining entries were sorted according to fold-
change of expression. The list was further filtered by q value (<0.4). The top 50 transcripts (at 
this point, different transcripts of the same gene represent will represent a different entry), as 
well as the top 50 genes that were up~ and down-regulated are shown in tables 4.2-4.3 and 4.4-
4.5 respectively. Unless referenced otherwise on the table, the gene descriptions were provided 
by the RefSeq Gene project (Pruitt et al., 2005, Pruitt et al., 2014). In these tables the gene 
symbol along with the log2 fold change and q value can be seen. 
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Figure 4-6 Histogram of P values generated from the DESEQ package 
A histogram of P values was generated by the DESEQ package to assess the quality of the 
samples. The histogram is used to visualize the distribution of p-values within certain intervals 
and to assess whether problems are present with the analysis.  
Figure 4-5 MDS plots of raw and normalized count data showing the similarities between 
control and treated samples 
Multidimensional scaling (MDS) plots were generated from the raw (A) and normalized (B) 
count reads using the DESEQ analysis package on Galaxy. MDS plots are used to visualize the 
level of similarity between samples of a dataset. In the raw counts plot the control samples are 
shown in blue color and the treated samples are shown in pink. In the MDS plot of normalized 
counts the control samples are shown in black color while the treated samples are shown in red.  
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Figure 4-7 Heatmaps portraying the differential expression of the most affected genes and 
the clustering between the control and treated samples 
The DESEQ package was employed to generate heatmaps, which are two-dimensional grids 
depicting data from a count table. Left: A gene expression heatmap shows the expression 
variance between control and treated genes for the top 100 genes/transcripts affected by the 
treatment and sorted by p value. Right: The Euclidean distances between the samples as 
calculated from the variance-stabilizing transformation of the count data can be seen in the 
sample heatmap. The dendrogram at the sides demonstrate the overall similarity between 
samples. 
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Figure 4-8 Volcano plot summarizing the significant and highly deregulated genes 
In this scatterplot, genes that are highly deregulated will appear to the upper left and right on 
the outside of the pair of threshold vertical red dotted lines. Significant changes according to Q 
value are shown towards the higher top of the plot above the horizontal red dotted line. The 
graph was produced using MATLAB. 
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Table 4-2 Top 50 up-regulated gene transcripts, sorted according to fold change, as a result 
of cell-cycle block treatment in 226LDM cells, discovered with the DESEQ package 
Transcript ID Gene ID 
log2 
FoldChange 
Q-value 
1. KRT23:NM_015515 KRT23 8.599638 7.85E-06 
2. KRT23:NM_001282433 KRT23 8.495657 7.75E-06 
3. CHP2:NM_022097 CHP2 7.78822 0.000613 
4. C15orf48:NM_032413 C15orf48 7.600153 5.03E-53 
5. C15orf48:NM_197955 C15orf48 7.592132 5.03E-53 
6. MUC4:NM_004532 MUC4 7.36881 9.71E-13 
7. MUC4:NM_138297 MUC4 7.362573 1.10E-12 
8. MUC4:NM_018406 MUC4 7.335745 1.78E-07 
9. S100A7A:NM_176823 S100A7A 7.073195 7.06E-09 
10. KRT34:NM_021013 KRT34 7.027633 1.18E-43 
11. CKB:NM_001823 CKB 6.923193 5.60E-05 
12. KPNA7:NM_001145715 KPNA7 6.631406 6.36E-10 
13. GNGT2:NM_001198755 GNGT2 6.485113 8.02E-07 
14. GNGT2:NM_031498 GNGT2 6.485113 8.02E-07 
15. GNGT2:NM_001198754 GNGT2 6.433824 1.29E-06 
16. GNGT2:NM_001198756 GNGT2 6.424219 1.47E-06 
17. CIB3:NM_054113 CIB3 6.398279 0.001035 
18. LCN2:NM_005564 LCN2 6.31412 1.78E-08 
19. SPDEF:NM_001252294 SPDEF 6.289303 3.12E-06 
20. CRCT1:NM_019060 CRCT1 6.230484 1.51E-27 
21. CNFN:NM_032488 CNFN 6.213195 5.81E-06 
22. DES:NM_001927 DES 6.167984 0.026839 
23. SPDEF:NM_012391 SPDEF 6.150613 4.85E-06 
24. IGF2:NM_001291861 IGF2 6.140172 6.55E-08 
25. IGF2:NM_000612 IGF2 6.127075 1.69E-07 
26. S100A7:NM_002963 S100A7 6.122937 8.40E-14 
27. IGF2:NM_001127598 IGF2 6.117659 1.09E-07 
28. IGF2:NM_001291862 IGF2 6.117659 1.09E-07 
29. IGF2:NM_001007139 IGF2 6.117659 1.09E-07 
30. CIB3:NM_001300922 CIB3 6.077545 0.004625 
31. MUC16:NM_024690 MUC16 6.010402 0.003392 
32. RAB33A:NM_004794 RAB33A 5.89684 0.000178 
33. LOC388282:NM_001278081 LOC388282 5.843758 0.011923 
34. MUC20:NM_001291833 MUC20 5.803648 7.42E-09 
35. MUC20:NM_020790 MUC20 5.799892 2.13E-08 
36. S100A12:NM_005621 S100A12 5.792389 7.50E-14 
37. MGARP:NM_032623 MGARP 5.784396 2.95E-11 
38. TCHHL1:NM_001008536 TCHHL1 5.772711 0.000382 
39. SPANXB1:NM_032461 SPANXB1 5.765314 1.64E-07 
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40. SPANXB1.1:NM_032461.1 SPANXB1.1 5.733483 2.43E-07 
41. MUC20:NM_152673 MUC20 5.730657 3.34E-08 
42. LYPD2:NM_205545 LYPD2 5.709685 0.000902 
43. MUC20:NM_001282506 MUC20 5.658244 1.01E-07 
44. SPRR2A:NM_005988 SPRR2A 5.648773 7.49E-18 
45. PRAP1:NM_001145201 PRAP1 5.638928 8.83E-06 
46. DEFB103B:NM_018661 DEFB103B 5.622059 0.002648 
47. DEFB103A:NM_001081551 DEFB103A 5.622059 0.002648 
48. RASGEF1C:NM_175062 RASGEF1C 5.571098 0.004904 
49. CARD17:NM_001007232 CARD17 5.549296 1.83E-06 
50. SPRR2B:NM_001017418 SPRR2B 5.54848 3.31E-21 
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Table 4-3. Top 50 up-regulated genes (and their descriptions) due to treatment of 226LDM 
cells with HU and NO resulting in cell-cycle block. The DESEQ package was used to 
generate this data 
Gene ID Description 
1. KRT23 
The protein encoded by this gene is a member of the keratin family. The keratins are 
intermediate filament proteins responsible for the structural integrity of epithelial cells and are 
subdivided into cytokeratins and hair keratins. The type I cytokeratins consist of acidic 
proteins which are arranged in pairs of heterotypic keratin chains. The type I cytokeratin 
genes are clustered in a region of chromosome 17q12-q21. Alternative splicing results in 
multiple transcript variants. 
2. CHP2 
This gene product is a small calcium-binding protein that regulates cell pH by controlling 
plasma membrane-type Na+/H+ exchange activity. This protein shares sequence similarity 
with calcineurin B and can bind to and stimulate the protein phosphatase activity of 
calcineurin A (CnA) and functions in the calcineurin/NFAT (nuclear factor of activated T 
cells) signaling pathway. Another member of the CHP subfamily, Calcineurin B homologous 
protein 1, is located on Chromosome 15 and is an inhibitor of calcineurin activity and has a 
genetic phenotype associated with Parkinson's Disease (OMIM:606988). This gene was 
initially identified as a tumor-associated antigen and was previously referred to as 
Hepatocellular carcinoma-associated antigen 520. 
3. C15orf48 
This gene was first identified in a study of human esophageal squamous cell carcinoma 
tissues. Levels of both the message and protein are reduced in carcinoma samples. In adult 
human tissues, this gene is expressed in the the esophagus, stomach, small intestine, colon 
and placenta. Alternatively spliced transcript variants that encode the same protein have been 
identified.  
4. MUC4 
The major constituents of mucus, the viscous secretion that covers epithelial surfaces such as 
those in the trachea, colon, and cervix, are highly glycosylated proteins called mucins. These 
glycoproteins play important roles in the protection of the epithelial cells and have been 
implicated in epithelial renewal and differentiation. This gene encodes an integral membrane 
glycoprotein found on the cell surface, although secreted isoforms may exist. At least two 
dozen transcript variants of this gene have been found, although for many of them the full-
length transcript has not been determined or they are found only in tumor tissues. This gene 
contains a region in the coding sequence which has a variable number (>100) of 48 nt tandem 
repeats. 
5. S100A7A -No known function- 
6. KRT34 
The protein encoded by this gene is a member of the keratin gene family. As a type I hair 
keratin, it is an acidic protein which heterodimerizes with type II keratins to form hair and 
nails. The type I hair keratins are clustered in a region of chromosome 17q12-q21 and have 
the same direction of transcription. 
7. CKB 
The protein encoded by this gene is a cytoplasmic enzyme involved in energy homeostasis. 
The encoded protein reversibly catalyzes the transfer of phosphate between ATP and various 
phosphogens such as creatine phosphate. It acts as a homodimer in brain as well as in other 
tissues, and as a heterodimer with a similar muscle isozyme in heart. The encoded protein is a 
member of the ATP:guanido phosphotransferase protein family. A pseudogene of this gene 
has been characterized. 
8.  -No known function- 
9. GNGT2 
Phototransduction in rod and cone photoreceptors is regulated by groups of signaling 
proteins. The encoded protein is thought to play a crucial role in cone phototransduction. It 
belongs to the G protein gamma family and localized specifically in cones. Several transcript 
variants encoding the same protein have been found for this gene. 
10. CIB3 
This gene product shares a high degree of sequence similarity with DNA-dependent protein 
kinase catalytic subunit-interacting protein 2 in human and mouse, and like them may bind 
the catalytic subunit of DNA-dependent protein kinases. The exact function of this gene is not 
known. Alternative splicing results in multiple transcript variants. 
11. LCN2 -No known function- 
12. SPDEF 
The protein encoded by this gene belongs to the ETS family of transcription factors. It is 
highly expressed in the prostate epithelial cells, and functions as an androgen-independent 
transactivator of prostate-specific antigen (PSA) promoter. Higher expression of this protein 
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has also been reported in brain, breast, lung and ovarian tumors, compared to the 
corresponding normal tissues, and it shows better tumor-association than other cancer-
associated molecules, making it a more suitable target for developing specific cancer 
therapies. Alternatively spliced transcript variants encoding different isoforms have been 
found for this gene. 
13. DES 
This gene encodes a muscle-specific class III intermediate filament. Homopolymers of this 
protein form a stable intracytoplasmic filamentous network connecting myofibrils to each 
other and to the plasma membrane. Mutations in this gene are associated with desmin-related 
myopathy, a familial cardiac and skeletal myopathy (CSM), and with distal myopathies. 
14. IGF2 
This gene encodes a member of the insulin family of polypeptide growth factors, which are 
involved in development and growth. It is an imprinted gene, expressed only from the 
paternal allele, and epigenetic changes at this locus are associated with Wilms tumour, 
Beckwith-Wiedemann syndrome, rhabdomyosarcoma, and Silver-Russell syndrome. A read-
through INS-IGF2 gene exists, whose 5' region overlaps the INS gene and the 3' region 
overlaps this gene. Alternatively spliced transcript variants encoding different isoforms have 
been found for this gene. 
15. S100A7 
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-
hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a 
wide range of cells, and involved in the regulation of a number of cellular processes such as 
cell cycle progression and differentiation. S100 genes include at least 13 members which are 
located as a cluster on chromosome 1q21. This protein differs from the other S100 proteins of 
known structure in its lack of calcium binding ability in one EF-hand at the N-terminus. The 
protein is overexpressed in hyperproliferative skin diseases, exhibits antimicrobial activities 
against bacteria and induces immunomodulatory activities. 
16. MUC16 -No known function- 
17. RAB33A 
The protein encoded by this gene belongs to the small GTPase superfamily, Rab family. It is 
GTP-binding protein and may be involved in vesicle transport. 
18. MUC20 
This gene encodes a member of the mucin protein family. Mucins are high molecular weight 
glycoproteins secreted by many epithelial tissues to form an insoluble mucous barrier. The C-
terminus of this family member associates with the multifunctional docking site of the MET 
proto-oncogene and suppresses activation of some downstream MET signaling cascades. The 
protein features a mucin tandem repeat domain that varies between two and six copies in most 
individuals. Multiple variants encoding different isoforms have been found for this gene. A 
related pseudogene, which is also located on chromosome 3, has been identified. 
19. S100A12 
The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-
hand calcium-binding motifs. S100 proteins are localized in the cytoplasm and/or nucleus of a 
wide range of cells, and involved in the regulation of a number of cellular processes such as 
cell cycle progression and differentiation. S100 genes include at least 13 members which are 
located as a cluster on chromosome 1q21. This protein is proposed to be involved in specific 
calcium-dependent signal transduction pathways and its regulatory effect on cytoskeletal 
components may modulate various neutrophil activities. The protein includes an antimicrobial 
peptide which has antibacterial activity. 
20. TCHHL1 
This gene belongs to the S100 fused-type protein (SFTP) gene family, and is located in a 
cluster of SFTP genes on chromosome 1q21. Several members of this family have been 
implicated in the development of complex skin disorders. This gene is evolutionarily 
conserved; its expression appears to be hair-specific and spatially restricted within the distal 
inner root sheath of the hair follicle. It thus may have an important role in hair 
morphogenesis. 
21. SPANXB1 
Temporally regulated transcription and translation of several testis-specific genes is required 
to initiate the series of molecular and morphological changes in the male germ cell lineage 
necessary for the formation of mature spermatozoa. This gene is a member of the SPANX 
family of cancer/testis-associated genes, which are located in a cluster on chromosome X. 
The SPANX genes encode differentially expressed testis-specific proteins that localize to 
various subcellular compartments. This particular family member contains an additional 18 
nucleotides in its coding region compared to the other family members in the same gene 
cluster. This family member is also subject to gene copy number variation. Although the 
protein encoded by this gene contains consensus nuclear localization signals, the major site 
for subcellular localization of expressed protein is in the cytoplasmic droplets of ejaculated 
spermatozoa. This protein provides a biochemical marker for studying the unique structures 
in spermatazoa, while attempting to further define its role in spermatogenesis. 
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22. SPRR2A -No known function- 
23. PRAP1 -No known function- 
24. DEFB103B 
Defensins form a family of microbicidal and cytotoxic peptides made by neutrophils. 
Members of the defensin family are highly similar in protein sequence. This gene encodes 
defensin, beta 103, which has broad spectrum antimicrobial activity and may play an 
important role in innate epithelial defense. 
25. DEFB103A 
Defensins form a family of microbicidal and cytotoxic peptides made by neutrophils. 
Members of the defensin family are highly similar in protein sequence. This gene encodes 
defensin, beta 103, an antibiotic peptide which is induced by bacteria and interferon gamma, 
and which displays antimicrobial activity against S. aureus, S. pyogenes, P. aeruginosa, E. 
coli, and C. albicans. 
26. BCL2A1 
This gene encodes a member of the BCL-2 protein family. The proteins of this family form 
hetero- or homodimers and act as anti- and pro-apoptotic regulators that are involved in a 
wide variety of cellular activities such as embryonic development, homeostasis and 
tumorigenesis. The protein encoded by this gene is able to reduce the release of pro-apoptotic 
cytochrome c from mitochondria and block caspase activation. This gene is a direct 
transcription target of NF-kappa B in response to inflammatory mediators, and is up-regulated 
by different extracellular signals, such as granulocyte-macrophage colony-stimulating factor 
(GM-CSF), CD40, phorbol ester and inflammatory cytokine TNF and IL-1, which suggests a 
cytoprotective function that is essential for lymphocyte activation as well as cell survival. 
Alternatively spliced transcript variants encoding different isoforms have been found for this 
gene. 
27. VNN3 
This gene is the central gene in a cluster of three vanin genes on chromosome 6q23-q24. 
Extensive alternative splicing has been described; the two most common variants are 
represented as RefSeqs. 
28. FXYD2 
This gene encodes a member of the FXYD family of transmembrane proteins. This particular 
protein encodes the sodium/potassium-transporting ATPase subunit gamma. Mutations in this 
gene have been associated with Renal Hypomagnesemia-2. Alternatively spliced transcript 
variants have been described. Read-through transcripts have been observed between this locus 
and the upstream FXYD domain-containing ion transport regulator 6 (FXYD6, GeneID 
53826) locus. 
29. TMEM71 -No known function- 
30. KRT75 
This gene is a member of the type II keratin family clustered on the long arm of chromosome 
12. Type I and type II keratins heteropolymerize to form intermediate-sized filaments in the 
cytoplasm of epithelial cells. This gene is expressed in the companion layer, upper 
germinative matrix region of the hair follicle, and medulla of the hair shaft. The encoded 
protein plays an essential role in hair and nail formation. Variations in this gene have been 
associated with the hair disorders pseudofolliculitis barbae (PFB) and loose anagen hair 
syndrome (LAHS).  
31. VTCN1 
This gene encodes a protein belonging to the B7 costimulatory protein family. Proteins in this 
family are present on the surface of antigen-presenting cells and interact with ligand bound to 
receptors on the surface of T cells. Studies have shown that high levels of the encoded protein 
has been correlated with tumor progression. A pseudogene of this gene is located on 
chromosome 20. Multiple transcript variants encoding different isoforms have been found for 
this gene. 
32. MYL9 
Myosin, a structural component of muscle, consists of two heavy chains and four light chains. 
The protein encoded by this gene is a myosin light chain that may regulate muscle contraction 
by modulating the ATPase activity of myosin heads. The encoded protein binds calcium and 
is activated by myosin light chain kinase. Two transcript variants encoding different isoforms 
have been found for this gene. 
33. LAMA4 
Laminins, a family of extracellular matrix glycoproteins, are the major noncollagenous 
constituent of basement membranes. They have been implicated in a wide variety of 
biological processes including cell adhesion, differentiation, migration, signaling, neurite 
outgrowth and metastasis. Laminins are composed of 3 non identical chains: laminin alpha, 
beta and gamma (formerly A, B1, and B2, respectively) and they form a cruciform structure 
consisting of 3 short arms, each formed by a different chain, and a long arm composed of all 3 
chains. Each laminin chain is a multidomain protein encoded by a distinct gene. Several 
isoforms of each chain have been described. Different alpha, beta and gamma chain isomers 
combine to give rise to different heterotrimeric laminin isoforms which are designated by 
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Arabic numerals in the order of their discovery, i.e. alpha1beta1gamma1 heterotrimer is 
laminin 1. The biological functions of the different chains and trimer molecules are largely 
unknown, but some of the chains have been shown to differ with respect to their tissue 
distribution, presumably reflecting diverse functions in vivo. This gene encodes the alpha 
chain isoform laminin, alpha 4. The domain structure of alpha 4 is similar to that of alpha 3, 
both of which resemble truncated versions of alpha 1 and alpha 2, in that approximately 1,200 
residues at the N-terminus (domains IV, V and VI) have been lost. Laminin, alpha 4 contains 
the C-terminal G domain which distinguishes all alpha chains from the beta and gamma 
chains. The RNA analysis from adult and fetal tissues revealed developmental regulation of 
expression, however, the exact function of laminin, alpha 4 is not known. Tissue-specific 
utilization of alternative polyA-signal has been described in literature. Alternative splicing 
results in multiple transcript variants encoding distinct isoforms. 
34. UPK2 
This gene encodes one of the proteins of the highly conserved urothelium-specific integral 
membrane proteins of the asymmetric unit membrane which forms urothelium apical plaques 
in mammals. The asymmetric unit membrane is believed to strengthen the urothelium by 
preventing cell rupture during bladder distention. The encoded protein is expressed in the 
peripheral blood of bladder cancer patients with transitional cell carcinomas. 
35. IL32 
This gene encodes a member of the cytokine family. The protein contains a tyrosine sulfation 
site, 3 potential N-myristoylation sites, multiple putative phosphorylation sites, and an RGD 
cell-attachment sequence. Expression of this protein is increased after the activation of T-cells 
by mitogens or the activation of NK cells by IL-2. This protein induces the production of 
TNFalpha from macrophage cells. Alternate transcriptional splice variants, encoding different 
isoforms, have been characterized. 
36. CLIC3 
Chloride channels are a diverse group of proteins that regulate fundamental cellular processes 
including stabilization of cell membrane potential, transepithelial transport, maintenance of 
intracellular pH, and regulation of cell volume. Chloride intracellular channel 3 is a member 
of the p64 family and is predominantly localized in the nucleus and stimulates chloride ion 
channel activity. In addition, this protein may participate in cellular growth control, based on 
its association with ERK7, a member of the MAP kinase family. 
37. MT1M 
This gene encodes a member of the metallothionein superfamily, type 1 family. 
Metallothioneins have a high content of cysteine residues that bind various heavy metals. 
These genes are transcriptionally regulated by both heavy metals and glucocorticoids. 
38. CDH5 
This gene is a classical cadherin from the cadherin superfamily and is located in a six-
cadherin cluster in a region on the long arm of chromosome 16 that is involved in loss of 
heterozygosity events in breast and prostate cancer. The encoded protein is a calcium-
dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a 
transmembrane region and a highly conserved cytoplasmic tail. Functioning as a classic 
cadherin by imparting to cells the ability to adhere in a homophilic manner, the protein may 
play an important role in endothelial cell biology through control of the cohesion and 
organization of the intercellular junctions. An alternative splice variant has been described but 
its full length sequence has not been determined. 
39. CCL28 
This antimicrobial gene belongs to the subfamily of small cytokine CC genes. Cytokines are a 
family of secreted proteins involved in immunoregulatory and inflammatory processes. The 
CC cytokines are proteins characterized by two adjacent cysteines. The cytokine encoded by 
this gene displays chemotactic activity for resting CD4 or CD8 T cells and eosinophils. The 
product of this gene binds to chemokine receptors CCR3 and CCR10. This chemokine may 
play a role in the physiology of extracutaneous epithelial tissues, including diverse mucosal 
organs. Multiple transcript variants encoding two different isoforms have been found for this 
gene. 
40. KRT8 
This gene is a member of the type II keratin family clustered on the long arm of chromosome 
12. Type I and type II keratins heteropolymerize to form intermediate-sized filaments in the 
cytoplasm of epithelial cells. The product of this gene typically dimerizes with keratin 18 to 
form an intermediate filament in simple single-layered epithelial cells. This protein plays a 
role in maintaining cellular structural integrity and also functions in signal transduction and 
cellular differentiation. Mutations in this gene cause cryptogenic cirrhosis. Alternatively 
spliced transcript variants have been found for this gene. 
41. FXYD6-
FXYD2 
This locus represents naturally occurring read-through transcription between the neighboring 
FXYD domain-containing ion transport regulator 6 (GeneID 53826) and sodium/potassium-
transporting ATPase subunit gamma (GeneID 486) genes on chromosome 11. One read-
through transcript produces a fusion protein that shares sequence identity with each individual 
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gene product, while another read-through transcript encodes a protein that has a distinct C-
terminus and only shares sequence identity with the upstream locus (GeneID 53826). 
42. COL15A1 
This gene encodes the alpha chain of type XV collagen, a member of the FACIT collagen 
family (fibril-associated collagens with interrupted helices). Type XV collagen has a wide 
tissue distribution but the strongest expression is localized to basement membrane zones so it 
may function to adhere basement membranes to underlying connective tissue stroma. The 
proteolytically produced C-terminal fragment of type XV collagen is restin, a potentially 
antiangiogenic protein that is closely related to endostatin. Mouse studies have shown that 
collagen XV deficiency is associated with muscle and microvessel deterioration. 
43. SPRR2E 
This gene encodes a member of a family of small proline-rich proteins clustered in the 
epidermal differentiation complex on chromosome 1q21. The encoded protein, along with 
other family members, is a component of the cornified cell envelope that forms beneath the 
plasma membrane in terminally differentiated stratified squamous epithelia. This envelope 
serves as a barrier against extracellular and environmental factors. The seven SPRR2 genes 
(A-G) appear to have been homogenized by gene conversion compared to others in the cluster 
that exhibit greater differences in protein structure. 
44. C2orf72 -No known function- 
45. KRT33A 
This gene encodes a member of the keratin gene family. This gene is one of multiple type I 
hair keratin genes that are clustered in a region of chromosome 17q12-q21 and have the same 
direction of transcription. As a type I hair keratin, the encoded protein is an acidic protein 
which heterodimerizes with type II keratins to form hair and nails. There are two isoforms of 
this protein, encoded by two separate genes, keratin 33A and keratin 33B. 
46. TNNC2 
Troponin (Tn), a key protein complex in the regulation of striated muscle contraction, is 
composed of 3 subunits. The Tn-I subunit inhibits actomyosin ATPase, the Tn-T subunit 
binds tropomyosin and Tn-C, while the Tn-C subunit binds calcium and overcomes the 
inhibitory action of the troponin complex on actin filaments. The protein encoded by this 
gene is the Tn-C subunit. 
47. NLRP10 
Members of the NALP protein family typically contain a NACHT domain, a NACHT-
associated domain (NAD), a C-terminal leucine-rich repeat (LRR) region, and an N-terminal 
pyrin domain (PYD). The protein encoded by this gene belongs to the NALP protein family 
despite lacking the LRR region. This protein likely plays a regulatory role in the innate 
immune system. The protein belongs to the signal-induced multiprotein complex, the 
inflammasome, that activates the pro-inflammatory caspases, caspase-1 and caspase-5. Other 
experiments indicate that this gene acts as a multifunctional negative regulator of 
inflammation and apoptosis. 
48. SPRR2D -No known function- 
49. CXorf49 -No known function- 
50. CXorf49B -No known function- 
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Table 4-4. Top 50 down-regulated gene transcripts, sorted according to fold change, 
resulting from cell-cycle block treatment in 226LDM cells, discovered with the DESEQ 
package 
Transcript ID Gene ID 
log2 
FoldChange 
Q-value 
1. IFNE:NM_176891 IFNE -6.30539 1.17E-13 
2. KCNJ10:NM_002241 KCNJ10 -6.07528 0.000371 
3. CD37:NM_001774 CD37 -5.78961 0.105869 
4. CD37:NM_001040031 CD37 -5.78961 0.105869 
5. CHST4:NM_005769 CHST4 -5.56221 9.82E-08 
6. SBSPON:NM_153225 SBSPON -5.51535 5.88E-10 
7. SLC25A27:NM_004277 SLC25A27 -5.32327 0.000171 
8. SLC25A27:NM_001204051 SLC25A27 -5.30305 0.000171 
9. CHST4:NM_001166395 CHST4 -5.30287 3.30E-07 
10. ADAMTS15:NM_139055 ADAMTS15 -5.29835 6.33E-13 
11. PGLYRP1:NM_005091 PGLYRP1 -5.2588 0.013616 
12. MARCH1:NM_001166373 MARCH1 -5.21713 9.58E-07 
13. MARCH1:NM_017923 MARCH1 -5.21713 9.58E-07 
14. SLC25A27:NM_001204052 SLC25A27 -5.19801 0.000195 
15. FAM184B:NM_015688 FAM184B -4.97151 0.000322 
16. OCLM:NM_022375 OCLM -4.92508 0.003207 
17. SLITRK5:NM_015567 SLITRK5 -4.86939 0.002609 
18. SLC29A1:NM_001078175 SLC29A1 -4.83037 1.05E-25 
19. SLC29A1:NM_001078176 SLC29A1 -4.82799 3.14E-26 
20. SLC29A1:NM_001078174 SLC29A1 -4.82574 1.49E-26 
21. SLC29A1:NM_004955 SLC29A1 -4.82569 1.49E-26 
22. SLC29A1:NM_001078177 SLC29A1 -4.82535 8.54E-26 
23. SLC16A7:NM_004731 SLC16A7 -4.81848 4.69E-08 
24. FRMPD2:NM_001042512 FRMPD2 -4.76662 0.060652 
25. SLC16A7:NM_001270623 SLC16A7 -4.75744 7.07E-08 
26. SLC16A7:NM_001270622 SLC16A7 -4.75744 7.07E-08 
27. HOXD9:NM_014213 HOXD9 -4.74498 0.033306 
28. SLC47A2:NM_152908 SLC47A2 -4.73102 0.078496 
29. DSG1:NM_001942 DSG1 -4.71024 0.322558 
30. SLC47A2:NM_001256663 SLC47A2 -4.70516 0.079138 
31. SLC47A2:NM_001099646 SLC47A2 -4.70051 0.079915 
32. MXRA5:NM_015419 MXRA5 -4.65616 0.337272 
33. SLC34A1:NM_001167579 SLC34A1 -4.64595 0.082399 
34. GPRASP1:NM_001184727 GPRASP1 -4.60355 0.00573 
35. GPRASP1:NM_014710 GPRASP1 -4.58758 0.006117 
36. GPRASP1:NM_001099411 GPRASP1 -4.58758 0.006117 
37. GPRASP1:NM_001099410 GPRASP1 -4.58758 0.006117 
38. SPATA25:NM_080608 SPATA25 -4.57957 0.003438 
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39. METTL7A:NM_014033 METTL7A -4.56485 0.182034 
40. CYP3A5:NM_001291829 CYP3A5 -4.53891 0.009357 
41. CYP3A5:NM_001291830 CYP3A5 -4.52157 0.010025 
42. CYP3A5:NM_000777 CYP3A5 -4.48625 0.011512 
43. CHRNG:NM_005199 CHRNG -4.46742 0.249945 
44. ASIC1:NM_001256830 ASIC1 -4.44766 1.13E-22 
45. PPARGC1B:NM_001172699 PPARGC1B -4.4433 1.54E-25 
46. PNKD:NM_022572 PNKD -4.43 7.13E-06 
47. PPARGC1B:NM_001172698 PPARGC1B -4.42352 2.15E-25 
48. PPARGC1B:NM_133263 PPARGC1B -4.41747 2.15E-25 
49. ASIC1:NM_001095 ASIC1 -4.40213 2.22E-23 
50. ASIC1:NM_020039 ASIC1 -4.38977 2.47E-23 
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Table 4-5. Top 50 down-regulated genes (and their descriptions) due to treatment of 
226LDM cells with HU and NO resulting in cell-cycle block. The DESEQ package was used 
to generate this data 
Gene ID Description 
1. IFNE -No known function- 
2. KCNJ10 
This gene encodes a member of the inward rectifier-type potassium channel family, 
characterized by having a greater tendency to allow potassium to flow into, rather than 
out of, a cell. The encoded protein may form a heterodimer with another potassium 
channel protein and may be responsible for the potassium buffering action of glial 
cells in the brain. Mutations in this gene have been associated with seizure 
susceptibility of common idiopathic generalized epilepsy syndromes. 
3. CD37 
The protein encoded by this gene is a member of the transmembrane 4 superfamily, 
also known as the tetraspanin family. Most of these members are cell-surface proteins 
that are characterized by the presence of four hydrophobic domains. The proteins 
mediate signal transduction events that play a role in the regulation of cell 
development, activation, growth and motility. This encoded protein is a cell surface 
glycoprotein that is known to complex with integrins and other transmembrane 4 
superfamily proteins. It may play a role in T-cell-B-cell interactions. Alternate 
splicing results in multiple transcript variants encoding different isoforms. 
4. CHST4 
This gene encodes an N-acetylglucosamine 6-O sulfotransferase. The encoded enzyme 
transfers sulfate from 3'phosphoadenosine 5'phospho-sulfate to the 6-hydroxyl group 
of N-acetylglucosamine on glycoproteins. This protein is localized to the Golgi and is 
involved in the modification of glycan structures on ligands of the lymphocyte homing 
receptor L-selectin. Alternate splicing in the 5' UTR results in multiple transcript 
variants that encode the same protein. 
5. SBSPON -No known function- 
6. SLC25A27 
Mitochondrial uncoupling proteins (UCP) are members of the larger family of 
mitochondrial anion carrier proteins (MACP). UCPs separate oxidative 
phosphorylation from ATP synthesis with energy dissipated as heat, also referred to as 
the mitochondrial proton leak. UCPs facilitate the transfer of anions from the inner to 
the outer mitochondrial membrane and the return transfer of protons from the outer to 
the inner mitochondrial membrane. They also reduce the mitochondrial membrane 
potential in mammalian cells. Tissue specificity occurs for the different UCPs and the 
exact methods of how UCPs transfer H+/OH- are not known. UCPs contain the three 
homologous protein domains of MACPs. Transcripts of this gene are only detected in 
brain tissue and are specifically modulated by various environmental conditions. 
Alternative splicing results in multiple transcript variants. 
7. ADAMTS15 
This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase 
with thrombospondin motifs) protein family. ADAMTS family members share several 
distinct protein modules, including a propeptide region, a metalloproteinase domain, a 
disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members 
of this family differ in the number of C-terminal TS motifs, and some have unique C-
terminal domains. The protein encoded by this gene has a high sequence similarity to 
the proteins encoded by ADAMTS1 and ADAMTS8.  
8. MARCH1 
MARCH1 is a member of the MARCH family of membrane-bound E3 ubiquitin 
ligases (EC 6.3.2.19). MARCH proteins add ubiquitin (see MIM 191339) to target 
lysines in substrate proteins, thereby signaling their vesicular transport between 
membrane compartments. MARCH1 downregulates the surface expression of major 
histocompatibility complex (MHC) class II molecules (see MIM 142880) and other 
glycoproteins by directing them to the late endosomal/lysosomal compartment 
[supplied by OMIM, Mar 2010]. 
9. OCLM 
The protein encoded by this gene is induced by cyclic mechanical stretching in 
trabecular cells of the eye and it is also expressed in retina. This protein may play a 
role in trabecular meshwork function and the development of glaucoma.  
10. SLITRK5 
Members of the SLITRK family, such as SLITRK5, are integral membrane proteins 
with 2 N-terminal leucine-rich repeat (LRR) domains similar to those of SLIT proteins 
(see SLIT1; MIM 603742). Most SLITRKs, including SLITRK5, also have C-terminal 
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regions that share homology with neurotrophin receptors (see NTRK1; MIM 191315). 
SLITRKs are expressed predominantly in neural tissues and have neurite-modulating 
activity [supplied by OMIM, Mar 2008]. 
11. SLC29A1 
This gene is a member of the equilibrative nucleoside transporter family. The gene 
encodes a transmembrane glycoprotein that localizes to the plasma and mitochondrial 
membranes and mediates the cellular uptake of nucleosides from the surrounding 
medium. The protein is categorized as an equilibrative (as opposed to concentrative) 
transporter that is sensitive to inhibition by nitrobenzylthioinosine (NBMPR). 
Nucleoside transporters are required for nucleotide synthesis in cells that lack de novo 
nucleoside synthesis pathways, and are also necessary for the uptake of cytotoxic 
nucleosides used for cancer and viral chemotherapies. Multiple alternatively spliced 
variants, encoding the same protein, have been found for this gene. 
12. SLC16A7 
This gene is a member of the monocarboxylate transporter family. Members in this 
family transport metabolites, such as lactate, pyruvate, and ketone bodies. The protein 
encoded by this gene catalyzes the proton-linked transport of monocarboxylates and 
has the highest affinity for pyruvate. This protein has been reported to be more highly 
expressed in prostate and colorectal cancer specimens when compared to control 
specimens. Alternative splicing results in multiple transcript variants.  
13. FRMPD2 
This gene encodes a peripheral membrane protein and is located in a region of 
chromosome 10q that contains a segmental duplication. This copy of the gene is full-
length and is in the telomeric duplicated region. Two other more centromerically 
proximal copies of the gene are partial and may represent pseudogenes. This full-
length gene appears to function in the establishment and maintenance of cell 
polarization. The protein is recruited to cell-cell junctions in an E-cadherin-dependent 
manner, and is selectively localized at the basolateral membrane in polarized epithelial 
cells. Alternative splicing results in multiple transcript variants.  
14. HOXD9 
This gene belongs to the homeobox family of genes. The homeobox genes encode a 
highly conserved family of transcription factors that play an important role in 
morphogenesis in all multicellular organisms. Mammals possess four similar 
homeobox gene clusters, HOXA, HOXB, HOXC and HOXD, located on different 
chromosomes, consisting of 9 to 11 genes arranged in tandem. This gene is one of 
several homeobox HOXD genes located at 2q31-2q37 chromosome regions. Deletions 
that removed the entire HOXD gene cluster or 5' end of this cluster have been 
associated with severe limb and genital abnormalities. The exact role of this gene has 
not been determined.  
15. SLC47A2 
This gene encodes a protein belonging to a family of transporters involved in 
excretion of toxic electrolytes, both endogenous and exogenous, through urine and 
bile. This transporter family shares homology with the bacterial MATE (multidrug 
and toxin extrusion) protein family responsible for drug resistance. This gene is one of 
two members of the MATE transporter family located near each other on chromosome 
17. Alternatively spliced transcript variants encoding different isoforms have been 
identified for this gene. 
16. DSG1 
Desmosomes are cell-cell junctions between epithelial, myocardial and certain other 
cell types. Desmoglein 1 is a calcium-binding transmembrane glycoprotein component 
of desmosomes in vertebrate epithelial cells. Currently, three desmoglein subfamily 
members have been identified and all are members of the cadherin cell adhesion 
molecule superfamily. These desmoglein gene family members are located in a cluster 
on chromosome 18. The protein encoded by this gene has been identified as the 
autoantigen of the autoimmune skin blistering disease pemphigus foliaceus.  
17. MXRA5 
This gene encodes one of the matrix-remodelling associated proteins. This protein 
contains 7 leucine-rich repeats and 12 immunoglobulin-like C2-type domains related 
to perlecan. This gene has a pseudogene on chromosome Y. [provided by RefSeq, Mar 
2010]. 
18. SLC34A1 
This gene encodes a member of the type II sodium-phosphate cotransporter family. 
Mutations in this gene are associated with hypophosphatemia 
nephrolithiasis/osteoporosis 1. Alternative splicing results in multiple transcript 
variants. 
19. GPRASP1 
This gene encodes a member of the GPRASP (G protein-coupled receptor associated 
sorting protein) family. The protein may modulate lysosomal sorting and functional 
down-regulation of a variety of G-protein coupled receptors. It targets receptors for 
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degradation in lysosomes. The receptors interacting with this sorting protein include 
D2 dopamine receptor (DRD2), delta opioid receptor (OPRD1), beta-2 adrenergic 
receptor (ADRB2), D4 dopamine receptor (DRD4) and cannabinoid 1 receptor 
(CB1R). Multiple alternatively spliced transcript variants encoding the same protein 
have been identified. 
20. SPATA25 -No known function- 
21. METTL7A -No known function- 
22. CYP3A5 
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The 
cytochrome P450 proteins are monooxygenases which catalyze many reactions 
involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. 
The encoded protein metabolizes drugs as well as the steroid hormones testosterone 
and progesterone. This gene is part of a cluster of cytochrome P450 genes on 
chromosome 7q21.1. Two pseudogenes of this gene have been identified within this 
cluster on chromosome 7. Expression of this gene is widely variable among 
populations, and a single nucleotide polymorphism that affects transcript splicing has 
been associated with susceptibility to hypertensions. Alternative splicing results in 
multiple transcript variants. 
23. CHRNG 
The mammalian muscle-type acetylcholine receptor is a transmembrane pentameric 
glycoprotein with two alpha subunits, one beta, one delta, and one epsilon (in adult 
skeletal muscle) or gamma (in fetal and denervated muscle) subunit. This gene, which 
encodes the gamma subunit, is expressed prior to the thirty-third week of gestation in 
humans. The gamma subunit of the acetylcholine receptor plays a role in 
neuromuscular organogenesis and ligand binding and disruption of gamma subunit 
expression prevents the correct localization of the receptor in cell membranes. 
Mutations in this gene cause Escobar syndrome and a lethal form of multiple 
pterygium syndrome. Muscle-type acetylcholine receptor is the major antigen in the 
autoimmune disease myasthenia gravis. 
24. ASIC1 
This gene encodes a member of the acid-sensing ion channel (ASIC) family of 
proteins, which are part of the degenerin/epithelial sodium channel (DEG/ENaC) 
superfamily. Members of the ASIC family are sensitive to amiloride and function in 
neurotransmission. The encoded proteins function in learning, pain transduction, touch 
sensation, and development of memory and fear. Alternatively spliced transcript 
variants have been described. 
25. PPARGC1B 
The protein encoded by this gene stimulates the activity of several transcription 
factors and nuclear receptors, including estrogen receptor alpha, nuclear respiratory 
factor 1, and glucocorticoid receptor. The encoded protein may be involved in fat 
oxidation, non-oxidative glucose metabolism, and the regulation of energy 
expenditure. This protein is downregulated in prediabetic and type 2 diabetes mellitus 
patients. Certain allelic variations in this gene increase the risk of the development of 
obesity. Three transcript variants encoding different isoforms have been found for this 
gene. 
26. PNKD 
This gene is thought to play a role in the regulation of myofibrillogenesis. Mutations 
in this gene have been associated with the movement disorder paroxysmal non-
kinesigenic dyskinesia. Alternative splicing results in multiple transcript variants. 
27. SLFNL1 -No known function- 
28. CLEC7A 
This gene encodes a member of the C-type lectin/C-type lectin-like domain 
(CTL/CTLD) superfamily. The encoded glycoprotein is a small type II membrane 
receptor with an extracellular C-type lectin-like domain fold and a cytoplasmic 
domain with an immunoreceptor tyrosine-based activation motif. It functions as a 
pattern-recognition receptor that recognizes a variety of beta-1,3-linked and beta-1,6-
linked glucans from fungi and plants, and in this way plays a role in innate immune 
response. Alternate transcriptional splice variants, encoding different isoforms, have 
been characterized. This gene is closely linked to other CTL/CTLD superfamily 
members on chromosome 12p13 in the natural killer gene complex region. 
29. HOXD10 
This gene is a member of the Abd-B homeobox family and encodes a protein with a 
homeobox DNA-binding domain. It is included in a cluster of homeobox D genes 
located on chromosome 2. The encoded nuclear protein functions as a sequence-
specific transcription factor that is expressed in the developing limb buds and is 
involved in differentiation and limb development. Mutations in this gene have been 
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associated with Wilm's tumor and congenital vertical talus (also known as 'rocker-
bottom foot' deformity or congenital convex pes valgus) and/or a foot deformity 
resembling that seen in Charcot-Marie-Tooth disease.  
30. RNF128 
The protein encoded by this gene is a type I transmembrane protein that localizes to 
the endocytic pathway. This protein contains a RING zinc-finger motif and has been 
shown to possess E3 ubiquitin ligase activity. Expression of this gene in retrovirally 
transduced T cell hybridoma significantly inhibits activation-induced IL2 and IL4 
cytokine production. Induced expression of this gene was observed in anergic CD4(+) 
T cells, which suggested a role in the induction of anergic phenotype. Alternatively 
spliced transcript variants encoding distinct isoforms have been reported.  
31. BGN 
The protein encoded by this gene is a small cellular or pericellular matrix 
proteoglycan that is closely related in structure to two other small proteoglycans, 
decorin and fibromodulin. The encoded protein and decorin are thought to be the 
result of a gene duplication. Decorin contains one attached glycosaminoglycan chain, 
while this protein probably contains two chains. For this reason, this protein is called 
biglycan. This protein plays a role in assembly of collagen fibrils and muscle 
regeneration. It interacts with several proteins involved in muscular dystrophy, 
including alpha-dystroglycan, alpha- and gamma-sarcoglycan and collagen VI, and it 
is critical for the assembly of the dystrophin-associated protein complex. 
32. PTPRZ1 
This gene encodes a member of the receptor protein tyrosine phosphatase family. 
Expression of this gene is restricted to the central nervous system (CNS), and it may 
be involved in the regulation of specific developmental processes in the CNS. 
Alternatively spliced transcript variants encoding different isoforms have been 
described for this gene. 
33. KCNA7 
Potassium channels represent the most complex class of voltage-gated ion channels 
from both functional and structural standpoints. Their diverse functions include 
regulating neurotransmitter release, heart rate, insulin secretion, neuronal excitability, 
epithelial electrolyte transport, smooth muscle contraction, and cell volume. Four 
sequence-related potassium channel genes - shaker, shaw, shab, and shal - have been 
identified in Drosophila, and each has been shown to have human homolog(s). This 
gene encodes a member of the potassium channel, voltage-gated, shaker-related 
subfamily. This member contains six membrane-spanning domains with a shaker-type 
repeat in the fourth segment. The gene is expressed preferentially in skeletal muscle, 
heart and kidney. It is a candidate gene for inherited cardiac disorders. 
34. CLDN10 
This gene encodes a member of the claudin family. Claudins are integral membrane 
proteins and components of tight junction strands. Tight junction strands serve as a 
physical barrier to prevent solutes and water from passing freely through the 
paracellular space between epithelial or endothelial cell sheets, and also play critical 
roles in maintaining cell polarity and signal transductions. The expression level of this 
gene is associated with recurrence of primary hepatocellular carcinoma. Six 
alternatively spliced transcript variants encoding different isoforms have been 
reported, but the transcript sequences of some variants are not determined. 
35. TLL1 
This gene encodes an astacin-like, zinc-dependent, metalloprotease that belongs to the 
peptidase M12A family. This protease processes procollagen C-propeptides, such as 
chordin, pro-biglycan and pro-lysyl oxidase. Studies in mice suggest that this gene 
plays multiple roles in the development of mammalian heart, and is essential for the 
formation of the interventricular septum. Allelic variants of this gene are associated 
with atrial septal defect type 6. Alternatively spliced transcript variants encoding 
different isoforms have been found for this gene. 
36. DLX1 
This gene encodes a member of a homeobox transcription factor gene family similiar 
to the Drosophila distal-lessgene. The encoded protein is localized to the nucleus 
where it may function as a transcriptional regulator of signals from multiple TGF-beta 
superfamily members. The encoded protein may play a role in the control of 
craniofacial patterning and the differentiation and survival of inhibitory neurons in the 
forebrain. This gene is located in a tail-to-tail configuration with another member of 
the family on the long arm of chromosome 2. Alternatively spliced transcript variants 
encoding different isoforms have been described. 
37. ZNF540 -No known function- 
38. ATP8A1 
The P-type adenosinetriphosphatases (P-type ATPases) are a family of proteins which 
use the free energy of ATP hydrolysis to drive uphill transport of ions across 
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membranes. Several subfamilies of P-type ATPases have been identified. One 
subfamily catalyzes transport of heavy metal ions. Another subfamily transports non-
heavy metal ions (NMHI). The protein encoded by this gene is a member of the third 
subfamily of P-type ATPases and acts to transport amphipaths, such as 
phosphatidylserine. Two transcript variants encoding different isoforms have been 
found for this gene. 
39. MRGPRX3 
This gene encodes a member of the mas-related/sensory neuron specific subfamily of 
G protein coupled receptors. The encoded protein may be involved in sensory neuron 
regulation and in the modulation of pain. 
40. MFSD2A -No known function- 
41. EPB41L4A 
Members of the band 4.1 protein superfamily, including EPB41L4A, are thought to 
regulate the interaction between the cytoskeleton and plasma membrane [supplied by 
OMIM, Jul 2008].   
42. KRT1 
The protein encoded by this gene is a member of the keratin gene family. The type II 
cytokeratins consist of basic or neutral proteins which are arranged in pairs of 
heterotypic keratin chains coexpressed during differentiation of simple and stratified 
epithelial tissues. This type II cytokeratin is specifically expressed in the spinous and 
granular layers of the epidermis with family member KRT10 and mutations in these 
genes have been associated with bullous congenital ichthyosiform erythroderma. The 
type II cytokeratins are clustered in a region of chromosome 12q12-q13. 
43. FLRT2 
This gene encodes a member of the fibronectin leucine rich transmembrane protein 
(FLRT) family. FLRT family members may function in cell adhesion and/or receptor 
signalling. Their protein structures resemble small leucine-rich proteoglycans found in 
the extracellular matrix. 
44. ATP7B 
This gene is a member of the P-type cation transport ATPase family and encodes a 
protein with several membrane-spanning domains, an ATPase consensus sequence, a 
hinge domain, a phosphorylation site, and at least 2 putative copper-binding sites. This 
protein functions as a monomer, exporting copper out of the cells, such as the efflux of 
hepatic copper into the bile. Alternate transcriptional splice variants, encoding 
different isoforms with distinct cellular localizations, have been characterized. 
Mutations in this gene have been associated with Wilson disease (WD). 
45. C2orf88 -No known function- 
46. GPR63 
This gene encodes a G protein-coupled receptor. Multiple alternatively spliced 
variants, encoding the same protein, have been identified.  
47. MAGEE1 
This gene encodes an alpha-dystrobrevin-associated MAGE (melanoma-associated 
antigen) protein, which is a member of the MAGE family. The protein contains a 
nuclear localization signal in the N-terminus, 30 12-amino acid repeats beginning at nt 
60 with the consensus sequence ASEGPSTSVLPT, and two MAGE domains in the C-
terminus. It may play a signaling role in brain, muscle, and peripheral nerve. This 
gene is located on X chromosome in a region containing loci linked to mental 
retardation.  
48. INHBC 
This gene encodes the beta C chain of inhibin, a member of the TGF-beta superfamily. 
This subunit forms heterodimers with beta A and beta B subunits. Inhibins and 
activins, also members of the TGF-beta superfamily, are hormones with opposing 
actions and are involved in hypothalamic, pituitary, and gonadal hormone secretion, as 
well as growth and differentiation of various cell types.  
49. LHX4 
This gene encodes a member of a large protein family which contains the LIM 
domain, a unique cysteine-rich zinc-binding domain. The encoded protein is a 
transcription factor involved in the control of differentiation and development of the 
pituitary gland. Mutations in this gene cause combined pituitary hormone deficiency 
4. 
50. TMC2 
This gene is considered a member of a gene family predicted to encode 
transmembrane proteins. The specific function of this gene is unknown; however, 
expression in the inner ear suggests that it may be crucial for normal auditory 
function. Mutations in this gene may underlie hereditary disorders of balance and 
hearing. 
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 Gene Ontology Enrichment Analysis  4.3.4
The obtained lists of significantly differentially expressed genes were used to perform Gene 
Ontology analysis in order to visualize the common functional relationships between them. Gene 
Ontology annotation terms (GO terms) form a universally agreed vocabulary assigned to genes 
according to their attributes or functions. Multiple GO terms can be assigned to each gene 
depending on the current knowledge of the functions it is involved. REViGO is a web server that 
can manage long lists of gene GO terms by removing redundant terms and visualizing the 
remaining ones based on semantic similarity (Supek et al., 2011). This tool, along with the 
Cytoscape V3.2.1 software program (Shannon et al., 2003), was used to perform enrichment 
analysis and visualize the relationships on all the up-regulated and down-regulated genes from 
this study  (figure 4-9 and 4-10 respectively). 
The nodes and edges presented in GO graphs summarize some of the biological processes 
that the differentially expressed genes are known to participate in. Genes involved in the immune 
response, cell adhesion, regulation of cell activation and gene expression, are among others that 
get more actively transcribed in the treated cells. At the same time, genes mostly involved in cell 
signaling pathways, embryo morphogenesis, ion and transmembrane transport seem to be de-
activated during this cell cycle block.     
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Figure 4-9 Gene Ontology analysis for the genes with up-regulated expression in cell-cycle 
blocked 226LDM cells treated with hydroxyurea and nocodazole 
Differential expression analysis was performed on control and cell-cycle blocked 225LDM 
cells with the DESEQ package. A gene ontology analysis was performed with the ensuing 
ranked list of significantly up-regulated genes. GO annotation terms were assigned to each 
gene and statistical analysis and clustering of these terms was performed by the REViGO web 
server. The ontology relationships between the up-regulated genes are shown in the graph with 
nodes representing biological processes connected in a parent-child manner with edges. The 
size of the nodes represents the log_size of terms falling into the biological process described 
in the node label. The color of each node varies according to the value (from red to green, red 
representing the lowest q value). The editing of the graph was performed with the CytoScape 
V3.2.1 software.   
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Figure 4-10 Gene Ontology analysis for the genes with down-regulated expression in cell-
cycle arrested 226LDM cells treated with hydroxyurea and nocodazole 
Differential expression analysis was performed on control and cell-cycle blocked 225LDM cells 
with the DESEQ package. Gene Ontology analysis was performed with the ensuing ranked list of 
significantly down-regulated genes. GO annotation terms were assigned to each gene and 
statistical analysis and clustering of these terms was performed by the REViGO web server. The 
relationships between the up-regulated genes are shown in the graph with nodes representing 
biological processes connected in a parent-child manner with edges. The size of the nodes 
represents the log_size of terms falling into the biological process described in the node label. 
The color of each node varies according to the q-value (from red to green, red representing the 
lowest q value). The editing of the graph was performed with the CytoScape V3.2.1 software.   
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 Non-coding RNA 4.3.5
The function of non-coding RNAs remains to a great extent unknown; however their 
expression patterns have been reported to be dynamic and potentially purposeful. Considering 
this, further to the expression analysis on protein coding genes, we also explored the expression 
patterns of non-coding genes and identified significantly differentially expressed genes between 
the control and treated 226LDM cells.      
The raw sequenced RNA data, in FASTQ format, were aligned and mapped on the whole 
human genome and a pipeline was developed to screen for non-coding genes. Diagnostics plots 
and quality control was performed as described previously using the DESEQ package and the 
quality of the samples and the analysis was confirmed (figure 4-11, Error! Reference source 
not found.-12 and figure 4-12). 
 From the analysis, the differentially expressed genes were filtered to discard those that 
have a Q value higher than 0.05 and the remaining ones were divided in up-regulated and down-
regulated according to their fold change in between the two physiological conditions. The top 50 
up~ and down-regulated non-coding genes are presented in table 4-6 and table 4-7 respectively. 
In these tables the gene symbol along with the fold change and q value can be seen. 
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Figure 4-11 Non-coding RNA sample distances visualized in two-dimensional graphs by the 
DESEQ package 
The similarities between the control and treated samples are pictured in a multi-dimensional 
scaling (MDS) plot and a sample-distance heatmap. Left: In MDS plot, the level of similarity 
between samples of our dataset can be seen. The control samples are shown in blue color while 
the treated samples are shown in pink. Right: The Euclidean distances between the samples can 
be seen in the sample heatmap. The dendrogram at the sides demonstrate the overall similarity 
between samples. 
Figure 4-12 Histogram of P values generated from the DESEQ package 
A histogram of P values was generated by the DESEQ package to assess the quality of the 
samples. The histogram is used to visualize the distribution of  p values within certain intervals 
and to assess whether problems are present with the analysis. 
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Figure 4-12 Heatmap of differential expression of non-coding genes in control and treated 
226LDM cells 
The DESEQ package was used to generate the expression heatmap for non-coding transcripts. 
The expression divergence of the top 100 genes/transcripts affected by the treatment in 226LDM 
cells can be seen in the heatmap according to p value. A clustering dendrogram representing the 
clustering of the column data (samples) can be seen on top of the heatmap.  
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Table 4-6 Top 50 up-regulated non-coding gene transcripts, sorted according to fold 
change, as a consequence of cell cycle arrest in 226LDM cells, discovered using the DESEQ 
package 
Transcript ID 
log2 
FoldChange 
p-value 
adjusted 
1. RNU6-2.9:NR_125730.9 8.089406202 3.16E-31 
2. RNU6-2:NR_125730 7.757098858 1.05E-29 
3. RNU6-2.2:NR_125730.2 7.462141616 9.97E-27 
4. KRTAP5-AS1:NR_021489 6.584861497 5.95E-05 
5. TMCO5B:NR_046005 6.321300035 0.0018814 
6. RNVU1-19:NR_104086 6.316590435 0.0088546 
7. LINC01405:NR_036513 6.103343714 0.00015 
8. INS-IGF2:NR_003512 6.093284077 1.80E-08 
9. SPRR2C:NR_003062 5.771581929 4.56E-06 
10. ABHD11-AS1:NR_026690 5.753429704 6.32E-06 
11. RNU6-2.5:NR_125730.5 5.558473821 1.00E-24 
12. RNU6-2.4:NR_125730.4 5.552410981 1.40E-33 
13. TEX26-AS1:NR_038287 5.544292915 0.0061583 
14. RNU6-2.10:NR_125730.10 5.537704365 9.04E-27 
15. RNU6-2.8:NR_125730.8 5.506411466 4.49E-28 
16. VTCN1:NR_045603 5.435773714 0.0033258 
17. RNU6-2.1:NR_125730.1 5.422723069 3.16E-31 
18. VTCN1:NR_045604 5.421724439 0.0030636 
19. RNU6-2.7:NR_125730.7 5.371384241 4.05E-37 
20. RNU6-2.6:NR_125730.6 5.358272526 1.57E-31 
21. RNU6-2.3:NR_125730.3 5.35144416 4.94E-19 
22. WFDC21P:NR_030732 5.12062436 0.0001172 
23. LINC01269:NR_125769 5.118798495 0.0001259 
24. C1QTNF1-AS1:NR_040018 5.103587415 2.06E-12 
25. C1QTNF1-AS1:NR_040019 5.103587415 2.06E-12 
26. RNU6ATAC:NR_023344 4.968268105 3.30E-10 
27. SERPINB9P1:NR_033851 4.953280428 0.0001971 
28. APOBEC3B-AS1:NR_104187 4.920520368 4.75E-13 
29. LINC00273:NR_038368 4.897432426 0.0009009 
30. GLIPR2:NR_104639 4.788283528 1.33E-06 
31. GLIPR2:NR_104640 4.786723099 1.51E-06 
32. GLIPR2:NR_104638 4.77872 1.46E-06 
33. GLIPR2:NR_104637 4.776676104 1.72E-06 
34. ANO1-AS2:NR_103835 4.690662392 6.55E-07 
35. ANKRD30BL:NR_027020 4.651558571 0.0003838 
36. FMOD:NR_103757 4.650916487 0.023637 
37. GLIPR2:NR_104641 4.585937318 5.73E-07 
38. CHRNA4:NR_046317 4.443940678 0.0443368 
125 
 
 
39. LINC01133:NR_038849 4.39171289 1.24E-29 
40. C5orf66-AS1:NR_105050 4.382870174 0.0014902 
41. C5orf66-AS1:NR_105049 4.382870174 0.0014902 
42. KRT19P2:NR_036685 4.36634295 0.001897 
43. PDE6G:NR_026872 4.316991767 0.0129551 
44. FAM25BP:NR_104039 4.167544243 1.56E-15 
45. LINC01540:NR_110429 4.129800733 0.0062991 
46. LINC01540:NR_110428 4.09481155 0.0075615 
47. LINC00592:NR_027358 4.064977222 5.09E-09 
48. CIB2:NR_125435 3.879924246 0.0003211 
49. HSH2D:NR_111903 3.732336682 8.43E-19 
50. LINC00160:NR_024351 3.732053845 4.12E-05 
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Table 4-7 Top 50 down-regulated long non-coding gene transcripts, sorted according to 
fold change, as a result of cell-cycle arrest in 226LDM cells, discovered with the DESEQ 
package 
Transcript ID log2 
FoldChange 
p-value adjusted 
1. MLLT10P1:NR_045115 -6.296682603 1.80E-05 
2. FAM106A:NR_026809 -5.798489612 0.0013112 
3. KIZ-AS1:NR_109956 -5.515303113 0.0616641 
4. LINC00173:NR_027345 -5.296498623 0.0231589 
5. HCG8:NR_103542 -5.118264081 6.27E-10 
6. LINC01355:NR_110616 -5.110507631 0.0001508 
7. MANEA-AS1:NR_104136 -5.086470455 0.0243794 
8. MRPL23-AS1:NR_024471 -4.997112262 0.1149861 
9. CYP3A5:NR_033807 -4.979831552 0.0001357 
10. SLC16A7:NR_073055 -4.76189461 2.61E-10 
11. SLC16A7:NR_073056 -4.761369187 2.61E-10 
12. FRMPD2B.1:NR_033172.1 -4.699310133 0.0667126 
13. ZNF571-AS1:NR_038247 -4.672797079 0.0248735 
14. ZNF571-AS1:NR_038248 -4.617578806 0.0296082 
15. ZNF571-AS1:NR_038249 -4.617578806 0.0296082 
16. LINC00173:NR_027346 -4.588640859 0.0950188 
17. SCARNA27:NR_003703 -4.559327696 0.0053897 
18. LINC00852:NR_026829 -4.539455161 1.62E-05 
19. TSIX:NR_003255 -4.461121648 2.39E-15 
20. XIST:NR_001564 -4.423481431 1.93E-08 
21. GRTP1-AS1:NR_120385 -4.375893521 0.0732026 
22. ASIC1:NR_046389 -4.358679274 2.32E-25 
23. FRMPD2B:NR_033172 -4.340154087 0.0256721 
24. RPS15AP10:NR_026768 -4.289058273 0.0150915 
25. LINC00479:NR_027272 -4.259274125 0.0001975 
26. NPTN-IT1:NR_103844 -4.235113165 5.73E-07 
27. DPRXP4:NR_002221 -4.199329154 0.0075905 
28. LINC01179:NR_121676 -4.184252885 0.000336 
29. FLJ44511:NR_033963 -4.17057588 0.1460655 
30. MFSD2A:NR_109896 -4.154319272 6.62E-28 
31. LINC01004:NR_039981 -4.10359801 0.0004323 
32. INE1:NR_024616 -4.102383616 3.25E-12 
33. LINC01252:NR_033890 -4.101614637 0.0931621 
34. HCG27.2:NR_026791.2 -4.06847 0.0204587 
35. PWAR5:NR_022008 -4.046436951 0.032033 
36. LINC00086:NR_024359 -4.04028287 0.0869138 
37. STAM-AS1:NR_110370 -4.012747071 0.0008809 
38. DKFZP434I0714:NR_033797 -3.970170784 4.13E-05 
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39. LHX4-AS1:NR_037642 -3.960061996 1.38E-24 
40. RPL23AP64:NR_003040 -3.955597229 6.18E-05 
41. LINC00663:NR_026956 -3.940774443 0.006069 
42. HERC2P7:NR_036470 -3.925136331 8.03E-07 
43. HERC2P4:NR_109773 -3.92286214 3.58E-06 
44. N4BP2L2-IT2:NR_026928 -3.910954469 1.13E-07 
45. MTVR2:NR_027025 -3.87489278 0.1974436 
46. MBL1P:NR_002724 -3.81830226 3.21E-05 
47. ZNF154:NR_110974 -3.759754608 8.23E-06 
48. LINC00965:NR_027000 -3.741198478 0.0554387 
49. USP32P2:NR_003554 -3.723082332 5.28E-10 
50. SLC7A11-AS1:NR_038380 -3.715296713 0.0475209 
51. IL12RB2:NR_047584 -3.692018342 0.0121721 
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 Discussion 4.4
 
The objective of this chapter was to identify gene expression changes that took place in 
226LDM cells that were chemically induced to stop proliferating. This was accomplished by 
extracting, sequencing, analysing and comparing total RNA from two separate groups of cells: 
the first consisted of proliferating cells and the second population was treated with hydroxyurea 
and nocodazole to block cell cycle. Cells belonging to the latter group expressed only the 
CTCF180 isoform instead of both known CTCF isoforms.  
The extracted RNA was used in a massively parallel sequencing experiment and the output 
data were explored using an analysis pipeline based on bioinformatics tools and software. With 
the RNA-seq experiment it was possible to acquire virtually complete snapshots of the 
transcriptomes in the two cell populations. This allowed us to perform a comparison analysis and 
discover the pathways that are potentially activated or deactivated as a result of the treatment. 
Thousands of coding and non-coding genes were found to be significantly over~ or under-
expressed in the treated cells. 
From this investigation it was possible to retrieve lists of differentially expressed ranked 
genes and to visualize the functional relationships of the biological processes that they are 
involved in by exploiting the Gene Ontology project annotations and tools. In both groups, 
namely up and down-regulated genes, the actual results generally met the expectations.  For 
example, among the up-regulated genes in arrested cells there are those involved in processes 
such as cell adhesion, translation, immune response and gene expression. On the other hand, 
down-regulated genes are mostly involved in cell signaling pathways, ion transport, 
morphogenesis and polarity as well as cell adhesion. The number of the affected processes 
involved in RNA metabolism is particularly remarkable, including RNA processing and 
catabolism. The biological interpretation of this observation may be that in the general 
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requirement in the RNA-mediated processes is reduced in the arrested cells, which are less 
metabolically active. In the treated cells, pathways that are involved in response to stress and 
chemicals is activated and at the same time it appears that the immune response is also 
noticeably stimulated. In conclusion, the changes identified in the transcriptomes of the cells 
appear to reflect two different biological situations (healthy proliferating vs arrested/stressed 
cells).  
It should be noted that the GO annotation is a dynamic event and numerous terms can 
change; they can be assigned to different genes or even be discontinued. Moreover, many of the 
genes from the list of the differentially expressed genes could currently not be assigned a GO 
term at all, in which case they were not included in the GO analysis. 
Differential expression of non-coding RNA transcripts was also reported in this study.  
Although the identities of significantly affected non-coding transcripts were obtained, their 
functions remain still largely unknown. Known information regarding non-coding RNA is stored 
in online databases, most of which focus on miRNA. Databases specifically for long non-coding 
RNA, most prominently NONCODE (Xie et al., 2014), collect information from the existing 
literature and other available databases regarding expression profiles of known lncRNAs, 
potential links to disease and prediction of function. The challenges of lncRNA annotation and 
the need for more universal and consistently accessible information for long non-coding RNAs 
have been highlighted in previous studies (Paschoal et al., 2012, Pauli et al., 2015).   
In summary, in this Chapter the RNA profiles of proliferating and arrested 226LDM cells 
have been generated for the first time. A huge volume of novel data has been obtained and duly 
analyzed using a number of bioinformatics tools, which in turn allowed us to identify gene 
expression patterns characteristic for two populations of 226LDM cells. 
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With regards to both, coding and non-coding RNA, an inherent limitation of RNA-seq is 
that it can provide answers regarding gene expression without information on to how these 
changes occurred and/ or in which order it happened. The underlying molecular processes which 
are involved in the regulation of gene expression cannot be elucidated using the RNA-seq 
technique alone; a combination of RNA-seq experiments with other experimental techniques, 
such as ChIP-seq and real-time PCR, will be important to link the expression profiles to the 
function of particular transcription factors.  
More specifically, in our study the particular focus will be on a transcription factor, CTCF. 
We will investigate whether differential expression of the genes in two populations of 226LDM 
cells is associated with the occupancies of the promoters of these genes by CTCF130/CTCF180. 
This will be achieved by intersecting the RNA-seq data with the CTCF ChIP-seq data in 
proliferating and arrested 226LDM cells; it is described in the following Chapter 5.    
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 Integration of the ChIP-Seq and RNA-Seq data obtained Chapter 5
from the populations of proliferating and arrested 226LDM cells. 
 
 Introduction 5.1
The recent development of next generation high-throughput genomic technologies has led 
to an unprecedented progress in genomic research.  Techniques such as chromatin 
immunoprecipitation sequencing (ChIP-seq), RNA sequencing and genome-wide association 
studies (GWAS) are becoming increasingly accessible and have paved the way for new research 
opportunities. Many studies have been published using high throughput techniques and at the 
same time a variety of bioinformatics tools has been developed to aid the analysis of the large 
output datasets (Cullum et al., 2011).  
It remains challenging to elucidate the interplay between genetics and epigenetics and the 
combination of next generation techniques allows for more complex research questions like this 
to be asked and more informative answers to be generated (Hawkins et al., 2010, Angelini and 
Costa, 2014).   
The integration of ChIP and RNA-seq can provide the information about a possible 
association between the binding of a transcription factor and the effects of this binding on gene 
expression. Other studies have used the combination of these techniques to predict changes in 
expression according to differential transcription factor binding (Ouyang et al., 2009). 
More research is needed to accurately and quantitatively understand the existing, complex 
genome-wide networks however these techniques are a considerable step forward by elucidating 
the roles of key players in main events.  
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 Experimental Aims 5.2
For the experiments conducted in the two previous chapters, the 226LDM cell model was 
used in which the control population expressed both CTCF isoforms (CTCF130, CTCF180) and 
the treated expressed the CTCF180 only. The treatment, with hydroxyurea and nocodazole, 
caused cell-cycle arrest in the G2-M phase and induced a switch in the CTCF isoforms. 
  In chapter 3, the polyclonal and the monoclonal CTCF antibody were used in ChIP-seq 
that revealed the CTCF binding sites across the genomes of control and treated cells. In the 
following chapter 4, the global mRNA expression profiles of the two conditions were compared.  
The aim of this chapter is to integrate the results from the results from these chapters. We 
hypothesize that there is correlation between CTCF binding at specific sites and changes in the 
expression of the associated genes. The investigation will focus on genes which: 
1. Were bound by CTCF in the control and/or treated cells and 
2. Were differentially expressed between the control and treated 226LDM cells 
The analysis will be performed by intersecting the datasets produced from each of the two 
experiments and the account of the up and down-regulated CTCF targets will be given. 
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 Results 5.3
In this study, the differentially expressed transcripts identified in the control and treated 
226LDM cells by RNA-Seq (Chapter 4) were linked to the binding of CTCF isoforms revealed 
by ChIP-Seq (Chapter 3) (p-value filtered results).  The CTCF binding sites within 1000bp of the 
transcription start site (TSS) of genes were selected for these analyses (p value threshold 0.05). 
Intersection of these data showed that multiple links appear to exist between changes in gene 
expression and the loss or gain of CTCF binding, as illustrated in the Venn diagram (figure 5-1).  
Out of 2051 CTCF binding sites in control 226LDM cells identified using the polyclonal 
CTCF antibody (which recognizes both isoforms, CTCF130 and CTCF180), 1009 were 
associated with differentially expressed transcripts. Among those, 520 were up-regulated while 
the remaining 489 were down-regulated.  
From 64 binding sites identified in the treated cells (CTCF180 only), 26 were associated 
with genes that were differentially expressed; 16 were up-regulated and 10 were down-regulated. 
There were 8 common CTCF binding sites between control and treated cells in the up-regulated 
and 6 in the down-regulated group (figure 5-1).  
Aiming to evidence more robustly the true targets, the more stringent Q value was used 
to generate the lists of targets shown in this chapter. Using a q value threshold of 0.4, we found 
180 targets bound by CTCF whose expression changed in the treated cells. In particular, 83 
targets were up-regulated (2 of them remained bound in the treated condition) while 97 were 
down-regulated (3 remained bound in treated cells).      
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Figure 5-1 Venn Diagram presenting the differentially expressed CTCF binding targets in 
control and treated 226LDM cells 
ChIP and RNA sequencing was conducted in control and treated 226LDM cells. Intersection of 
the sequencing results revealed the binding targets of CTCF (CTCF130/180 in control and 
CTCF180 in treated cells, identified with the polyclonal antibody), which were differentially 
expressed in the treated cells. Number of CTCF130 binding sites in control cells is indicated as a 
white number in the dashed shape in the intersections. (See main text for detailed explanation). 
135 
 
 
 CTCF association with up-regulated genes in 226LDM cells 5.3.1
By intersecting ChIP and RNA-seq data, filtered by Q value, we discovered that 85 genes 
occupied by CTCF in control 226LDM cells were significantly up-regulated in treated cells. 
Among these genes, 2 were also targets both in control and treated cells (table 5.1).  
The remaining 83 binding sites were associated with increased expression in the treated 
cells coupled with the loss of CTCF binding. The top 50 transcripts that displayed increased 
expression are listed in table 5.2 in order of the decreasing fold change. Based on this and 
pending experimental validation, their expression is potentially influenced directly or indirectly 
by CTCF binding. 
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Table 5-1 Up-regulated targets bound by CTCF in both control and in treated 226LDM 
cells 
Transcript ID 
Gene 
Symbol 
Fold 
Change 
1. S100A13:NM_001024213 S100A13 6.677046 
2. S100A13:NM_001024212 S100A13 6.660637 
 
Table 5-2 Top 50 targets associated with CTCF whose expression was up-regulated in 
treated 226LDM cells and binding was lost 
Transcript ID Gene Symbol Log2 FoldChange 
1. UPK2:NM_006760 UPK2 5,162216 
2. LCN15:NM_203347 LCN15 3,42951 
3. HPD:NM_001171993 HPD 2,654225 
4. TTC39A:NM_001297666 TTC39A 2,504616 
5. TTC39A:NM_001297667 TTC39A 2,440188 
6. STARD10:NM_006645 STARD10 2,407431 
7. TP53I3:NM_001206802 TP53I3 2,257445 
8. MYOM3:NM_152372 MYOM3 2,145771 
9. MZT2A:NM_001085365 MZT2A 2,07671 
10. UNC13D:NM_199242 UNC13D 2,070984 
11. AKR1B1:NM_001628 AKR1B1 2,061382 
12. PSG4:NM_001276495 PSG4 2,032634 
13. PSG4:NM_213633 PSG4 2,030582 
14. PSG4:NM_002780 PSG4 2,029551 
15. RPL39L:NM_052969 RPL39L 1,926199 
16. CLTB:NM_001834 CLTB 1,891354 
17. CLTB:NM_007097 CLTB 1,890508 
18. UQCC2:NM_032340 UQCC2 1,846334 
19. KLC3:NM_177417 KLC3 1,780857 
20. RPL7:NM_000971 RPL7 1,764561 
21. SLC27A5:NM_012254 SLC27A5 1,746649 
22. CEACAM1:NM_001712 CEACAM1 1,698591 
23. CEACAM1:NM_001024912 CEACAM1 1,697494 
24. CEACAM1:NM_001205344 CEACAM1 1,697494 
25. C15orf40:NM_001160115 C15orf40 1,679434 
26. C15orf40:NM_001160116 C15orf40 1,667749 
27. CEACAM1:NM_001184813 CEACAM1 1,654582 
28. CEACAM1:NM_001184816 CEACAM1 1,653375 
29. CEACAM1:NM_001184815 CEACAM1 1,652473 
30. SMAGP:NM_001033873 SMAGP 1,650975 
31. HPCAL1:NM_002149 HPCAL1 1,629145 
32. MESP1:NM_018670 MESP1 1,625055 
33. C14orf2:NM_004894 C14orf2 1,625011 
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34. C14orf2:NM_001127393 C14orf2 1,62355 
35. HPCAL1:NM_134421 HPCAL1 1,606879 
36. MRPL23:NM_021134 MRPL23 1,598766 
37. ISY1-RAB43:NM_001204890 ISY1-RAB43 1,510335 
38. ZNF425:NM_001001661 ZNF425 1,48103 
39. C15orf40:NM_001160113 C15orf40 1,46562 
40. MRPL38:NM_032478 MRPL38 1,43757 
41. NOP10:NM_018648 NOP10 1,423719 
42. NABP2:NM_024068 NABP2 1,412168 
43. C15orf40:NM_001160114 C15orf40 1,401653 
44. NME1-NME2:NM_001018136 NME1-NME2 1,400934 
45. C10orf54:NM_022153 C10orf54 1,379281 
46. C15orf40:NM_144597 C15orf40 1,349093 
47. C11orf1:NM_022761 C11orf1 1,343673 
48. SFN:NM_006142 SFN 1,312197 
49. RPL26L1:NM_016093 RPL26L1 1,227189 
50. FIBP:NM_004214 FIBP 1,222373 
51. FIBP:NM_198897 FIBP 1,217752 
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 CTCF association with down-regulated genes in 226LDM cells 5.3.2
 
The intersection of ChIP and RNA-seq (Q value filtered) revealed that 97 targets were 
down-regulated in the treated cells. Out of these 97 transcripts, 3 were also associated with 
CTCF180 in treated cells (table 5-3). The remaining 94 were not associated with CTCF in 
treated cells; top 50 of these transcripts are shown in table 5.4, ranked according to fold change. 
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Table 5-3 List of down-regulated targets bound by CTCF both in control and treated 
226LDM cells 
Transcript ID Gene Symbol Log2FoldChange 
1. SGPL1:NM_003901 SGPL1 -2,3565 
2. TCTN3:NM_001143973 TCTN3 -1,87127 
3. S100A1:NM_006271 S100A1 -1.0968 
 
Table 5-4 Top 50 CTCF targets whose expression was down-regulated in treated 226LDM 
cells and binding was lost 
Transcript ID Gene Symbol Log2 FoldChange 
1. ARL6IP1:NM_015161 ARL6IP1 -3,92177 
2. SLC6A15:NM_018057 SLC6A15 -3,43998 
3. KCNIP2:NM_173194 KCNIP2 -3,34652 
4. LTB4R2:NM_001164692 LTB4R2 -3,03998 
5. JRK:NM_003724 JRK -3,0288 
6. LTB4R2:NM_019839 LTB4R2 -3,02425 
7. SLC6A15:NM_001146335 SLC6A15 -2,91716 
8. SLC6A15:NM_182767 SLC6A15 -2,90977 
9. MAT2A:NM_005911 MAT2A -2,87756 
10. JRK:NM_001077527 JRK -2,83656 
11. GSTA4:NM_001512 GSTA4 -2,79356 
12. JRK:NM_001279352 JRK -2,63189 
13. SAMD5:NM_001030060 SAMD5 -2,43252 
14. COL27A1:NM_032888 COL27A1 -2,33791 
15. KIAA1919:NM_153369 KIAA1919 -2,19629 
16. KMT2A:NM_001197104 KMT2A -2,07487 
17. KMT2A:NM_005933 KMT2A -2,07487 
18. DST:NM_001144770 DST -2,06823 
19. DST:NM_183380 DST -2,06722 
20. XYLB:NM_005108 XYLB -1,94564 
21. XXYLT1:NM_152531 XXYLT1 -1,90918 
22. LPGAT1:NM_014873 LPGAT1 -1,8628 
23. GDPD1:NM_001165993 GDPD1 -1,74502 
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24. LRIG2:NM_014813 LRIG2 -1,73306 
25. ABCC5:NM_001023587 ABCC5 -1,6847 
26. PIGO:NM_032634 PIGO -1,65188 
27. GLTPD2:NM_001014985 GLTPD2 -1,64126 
28. PIGO:NM_001201484 PIGO -1,63659 
29. PIGO:NM_152850 PIGO -1,63423 
30. ARRDC3:NM_020801 ARRDC3 -1,58151 
31. ZNF783:NM_001195220 ZNF783 -1,54794 
32. SYNM:NM_015286 SYNM -1,534 
33. SYNM:NM_145728 SYNM -1,51835 
34. SLC3A2:NM_001013251 SLC3A2 -1,48721 
35. PVRL1:NM_002855 PVRL1 -1,47781 
36. PGBD2:NM_170725 PGBD2 -1,43834 
37. TMTC2:NM_152588 TMTC2 -1,42514 
38. TM2D3:NM_025141 TM2D3 -1,40488 
39. ABCC5:NM_005688 ABCC5 -1,40468 
40. CREB3L2:NM_194071 CREB3L2 -1,40402 
41. EGR1:NM_001964 EGR1 -1,40144 
42. TM2D3:NM_078474 TM2D3 -1,40017 
43. PTPRU:NM_005704 PTPRU -1,37153 
44. PTPRU:NM_001195001 PTPRU -1,37126 
45. PTPRU:NM_133178 PTPRU -1,37126 
46. PTPRU:NM_133177 PTPRU -1,37119 
47. SLC29A3:NM_001174098 SLC29A3 -1,33866 
48. SLC29A3:NM_018344 SLC29A3 -1,33866 
49. RBM4B:NM_001286135 RBM4B -1,29116 
50. GEMIN4:NM_015721 GEMIN4 -1,28311 
 
141 
 
 
 The CTCF binding sites associated with the alteration in gene expression in control 5.3.3
and treated cells are distributed in a non-uniformed manner in all chromosomes  
The results described previously suggest that in our model of proliferating and cell-cycle 
blocked 226LDM cells, the binding of CTCF can affect expression of the genes associated with 
it; the same applies for the loss of CTCF binding or change in the PARylation status.  
Interestingly, there are chromosomes where this causal relationship appears to be more 
pronounced, such as chromosome 17 or 20. On other chromosomes (e.g. chromosome 7 and 11) 
this effect is less prominent. These spatial arrangements and clustering of binding sites, which 
may be unique for our model and dynamically change depending on the treatment that the cells 
undergo, are presented in figure 5.2. The graphs were generated using MATLAB. 
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Figure 5-2 Diagrammatic representation of CTCF binding events on chromosomes and the effect on mRNA expression 
ChIP and RNA sequencing experiments were conducted in a cell line model generated from control and treated 226LDM cells. The treated cells 
underwent a hydroxyurea and nocodazole treatment which led to cell-cycle blockage and a switch to the expression of CTCF180 only, in 
comparison to control cells which express both known CTCF isoforms, namely CTCF130 and CTCF180. The binding events discovered with the 
polyclonal CTCF antibody (which recognizes both isoforms) are shown on top of the chromosomes. Blue lines represent the binding targets in 
control cells while red lines represent the binding in treated cells. For each binding, the expression level (in the form of FPKM counts) is shown; 
blue represents the expression in control cells while red represents the expression in treated cells. The graphs were prepared using MATLAB.  
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 Discussion 5.4
Previously, a cell line model was generated using control 226LDM cells together with a 
population that underwent treatment with hydroxyurea and nocodazole. This treatment which 
induces cell cycle arrest also causes a transition in CTCF PARylation status in these cells. 
Control cells express both known isoforms, CTCF130 and CTCF180, while in the treated cells, 
only CTCF180 is detected.   
This cell model was used in ChIP-seq experiments that were aimed to identify binding 
sites of CTCF in both cell populations. Using the polyclonal CTCF antibodies, sites bound to 
both CTCF130 and CTCF180 isoforms of CTCF could be selected; the monoclonal antibody was 
used to precipitate sites bound to CTCF130 (described in Chapter 3). The same two cell 
populations were employed to generate global RNA profiles (described in Chapter 4).  
In this chapter, we presented the intersection of the two datasets. Combining these next 
generation sequencing assays is a very important step in extracting biological value from the rich 
and complex data that each of them generates. This allows to link binding of a particular 
transcription factor (CTCF in this study) to gene expression.  
By comparing the ChIP-Seq and RNA-Seq data (filtered by p-value), 1009 CTCF sites 
discovered in control cells, approximately half of the total binding sites, were associated with 
differential gene expression in treated cells. More specifically, over 500 were up-regulated and 
just under 500 were down-regulated as a result of losing CTCF binding. With the exception of 
only 14 targets (8 for the up- and 6 for the down-regulated) all targets lost binding of CTCF in 
treated cells.  
In treated cells, the number of discovered CTCF binding events was considerably smaller 
that in control cells (64 targets compared to the 2051 in the control). From these, 26 were found 
significantly affected by the treatment and 14 of them were commonly bound in control cells (8 
of the up-regulated and 6 of the down-regulated targets).  
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Notably among the sites associated with up-regulated genes in treated cells, there were 8 
binding sites (all associated with the same gene) that were also bound by the CTCF130 in the 
control cells. This gene, FXYD3, codes for a protein that belongs to a small family of proteins 
which contain an FXYD sequence and may regulate the function of ion-pumps and ion-channels 
(Pruitt et al., 2014). The protein has also been shown to demonstrate interesting yet varying 
expression changes in various cancers including gastric adenocarcinoma, lung and breast cancer 
(Okudela et al., 2009, Yamamoto et al., 2009, Zhu et al., 2010).  
 On the other hand, 10 down-regulated targets were discovered and four of these were not 
present in any other of the datasets; AKAP5, SCAF11, SCAP and DUSP11.  
AKAP5 encodes the A kinase anchor protein 5, member of a family of proteins which 
facilitate signal transduction by guiding enzymes in the proximity of their substrates, mostly 
known to do so for protein-kinase-A. Members of this family are involved in various functions 
including cell cycle and cancer progression (Esseltine and Scott, 2013, Saini et al., 2013). 
 SCAF11, also known as SIP1, is reportedly involved in mRNA splicing events (Zhang 
and Wu, 1998). SCAP is a protein with a function as a regulator of cholesterol biosynthesis (Sun 
et al., 2007). DUSP11 is a target of the p53 transcription factor, it is reportedly activated after 
DNA damage and is also involved in RNA splicing events and cell growth (Caprara et al., 2009).  
Following further filtering of the target lists by using the more stringent Q value, the 
number of hits was reduced as expected. We found 83 up-regulated targets, out of which only 2 
were still binding in the treated cells. This means that, for the remaining 81, loss of CTCF 
binding lead to increased expression. On the other hand, 97 targets were down-regulated; in the 
majority of cases (94) the change seems to be associated with loss of CTCF binding. 
The genes described above and those associated with the rest of the binding sites discussed 
in this chapter are involved in a wide spectrum of functions. Due to time restrictions it was not 
possible to analyze in depth all the pathways that the genes are involved in. For the same reason, 
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the validation of our findings by molecular methods in the laboratory was not performed. Taking 
into consideration the underlying limitations of both sequencing techniques this validation will 
be necessary. Pending experimental validation, our study suggests that CTCF binding can be 
essential for the regulation of key genes involved in a variety of functions linked to different 
biological situations. 
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 CTCF PARylation and DNA Damage Response Chapter 6
 
 Introduction 6.1
 DNA Damage Response (DDR) 6.1.1
Cells need to maintain the integrity of their genetic information and to pass this 
information to the daughter cells in an accurate and controlled manner. This genetic inheritance 
can be compromised by damage in the DNA of the mother cells caused by errors in the internal 
replication machinery, the cellular environment or by external events and agents. Events of this 
nature are not a rarity and therefore it is important to have prompt and efficient mechanisms in 
place to correct the errors in DNA or eliminate cells in case of substantial damage. The pathways 
that are activated as a reaction to damage are collectively referred to as the DNA Damage 
Response (DDR) (for reviews see Zhou and Elledge (2000) and Ljungman (2010)). 
The front runner in the protection system against damage is a multi-component signaling 
network, responsible for the detection of cellular structure abnormalities by using specific 
checkpoints. The cellular responses after the initial detection of the damage are common 
between all eukaryotic cells and include cell cycle arrest and/or block of the DNA replication 
process (Pieper et al., 1999, Zhou and Elledge, 2000, Jackson and Bartek, 2009).  
 PARylation is involved in DNA Damage Response 6.1.2
PARylation caused mainly by PARP1, but also PARP2, is one of the first events following 
a lesion in DNA. PARP1 acts as a sensitive “nick sensor” and at the same time as a recruiter of 
“repairmen” to the disrupted area (Malanga and Althaus, 2005, Kim et al., 2005a). Upon 
discovering a lesion, the activated PARP1 modifies itself and recruits important repair factors 
such as XRCC1, DNA ligase III and others (El-Khamisy et al., 2003, Malanga and Althaus, 
2005).  
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The importance of PARylation in DDR has been proved in experiments where PARP1-
knockdown cells exhibit defective repair capacity and hyper-sensitivity to damaging agents 
(Pieper et al., 1999, Malanga and Althaus, 2005).   
 CTCF isoforms and DNA Damage Response 6.1.3
 A growing body of evidence support the hypothesis that CTCF could be involved in DDR. 
Firstly, CTCF has been a documented factor in the regulation of cellular processes such as cell 
growth, proliferation and cell cycle progression (Heath et al., 2008), all of which are affected 
during DDR. Furthermore, CTCF has been linked with key proteins, including p53 and cohesin, 
which are involved in DNA damage repair (Ohlsson et al., 2001, Millau and Gaudreau, 2011).  
Of particular relevance for this study is the fact that CTCF has been linked with PARP1 
and can be PARylated (Yu et al., 2004b, Farrar et al., 2010). An investigation by Guastafierro et 
al. (2008) revealed another link between the two proteins by showing that CTCF can activate 
PARP1 auto-modification. The potential significance of this modification of CTCF in DDR is 
the main focus of this study.  
 Experimental Aims 6.2
The main hypothesis which this study will address is that the PARylation of CTCF could 
be important or required in the context of DDR. The underlying assumption implies that the 
activated PARP pathway is responsible for the recruitment and PARylation of CTCF at the 
damaged sites. Supposing that this is the case, CTCF could then function in cellular defense 
against instability and damage.  
The first objective of the work described in this chapter is to establish that DNA damage 
affects CTCF with regards to “how much” and “where” it is in the cell. It will be pursued by 
determining the expression (western blot) and localization patterns (immunofluorescence 
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staining) of CTCF following the induction of small, non-lethal lesions to cells treated with the 
DNA damaging agent hydrogen peroxide (H2O2).  
The second objective of the work is to investigate the importance of CTCF PARylation 
during DDR.  To achieve this, two experimental tools will be used: (1) the mutant variant of 
CTCF deficient for PARylation and (2) PARP inhibitors.   
In the first case, EGFP plasmids containing the PARylation-deficient CTCF constructs,  
previously produced by Farrar et al. (2011) will be transfected into cells and the response to 
damage will be compared to that of cells transfected with the wild-type CTCF.  In the second 
case, the PARP inhibitor ABT-888 will be used to block PARylation activity (Wahlberg et al., 
2012) and the results of this inhibition will be monitored in control as well as in H2O2-treated 
cells. The states of CTCF and PARP1 will be monitored by Immunofluorescent staining (IF) and 
microscopy.  
The immunostaining experiments can help with the interpretation of events that take 
place in individual cells   or a small population of cells. To investigate the effects of the 
treatments in total cell populations, another technique will be employed, namely the automated 
fluorimetric analysis of DNA unwinding (FADU) assay. This automated technique, discussed in 
more detail in chapter 1, offers the option of robust, high throughput detection and quantification 
of DNA damage and repair (Moreno-Villanueva et al., 2011). In our study, FADU will be used 
to determine the extent of DNA damage in cells treated with a damaging agent when the 
PARylation of CTCF is blocked through either of the aforementioned methods.   
The cell line to be used in the majority of the experiments described in this chapter  is 
226LDM, derived from normal breast luminal cells and immortalized by viral constructs 
carrying the modified T antigen TAg (U19dl89-97) and hTERT (Docquier et al., 2009). This cell 
line was chosen because of its closeness to the healthy normal cell in vivo. For purpose of 
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comprehensiveness and in order to explore whether the nature of the results was global, a further 
panel of selected normal and cancer cell lines was used for some of the experiments.  
 Results 6.3
In a series of experiments described below, CTCF cellular distribution was investigated in   
226LDM cells treated with low concentrations of H2O2, which is a known DNA 
damaging/oxidizing agent (Imlay et al., 1988, Henle and Linn, 1997). The concentration of H2O2 
for these experiments was optimized at 200μM; this amount of the reagent on the micro- and 
milimolar scale is effective in generating small DNA lesions that trigger the activation of a repair 
mechanism without causing damage serious enough to trigger apoptotic cell death (Nakamura et 
al., 2003).   
 The localization pattern of CTCF in 226LDM cells changes after 30 minutes of 6.3.1
treatment with H2O2, while its expression  remains unaltered 
In the first set of experiments, the 226LDM cells, seeded in wells of a 12-well plate, were 
treated with 200 μM of H2O2 and samples of these cells were harvested at a range of different 
time-points. Alongside, non-treated cell samples were used as a control to verify that cell cycle 
stage/events are not interfering with the interpretation of the results. The cells were prepared for 
Western Blotting (WB) and Immunofluorescence (IF) staining experiments in order to 
demonstrate the CTCF expression and localization patterns, respectively.  
Western blotting experiments on the treated cells did not portray significant changes in 
the expression of CTCF or the ratio between the two isoforms in the course of time (figure 6-1).  
This implies that if CTCF is involved in the damage response mechanism, as hypothesized, then 
this would occur most likely by utilizing the existing molecules rather than producing new ones.  
Although WB revealed no obvious variance in CTCF abundance following the treatment, 
a change was detected in the localization and distribution patterns of CTCF after 30 minutes of 
exposure to the damaging agent.  As shown in figure 6-2, in control cells and in cells after 15 
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min and 60 min of treatment CTCF is characterized by generally diffuse distribution in the 
nucleoplasm, with no considerable co-localization between CTCF and PARP1.  However, after 
30 min CTCF is detected in the nucleoli as confirmed by the nucleolar marker UBF (Goenechea 
et al., 1992) (examples are indicated with white arrows). At this time point, extensive overlap 
between CTCF and PARP1 can be observed (examples are indicated with yellow arrows); this 
co-localization disappears after 60 min of treatment.  Control cells exhibited the same 
localization for all time-points (data not shown).  
The re-localization of CTCF from nucleoplasm into nucleoli had been reported previously 
shown to be associated with growth inhibition, cell differentiation and apoptosis. Interestingly,  
CTCF inhibited nucleolar transcription through mechanisms involving CTCF PARylation 
(Torrano et al., 2006).  
To obtain more detailed visual information of these events, the stained cells were also 
viewed using confocal microscopy. As shown in figure 6-3, both CTCF and PARP1 are 
dispersed throughout the nuclei of the untreated 226LDM cells,  although  their distribution 
patterns differ, whereby CTCF appears diffused in the nucleus  and PARP1 is more concentrated 
on specific areas.   However, the distribution pattern of CTCF and PARP1 changes in 226LDM 
cells after 30 min with H2O2, revealing considerable co-localization between these proteins 
(figure 6-4).  
PARP1 (and PARP2) have been reported to accumulate in nucleoli in a complex with B23 
(Meder et al., 2005) Moreover, the interactions have been documented between PARP-1 and 
B23, CTCF and B23 (Yusufzai et al., 2004) between CTCF and PARP1 (Guastafierro et al., 
2008)  CTCF and UBF (van de Nobelen et al., 2010) . It is therefore possible CTCF may be a 
part of a large multifunctional protein complex involved in the regulation of nucleolar 
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function(s) dependent on PARPs.    These aspects will be further addressed in the “Discussion” 
section of this Chapter.  
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Figure 6-1 Analysis of CTCF expression in non-treated 226LDM cells and in cells treated 
with H2O2 
226LDM cells seeded in wells were treated with 200 μM of H2O2. After 15, 30 and 60 minutes 
cells were harvested and samples were prepared for WB. For the same time-points, samples were 
prepared from control non-treated cells. For the blotting experiment, the polyclonal anti-CTCF 
antibody which recognizes both of the CTCF isoforms, 130kD and 180kD, was used. Tubulin 
was used as a loading control.    
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Figure 6-2 Widefield microscopy of 226LDM cells  immunofluorescently stained  with the 
anti-CTCF, anti-PARP1 and anti-UBF antibodies 
226LDM cells were cultured on glass cover-slips placed in the wells of 12 well-plates, treated 
withH2O2, fixed and prepared for IF staining experiments. Green (FITC), staining with the anti-
CTCF antibody. Red (TRITC), staining with the anti-PARP1 or –UBF antibodies (as indicated). 
Nuclei were visualized with 4′,6-diamidino-2-phenylindole (DAPI) staining (blue). Right, merge 
of the green and red channels. CTCF co-localization with PARP1 is indicated with yellow arrows 
and with UBF with white arrows). Images were taken at 60x magnification using the Nikon Ti-
Eclipse widefield microscope. Scale bar shows 20 μm.  
   
CTCF – PARP1 
CTCF – PARP1 
CTCF – PARP1 
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Figure 6-3 Analysis of  untreated  226LDM cells, stained with the anti-CTCF and anti-
PARP1 antibodies, using confocal microscopy 
The 226LDM cells grown under normal conditions without treatment were prepared as described 
in figure 6.2.  Green (FITC), staining with the anti-CTCF antibody. Red (TRITC), staining with 
the anti-PARP1 antibody. Nuclei were visualized with 4′,6-diamidino-2-phenylindole (DAPI) 
staining (blue). Bottom right, merge of the green and red channels. Images were taken at 
60×magnification using the Nikon A1Rconfocal microscope.  
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Figure 6-4 Analysis of   226LDM cells after  30 minutes of treatment with H2O2  and stained 
with the anti-CTCF and anti-PARP1 antibodies, using confocal microscopy 
The 226LDM cells grown under normal conditions without treatment were prepared as described in 
figure 6.2.  Green (FITC), staining with the anti-CTCF antibody. Red (TRITC) , staining with the 
anti-PARP1 antibody. Nuclei were visualized with 4′,6-diamidino-2-phenylindole (DAPI) staining 
(blue). Bottom right, merge of the green and red channels. Images were taken at 60×magnification 
using the Nikon A1Rconfocal microscope.  
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 CTCF is detected in the nucleoli co-localizing with PARP1 in response to treatment 6.3.2
with H2O2 in a panel of normal-immortalized cell lines, whereas these features were 
not observed in cancer cell lines. 
From the experimental results described in the previous section, it can be inferred that in 
226LDM cells treated with H2O2  there is an obvious change in the localization from 
nucleoplasm to nucleoli rather than in the amount of CTCF, and in these cells CTCF co-localizes 
with PARP1(figures 6.1-6.2). To establish whether this phenomenon was cell line specific or if 
this is a global event, the experiment was conducted using a panel of cell lines with different 
characteristics. 
 Firstly, experiments were carried out using ZR-75.1 (breast cancer cells) (figure 6-5), 
HeLa (cervical cancer cells) (figure 6-6) and 293T cells (transformed human kidney embryonic 
cells) (figure 6-7). In all cases, the cells were grown on coverslips, treated with 200 μM H2O2, 
fixed and stained following the same protocol as for the 226LDM cells in the previous section.  
Several post –treatment time-points were selected, however the distribution patterns of CTCF 
and PARP1 did not resemble those in 226LDM cells at any of these points. 
On the other hand, in the experiments conducted with Hs27 (normal foreskin fibroblast) 
and BPH-1 (benign prostate hyperplasia) cells, 5 min post-treatment, CTCF appeared in the 
nucleoli, co-localizing with PARP1. 226LDM cells (figures 6.8-6.9).This can be explained by 
the fact that the immortalized 226LDM, Hs27 and BPH-1 cells were generated from primary 
cells and have characteristics of normal cells. The earlier response time may reflect different 
origin of these cells.  
From these experiments it can be concluded that, in response to treatment with H2O2, 
CTCF is detected in the nucleoli co-localizing with PARP1, in a panel of normal-immortalized 
cell lines, however these features were not present in cancer cell lines. 
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Figure 6-5 Widefield microscopy of  ZR-75.1 cells  after treatment with H2O2 immunofluorescently 
stained  with the anti-CTCF and anti-PARP antibodies 
ZR-75.1 cells were cultured on glass coverslips, placed in the wells of a 12 well-plates, treated with H2O2  
fixed  and prepared for IF staining experiments. Green (FITC), staining with the anti-CTCF antibody. 
Red (TRITC), staining with the anti-PARP1 antibody. Nuclei were visualized with 4′,6-
diamidino-2-phenylindole (DAPI) staining (blue). Right, merge of the green and red channels 
Images were taken at ×60 magnification using the Nikon Ti-Eclipse widefield microscope. Scale 
bar shows 20 μm. 
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Figure 6-6 Widefield microscopy of HeLa cells  after treatment with H2O2 
immunofluorescently stained  with the anti-CTCF and anti-PARP antibodies 
HeLa cells were cultured on glass cover-slips placed in the wells of a 12 well-plates, treated with 
H2O2 fixed  and prepared for IF staining experiments. Green (FITC), staining with the anti-CTCF 
antibody. Red (TRITC) , staining with the anti-PARP1  antibody. Nuclei were visualized with 
4′,6-diamidino-2-phenylindole (DAPI) staining (blue). Right, merge of the green and red 
channels. Images were taken at ×60 magnification using the Nikon Ti-Eclipse widefield 
microscope. Scale bar shows 20 μm. 
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Figure 6-7 Widefield microscopy of  293T cells  after treatment with H2O2 
immunofluorescently stained  with the anti-CTCF and anti-PARP antibodies 
293T cells  were cultured on glass cover-slips placed in the wells of a 12 well-plates, treated with 
H2O2  fixed  and prepared for IF staining experiments. Green (FITC), staining with the anti-
CTCF antibody. Red (TRITC), staining with the anti-PARP1 antibody. Nuclei were visualized 
with 4′,6-diamidino-2-phenylindole (DAPI) staining (blue). Right, merge of the green and red 
channels. Images were taken at ×60 magnification using the Nikon Ti-Eclipse widefield 
microscope. Scale bar shows 20 μm.  
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Figure 6-8 Immunofluorescence staining on BPH-1 cells after treatment with H2O2 using 
anti-CTCF and anti-PARP1 antibodies viewed by widefield microscopy 
BPH-1 cells cultured, treated with H2O2, fixed and stained following the same protocol as for the 
cells in figure 6.1. Several time-points were tested and compared to the healthy situation. At 5 
minutes after treatment CTCF and PARP1 appear to co-localize inside the nucleus (shown with 
white arrows). Images were taken at ×60 magnification using the Nikon Ti-Eclipse widefield 
microscope. Scale bar shows 20 μm. 
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Figure 6-9 Immunofluorescence staining on Hs27 cells after treatment with H2O2 using 
anti-CTCF and anti-PARP1 antibodies viewed by widefield microscopy 
Hs27 cells cultured, treated with H2O2, fixed and stained following the same protocol as for the 
cells in figure 6.1. Several time-points were tested and compared to the healthy situation. At 5 
minutes after treatment CTCF and PARP1 appear to co-localize inside the nucleus (shown with 
white arrows). Images were taken at ×60 magnification using the Nikon Ti-Eclipse widefield 
microscope. Scale bar shows 20 μm. 
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 PARylation of CTCF is important in its involvement in DDR 6.3.3
The observations described in the previous sections indicated that CTCF and PARP1 may 
be involved in the regulation of the DDR pathways. This section will further explore the 
relationship between CTCF and PARP1, in particular the importance of CTCF PARylation, in 
the context of DDR. 
To achieve this, two experimental approaches will be utilized: (1) transient transfections 
using the PARylation-deficient CTCF vector and (2) application of the PARP inhibitor, ABT-
888. The effects of the aforementioned methods will be studied in cells after DNA damage. The 
experiments described in this section were all conducted on 226LDM cells.  
 Exogenous PARylation-deficient CTCF does not co-localize with PARP1 6.3.3.1
nor UBF in the event of DNA damage and appears to affect the formation 
of the nucleolus  
Two types of EGFP-CTCF hybrid plasmids generated in our laboratory (Farrar et al., 
2010) were used for the transfection experiments: the wild-type CTCF and the PARylation-
deficient CTCF mutant. The transfected 226LDM cells grown on coverslips were transfected 
with these plasmids and then subjected to the DNA damage experiment with H2O2 as described in 
the previous section. The IF staining images, obtained with the aid of widefield microscopy, 
revealed that in the cells with exogenous wild-type CTCF a similar localization pattern could be 
observed as in the cells with endogenous CTCF  (figure 6-10). On the other hand, in cells 
transfected with the PARylation-deficient CTCF mutant no nucleolar co-localization of the 
exogenous EGFP-tagged CTCF with PARP1, and also with UBF, could be observed at any time-
point. (figure 6-11). Furthermore,   Remarkably, UBF and PARP1 appeared to lose their own 
normal spatial pattern in the cells transfected with the mutant CTCF, compared with non-
transfected cells. These observations indicate that PARylation of CTCF may play a role in the 
stabilization of the nucleoli structure, at least in the context of DNA damage.  
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Figure 6-10 Imaging of 226LDM cells, transfected with the exogenous, EGFP-tagged, wild-
type CTCF following treatment with H2O2 and viewed by widefield microscopy 
226LDM cells grown on glass coverslips in wells of a 12-well plate were transfected with 
plasmids carrying the wild-type EGFP-CTCF constructs. The cells were then treated with 200 
μM H2O2 for various time-points, fixed and stained using the monoclonal anti-PARP1 antibody. 
Exogenous wild-type CTCF (green – EGFP) is localized in the nucleus and co-localizes with 
PARP1 (red – TRITC) following DNA damage. Images were taken at ×60 magnification using 
the Nikon Ti-Eclipse widefield microscope. Scale bar shows 20 μm. 
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Figure 6-11  Imaging 226LDM cells, transfected with the EGFP-tagged, PARylation-
deficient CTCF mutant following treatment with H2O2 and viewed by widefield microscopy 
226LDM cells were grown on glass coverslips, transfected with the plasmid expressing the 
EGFP-CTCF mutant deficient for PARylation.  The cells were treated with 200 μM H2O2 for 
various time-points, fixed and stained using a monoclonal anti-PARP1 antibody. Note that the 
diffuse localization of exogenous CTCF (green – EGFP) in nucleoplasm and absence of co-
localization with PARP1 (red – TRITC) or UBF (red – TRITC) following DNA damage. The 
normal distribution pattern of UBF and PARP1 seen in untransfected cells (dashed line circles) is 
compromised in transfected cells (solid line circles). Nuclei were visualized with 4′,6-diamidino-
2-phenylindole (DAPI) staining (blue). Right, merge of the green and red channels. Images were 
taken at ×60 magnification using the Nikon Ti-Eclipse widefield microscope. Scale bar shows 20 
μm. 
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 Cells treated with the PARP inhibitor ABT-888 repair DNA damage slower / less 6.3.4
efficiently than control cells 
To confirm the general importance of PARP activity in the cellular response to DNA 
damage the ABT-888 PARP inhibitor, which has been reported to block the activity of PARP1-
PARP4 (Wahlberg et al., 2012), was employed for our experiments. The extent of DNA damage 
was determined through the abundance of the modified histone γ-H2AX, which represents a 
phosphorylated H2AX histone and is a known marker for DNA damage (Kuo and Yang, 2008, 
Sharma et al., 2012).  
In these experiments, 226LDM cells grown on coverslips were treated with 5μM ABT-
888 overnight and fresh inhibitor was added to the cells together with H2O2. Cells, with and 
without ABT-888, were then fixed and stained with the anti γ-H2AX antibody at different time-
points.   
The IF staining images, obtained  with widefield microscopy, revealed that in cells where 
PARPs were inhibited the levels of γ-H2AX following treatment with H2O2  were still 
considerable after 60 min, whereas in control cells  staining almost disappeared at this time point 
(figure 6-12). This result can be interpreted as slower and/ or defective function of the DNA 
repair machinery.   
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Figure 6-12  Distribution of γ-H2AX, a marker for DNA damage, in  untreated 226LDM 
cells and cells treated with 5 μM ABT-888 following H2O2-induced DNA damage: widefield 
microscopy   
226LDM cells cultured on coverslips in 12-well plates were exposed overnight to 5 μM ABT-
888 or left untreated to be used as control. To induce DNA damage, 200 μM H2O2 were applied 
to all cells fresh ABT-888 was added at the same time in the relevant wells). Green (FITC), 
staining with the anti- γ-H2AX antibody. Nuclei were visualized with 4′,6-diamidino-2-
phenylindole (DAPI) staining (blue). Images were taken at ×60 magnification using the Nikon 
Ti-Eclipse widefield microscope. Scale bar =20 μm.  
172 
 
 
 High throughput measurement of DNA Damage - FADU assay 6.3.5
In the previous section, through use of the γ-H2AX antibody the visualization of the 
repair progress was possible in the single cells/small populations of cells. The employment of the 
FADU assay (described in Section 2.5) enabled the monitoring of the repair process at the total 
cell population level. 
 Overview of the DNA damage repair pattern in cell lines 6.3.5.1
In the first series of FADU experiments, 226LDM cells were seeded in nontransparent 
FADU well plates (1 x 10
6
 cells/ well – 4 replicates for each time point). Once the attachment of 
cells to the surface of the wells was confirmed, the plates were left overnight in the CO2 
incubator.  On the following day, the cells were exposed to 200 μM H2O2 for a wide range of 
time points. The plates were then placed in the FADU machine and at the end of the experiment 
the fluorescence emitted from the wells was measured in a plate reader. The fluorescence in this 
case represents double-stranded DNA and therefore the level of fluorescence is inversely 
proportional to the damage within the cell population. Two controls were used in each FADU 
experiment; T0 included undamaged cells that did not undergo the alkaline unwinding step and 
P0 contained undamaged cells. 
The results obtained from this initial experiment showed the repair pattern of 226LDM 
displaying a gradual repair in the course of 60 minutes from the introduction of DNA damage. 
This pattern is in agreement with the general existing model (Moreno-Villanueva et al., 2011, 
Moreno-Villanueva et al., 2009) (figure 6-13 – A).  The T0 control confirmed that the cells at the 
time of these experiments were viable and healthy.  The same protocol, as described above for 
226LDM cells, was used in the experiment with breast cancer cells, ZR-75.1.  A response pattern 
similar to the 226LDM cells was observed in this case (figure 6-13 – B). It should be noted that 
in both experiments the fluorescence levels at 60 minutes were lower than the P0 control (non-
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damaging conditions), therefore in our next experiments the final time point was extended to 90 
minutes to ensure maximal repair.  
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Figure 6-13 Repair pattern from H2O2 -induced damage in 226LDM and ZR-75.1 cells as 
recorded using the FADU assay 
226LDM (A) and ZR-75.1 (B) cells were seeded in FADU well plates in a concentration of 1 x 
10
6
/ well and grown overnight. On the following day, 200 μM H2O2 was introduced to the cells 
for various time points. Subsequently the plates were placed in the FADU robot and after the end 
of the assay the emitted fluorescence was measured in a plate reader. The results were plotted in 
a graph in which high fluorescence measurements represent lower damage levels. T0 and P0 are 
controls. T0 represents the level of SybrGreen fluorescence in cells that did not undergo the 
alkaline unwinding step. P0 represents the level of SybrGreen fluorescence obtained in 
undamaged cells. 
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 Introduction of PARylation-deficient CTCF in 226LDM cells affects their 6.3.5.2
repair pattern 
Following the experiments that produced the repair pattern in 226LDM cells, we asked 
how PARylation of CTCF affects this process. To investigate this, 226LDM cells were seeded in 
FADU well plates and then transfected with the plasmids expressing the wild-type CTCF and the 
mutant variant of CTCF deficient for PARylation. Cells transfected with the empty vector were 
used as control. The transfected cells were treated with 200 μM H2O2 at time points 15, 30, 45 
and 90 minutes followed by the FADU assay.   
The results of this experiment show that a similar pattern in all cell samples, namely a 
gradual repair which reached the plateau at ~ 90 minutes from the introduction of DNA damage 
(figure 6.15). The fluorescence levels were similar in all transfected cells and comparable with 
the control (P0, non-damaged cells). However, the rate of the repair is increased in  in the cells 
expressing the mutant CTCF deficient for PARylation. Although the exact events taking place 
within the cells and leading to this outcome are not yet known to us, it could be hypothesized 
that in these cells an alternative, more rapid, repair pathway is activated.  
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Figure 6-14 DNA damage repair patterns in control and transfected 226LDM cells 
226LDM cells were seeded in wells of FADU plates with a concentration of 1x10
6
 cells per well. 
Four replicates were prepared for each time-point.  On the following day the cells were 
transfected with Empty Vector, CTCF wild-type and CTCF mutant (deficient for PARylation). 
Control represent non-transfected cells. After treatment with 200μM H2O2 at the indicated time 
points, cells were used in the FADU assay and the fluorescence results were obtained.  Panel A 
represents the combined results of all experiments, whereas panels C-E represent results of 
transfections with individual plasmids and control. T0 and P0 are controls. T0 represents the 
level of SybrGreen fluorescence in cells that did not undergo the alkaline unwinding step. P0 
represents the level of SybrGreen fluorescence obtained in undamaged cells. 
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 The processes of DNA repair of the H2O2-induced DNA damage in 226LDM 6.3.5.3
is slower in cells treated with the PARP inhibitor ABT-888 than in 
untreated cells.  
The importance of the general PARylation activity in the DNA repair processes was 
discussed earlier, and the experiments shown in figure 6.13 demonstrated the reduced rate of 
repair in cells treated with the PARP inhibitor, ABT-888.  To confirm these observations, the 
effects of the ABT-888 on DNA repair in 226LDM cells were investigated using the FADU 
assay. For these experiments, 226LDM cells were seeded in wells of a FADU plate as described 
in previous sections, the cells were exposed to 5 μM ABT-888 overnight and then the following 
day 200 μM H2O2 was added; control cells were not treated with ABT-888. The findings suggest 
that since the fluorescence levels increase more rapidly  in  control cells  than in cells treated 
with ABT-888, the effectiveness and/or the rate of repair is effected by  PARP inhibition (figure 
6-15 - A). The damage was also expressed in the Gray unit which is an irradiation absorbance 
unit, used to allow comparisons between damaging agents (Barton, 1995). Conversely, the DNA 
damage is considerably higher in PARP-inhibited cells (figure 6.16 - B). 
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Figure 6-15 The DNA repair (A) and damage (B) patterns  in 226LDM cells treated with 
the PARP inhibitor ABT-888 and H2O2 and analyzed using the FADU assay 
226LDM cells were seeded in FADU plates and treated with 5 μM ABT-888 overnight; control 
cells were not treated. DNA damage was induced on the following day by addition of 200 μM 
H2O2 followed by FADU assay at the indicated time points (0-60 min). In (B) the results from 
selected time points are used to show the damage expressed in relative absorbance of irradiation 
units (Gy). 
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 The processes of DNA repair of the X-Ray -induced DNA damage in 226LDM are 6.3.5.1
slower in cells treated with the PARP inhibitor ABT-888 than in untreated cells.  
Many difference factors can cause DNA damage in cells. The rationale for selection of a   
chemical agent such as hydrogen peroxide (H2O2) for this study was the reagent availability, 
reproducibility and relatively low hazard. Ionizing X-radiation is another known factor which 
has been linked to  DNA damage (Bradley and Erickson, 1981). We therefore investigated 
whether ionizing X-radiation would lead to similar effects earlier described in 226LDM treated 
with H2O2. In these experiments, 226LDM cells were plated in FADU plates, irradiated and 
analyzed by the FADU assay. As shown in figure 6-16 –A, the low fluorescence levels that are 
present in the first time-points after damage increase with time until the repair is almost 
complete. The pattern appears to be similar to that resulting from the exposure to hydrogen 
peroxide (figures 6.14 and 6.15).  
The PARP inhibitor ABT-888 was then employed to confirm that the role of PARylation 
activity in DDR does not depend on the damage factor. In these experiments, 226LDM cells 
were exposed to PARP inhibitor (5 μM ABT-888) overnight. The untreated cells were used as 
control.  On the following day, cells were transferred in micro-centrifuge tubes and irradiated on 
ice with 3.8 Gy using an X-ray generator.  Cells were then transferred in a water bath for various 
time-points at 37
o
C to repair the damage (the longest time length was 90 minutes), and analyzed 
by the FADU assay.  As shown in (figure 6-16 – B), the fluorescence level the repair patterns 
are similar to those seen after hydrogen peroxide damage. Indeed, the repair seems to take place 
quicker in cells that have not been affected by a PARP inhibitor (figure 6-16 – B). 
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Figure 6-16 The  DNA repair  (A) and damage (B) patterns in 226LDM cells treated with 
the PARP inhibitor ABT-888 and ionizing X-radiation and analyzed using the FADU assay 
226LDM cells (6x10
5
/ sample) were exposed to PARP inhibitor (5 μM ABT-888) overnight and 
untreated cells were used as control. On the following day, cells were transferred in micro-
centrifuge tubes and irradiated on ice with 3.8 Gy using an X-ray generator. The cells were   then 
placed in a water bath at 37
o
C and exposed at several time points as indicated. Following repair, 
the samples underwent the FADU assay and the results were obtained from the fluorescence 
reader. The patterns of recovery from X-ray irradiation show low fluorescence (increased 
damage) right after irradiation which increases (decreased damage) with time (A). The exposure 
of cells to the PARP inhibitor (5 μM ABT-888) decreases the speed of recovery (B). 
Repair Pattern 
T0      P0 
      P0 
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 Discussion 6.4
The sources of DNA damage are diverse and the occurrence of damaging effects is 
frequent, therefore, various repair mechanisms evolved in the cells in order to survive. The 
robust DNA damage response and repair mechanisms are very important in the maintenance of 
the genomic integrity, and defective repair is associated with disease (cancer in particular), cell 
death and ageing (Wei et al., 2007, Ljungman, 2010, Kirkwood, 2005, Hoeijmakers, 2009).  
Despite extensive studies in this area, the DNA response pathways and the proteins 
participating in them have not been yet fully defined. The PARylation reactions performed by 
Poly(ADP-ribose) polymerases (PARPs), have been found to be one of the earliest post-
translational modification at the sites of the DNA single and double-strand breaks, resulting in 
changes local chromatin structure and the accumulation of several DDR response 
proteins(Robert et al., 2013, Golia et al., 2015).   
CTCF is an important regulator of many cellular functions and a key genome organizer 
(Phillips and Corces, 2009, Ohlsson et al., 2010, Handoko et al., 2011). However, the role of 
CTCF in DDR has not been studied. The aim of this chapter was to investigate whether CTCF is 
involved in the DDR and a possible role of CTCF PARylation in this process.  Our experimental 
findings support the existence of such a link and pave the way for further research on the subject. 
The 226LDM breast luminal cells were used for the majority of our experiments due to 
their non-cancerous nature and their closeness to the “normal” condition. Two CTCF isoforms, 
CTCF-130 (non-PARylated or hypo-PARylated) and CTCF-180 (hyper-PARylated), were 
detected in undamaged proliferating cells (Figure 6.1), in agreement with a previously published 
reports (Docquier et al., 2005), (Docquier et al., 2009).    
The amount of CTCF-130 and CTCF-180 and the ratio between them have not changed 
after DNA damage by H2O2 thus implying that the PARylation status of CTCF remained 
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unaltered. It is however possible that the amount of hypo-PARylated CTCF, co-migrating with 
non-PARylated CTCF, increased; such difference is not possible to resolve using Western 
analysis and further experiments (e.g. immunoprecipitations) (Farrar et al., 2010) will be 
required to confirm hypo-PARylation. Since the overall levels of CTCF protein have not 
changed after DNA damage, we concluded that if CTCF plays a role in DDR, it involves the 
existing CTCF protein molecules.  
In our further experiments we observed the appearance of CTCF in the nucleoli of 
226LDM cells and, furthermore, its co-localization with PARP-1 in these structures after DNA 
damage (figure 6-2). Translocation of CTCF from nucleoplasm into nucleoli of cells following 
growth inhibition, cell differentiation and apoptosis was reported previously (Torrano et al., 
2006). The findings described in this and another publication (van de Nobelen et al., 2010) link 
CTCF to nucleolar functions, in particular transcription from rDNA.  In the latter study CTCF 
was found to interact with UBF, a transcription factor involved in RNA polymerase I-mediated 
ribosomal (r)RNA transcription. Furthermore, CTCF binding sites were mapped to a site 
upstream of the rDNA spacer promoter (van de Nobelen et al., 2010). It should be noted that 
CTCF function appears to differ depending on particular biological situations. In ES and MEFs 
CTCF supports nucleolar transcription (van de Nobelen et al., 2010), however in differentiated 
cells such as rat neuron –like UR61 nucleolar transcription is inhibited by CTCF (Torrano et al., 
2006). Interestingly, inhibition of PARPs by 3-ABA restores nucleolar transcription in UR61 
cells transfected with CTCF, which indicates that PARylation may regulate CTCF function in 
the nucleoli (Torrano et al., 2006). Another notable difference is the timescale of the observed 
events; the changes in localization are detected within minutes in 226LDM cells after treatment 
with H2O2, whereas it is hours or days in other systems. This observation suggests that such 
rapid events may not require RNS and protein synthesis and rely on post-translational 
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modification (such as PARylation) and is supported by the equal levels of CTCF-130 and CTCF-
180 in damaged cells. 
It is conceivable that in the undamaged 226LDM cells CTCF and PARP1 are present at 
lower levels in the nucleoli, and the exposure to DNA damaging agents such as H2O2 leads to 
activation of PARP1, PARylation of CTCF and translocation of both proteins to the nucleoli 
where CTCF modification may be sustained by PARP1. It remains to be determined whether 
nucleolar transcription is affected by DNA damage in these cells, and if CTCF and PARylation 
of CTCF are important for this process.  
To examine whether nucleolar translocation of CTCF and PARP1 after DNA damage was 
a general characteristic or restricted to 226LDM cells, a wider panel of cell lines which included 
transformed cells (293T, HeLa and ZR-75.1) and “normal” cells ( Hs-27 and BPH-1).  These 
experiments revealed that, in response to treatment with H2O2, CTCF was detected in the 
nucleoli co-localizing with PARP1 in a panel of normal-immortalized cell lines and not in cancer 
cell lines.  
A possible interpretation of the results in cancer cells lines is that the activated pathways in 
these cells do not involve CTCF. On the other hand, it is also plausible that the higher tolerance 
of cancer cells to damage would require drastically higher H2O2 concentrations to initiate the 
repair processes, or that the events take place on a completely different time-scale. Indeed, it 
should be taken into consideration that the time point where these features could be observed in 
cancer cell lines were simply missed, although a range of time-points and H2O2 concentrations 
were used for all cell lines. Additional time points may need to be used in future experiments to 
explore this further. The exact damage repair mechanism operational in cancer cells, although of 
great interest, remains beyond the scope of this study. 
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In the previous study, the nucleolar localization signal (NuLS) was found to be within the 
DNA binding domain of CTCF, in fact, it appeared that there may be more than one NuLS in 
this domain (Torrano et al., 2006). However, the full length CTCF was necessary for the 
biological function of CTCF. It remains to be investigated whether these observations are 
applicable in the context of the DDR, or whether a different NuLS(s) may be responsible for the 
nucleolar localization. A possible relationship between the NuLS(s) and the PARylation sites 
within the N-terminal domain of CTCF, which may be important for the regulated transfer will 
also need to be addressed.  
Focusing on 226LDM cells, we showed through staining with γ-H2AX (figure 6-12) but 
also for the first time by using the automated FADU assay (figure 6-15), that PARP inhibition 
leads to a slower DNA damage repair capacity. These observations was confirmed when another 
DNA damaging agent (X –ray radiation) was used (figure 6-16). These results are supported by 
other studies demonstrating the correlation between inhibition of PARP and DDR (Durkacz et 
al., 1981a, Durkacz et al., 1981b, Villani et al., 2013, Curtin, 2012). 
 To examine the effects of CTCF PARylation in DDR in 226LDM cells, we used a 
mutant CTCF deficient for PARylation (Farrar et al., 2010). In cells expressing the wild type 
CTCF tagged with EGFP, the exogenous CTCF behaved similarly to the endogenous CTCF and 
was observed in nucleoli, together with PARP1, after 30 min post-treatment with H2O2 (figure 
6-10). However, in the cells containing the mutant CTCF the nucleoli structures collapsed 
following exposure to H2O2 (figure 6-17). This finding supports previous observations that 
CTCF is important for nucleolar stability and transcription (Torrano et al., 2006, Guerrero and 
Maggert, 2011, Huang et al., 2013). CTCF PARylation may also be important in the 
establishment and maintenance of nucleolar architecture, where appropriate short and long-range 
DNA interactions are important for proper nucleolar function. The disappearance of such 
interactions and also global changes in nuclear (Handoko et al., 2011, Guastafierro et al., 2013, 
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Soto-Reyes and Recillas-Targa, 2010) and nucleolar (Hernandez-Hernandez et al., 2012, van de 
Nobelen et al., 2010)  organization have been reported in CTCF-depleted cells, thus confirming 
the role of CTCF in these processes. Interestingly, counter-intuitively to the assumption that the 
repair effectiveness might decline in the presence of CTCF deficient for PARylation,  the FADU 
assay revealed that in the total cell population the rate of the DNA repair processes is more rapid 
than in cells with the wild-type CTCF. However, it should be acknowledged that the 
PARylation-dependent DDR pathways are very complex, and the observed inhibition of DDR in 
cells treated with a general PARP inhibitor represent the outcome integrated from multiple and 
probably opposing pathways. The introduction of the exogenous CTCF deficient for PARylation 
into 226LDM cells may disrupt the regulation of the DDR resulting in the situation when other 
pathways become predominant and PARylation of CTCF is no longer important or necessary. 
The alternative pathways used in these cells may be quicker however the accuracy may be 
compromised. Although this proposition is hypothetical, the link between decreased CTCF 
PARylation and breast tumourigenesis has been reported (Docquier et al., 2009). It is 
conceivable that CTCF PARylation may be important for regulation of DDR in normal breast 
(and other) cells, however in the process of tumour evolution CTCF PARylation decreases and 
the CTCF-dependent DDR pathway become deregulated.  Due to time limitations, no further 
FADU experiments were conducted; they will be considered in the future experiments to test this 
hypothesis.   
In summary, our research has shown that in normal/immortalized cells in response to 
DNA damage CTCF is translocated to the nucleoli. CTCF PARylation is important in this 
process because the use of the PARylation-deficient CTCF mutant results in destabilization of 
nucleoli. CTCF PARylation is therefore likely to play a regulatory role in DDR in normal cells, 
whereas in cancer cells the alternative, CTCF PARylation-independent mechanisms may be in 
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operation.  Future study is needed to prove the exact nature of the role of CTCF in the context or 
damage.  
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 General Discussion and Future work Chapter 7
 CTCF Poly(ADP-ribosyl)ation 7.1
CTCF is a multifunctional protein involved in many cellular processes and pathways. 
CTCF was originally thought to be as a transcription repressor due to its role in the negative 
regulation of c-myc gene (Klenova et al., 1993, Filippova et al., 1996). However, more and more 
evidence accumulated attributing several other roles to CTCF, including transcriptional activator 
and silencer, insulator, mediator of long range chromatin interactions and others (Ohlsson et al., 
2001, Holwerda and de Laat, 2013).  
As a transcription factor, CTCF can regulate specific genes directly by binding to DNA, 
but it has also been found to act indirectly by recruiting other transcription factors to their 
binding sites or disallowing them from binding (Kim et al., 2007, Chernukhin et al., 2007). Apart 
from DNA it also interacts with various proteins (Holwerda and de Laat, 2013). 
In this study, we examined the involvement of CTCF in cellular processes on two different 
levels. Firstly, we investigated CTCF occupancies in the DNA using a genome-wide technique, 
ChIP-Seq. Secondly, we looked into CTCF role in one particular cellular process, namely DNA 
damage response. In both parts of our investigation, the main focus was set on the properties of a 
post-translationally modified isoform of CTCF; this isoform is highly poly(ADP-ribosyl)ated 
and has a molecular weight of 180kDa (CTCF180) (Yu et al., 2004b, Docquier et al., 2009). 
Currently, the function of this isoform and the mechanism underlying why and when the switch 
between isoforms occurs remain unknown.  
A study using breast tissues revealed that the PARylated CTCF isoform is the only one 
present in healthy breast tissues as compared to cancer tissues where both CTCF130 and 
CTCF180 can be detected (Docquier et al., 2009). This finding, together with the known 
involvement of PARylation in numerous regulatory procedures (Kim et al., 2005b, Burkle, 2005) 
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provided an indication that CTCF180 could have a divergent role in cellular processes and 
motivated us to research this potential further. 
 Next generation sequencing for the analysis of CTCF180 binding targets  7.2
We used the next generation sequencing (NGS) methods to identify genome wide binding 
targets of the two CTCF isoforms and to explore the effects of these binding events in control 
and proliferating cells. The 226LDM cell line was used to generate a model that allowed us to 
study CTCF180. The cells normally express both isoforms, however under controlled exposure 
to treatment they can be manipulated into expressing CTCF180 only (figure 3.2). There is 
currently no available antibody able to specifically detect CTCF180, thus this model provided us 
with a unique opportunity to develop an experimental framework to study this isoform.   
Initially, the analysis of the ChIP sequencing results confirmed for the first time that 
CTCF180 has binding targets, paving the way for further research into the specifics of this 
binding in different conditions, cell lines or tissues.  
CTCF180 binding in treated cells was limited in numbers, especially when filtered by the 
Q value. Upon closer inspection, some of the targets interestingly appear to be involved in cell 
cycle regulation or to be linked to cancer. As an example, S100A13 is involved in cell cycle 
progression and differentiation. The target is bound by CTCF both in the control and in the 
treated cells. The protein encoded by this gene is known to play a role in the regulation of the 
Fibroblast Growth Factor (FGF) (Mouta Carreira et al., 1998) and also has been linked with 
tumourigenesis (Landriscina et al., 2006).  
Another gene bound by CTCF in the cell cycle blocked cells is TCTN3. The protein 
encoded by it belongs to the family of tectonic proteins and is part of the hedgehog pathway. In 
principle, this pathway is important during embryogenesis; however its members are also 
thought to play a role in cancer, in particular basal cell carcinoma.  
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Furthermore, the function of SGPL1, which is bound by CTCF in both conditions, is not 
yet clear however a study into its antineoplastic potential was previously conducted (Brizuela et 
al., 2012). From the experiments described in this study, it is not clear which isoform was 
binding to the targets in the control cells. It is possible that initially the CTCF130 isoform was 
binding and CTCF180 replaced it after treatment affecting the expression. It could also be the 
case that CTCF180 is bound on both occasions and the change in expression is the result of an 
event that cannot be accounted for within the scope of this experiment. Further experiments 
would be necessary to confirm either hypothesis.  
Evidence on the role of PARP1 and PARylation on cell cycle regulation has been provided 
by Ciccarone et al. (2014), (2015) who showed that PARP1 regulates the expression of TET1. 
The protein encoded by this gene regulates global methylation events, which affect nucleosome 
positioning and CTCF binding (Teif et al., 2014), and more specifically hydroxymethylation 
which is also crucial in tumorigenesis. Since methylation is an important factor affecting CTCF 
binding (Wang et al., 2012a) and PARylation can affect methylation events (Ciccarone et al., 
2015, Nalabothula et al., 2015), it is conceivable that during the cell cycle block caused by the 
HU and NO treatment, methylation status alterations were involved in changing the binding site 
profile of CTCF as discovered with ChIP-seq. 
Following the analysis of the ChIP-seq results, the global mRNA expression levels were 
compared between the control and treated cells. The RNA-seq experiment revealed that the cell 
cycle blocking treatment had a significant effect in the expression levels of a wide range of 
genes. Thousands of genes were up-regulated and thousands were down-regulated. Gene 
Ontology analysis on the affected genes showed an extensive up-regulation of genes that are part 
of the immune response pathway such as DEFB103B, NLRP10, MARCO and IL32. Also, genes 
coding for ribosomal proteins and metabolism as well as transcription regulation were also 
affected.  
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In the down-regulated entries, genes involved in cell adhesion were included. This was 
partially expected as the successful cell treatment lead to the physical detachment of the cells 
from the surface of the culture flask. As an example, many members of the protocadherin alpha 
cluster, which are linked to adhesion, were affected; CTCF is known to be involved in the 
expression of these genes and reduced CTCF levels due to treatment can lead to reduced 
expression of the genes. Not surprisingly given the experimental design, genes involved in cell 
proliferation were mostly down-regulated including several members of the E2F family of 
transcription factors, including E2F1, E2F5 and E2F7, which are crucial in cell cycle progression 
(Ren et al., 2002) 
The integration of the ChIP-seq output with global mRNA expression data obtained from 
RNA-seq further revealed that CTCF binding or loss of it may be responsible for changes in the 
expression of a target, leading to expression up-regulation or down-regulation.  
It should be acknowledged that the number of sites occupied by CTCF180 and associated 
with gene expression is small. This may be due to re-localization of at least some of the 
CTCF180 molecules into the cytoplasm after cell cycle arrest. Such CTCF distribution pattern 
had previously been reported in normal breast tissues where only CTCF180 is detected 
(Docquier et al., 2005, Docquier et al., 2009). Our preliminary experiments support this 
hypothesis (figure 7.1). The presence of smaller number of CTCF sites in the genome of the 
arrested cells may indicate that, individually, these sites organize and regulate larger chromatin 
domains; this hypothesis will need to be tested in the future.    
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Figure 7.1 Expression profile of CTCF on aging 226LDM and HeLa cells 
CTCF Immunocytochemistry stainig using control (untreated) and treated 226LDM cells.  With 
the monoclonal CTCF antibody that only recognizes the CTCF130 isoform, the signal appears 
more concentrated in the nuclear area (a). With the polyclonal antibody that recognizes both 
isoforms the cytoplasmic stainig can be detected (b). In treated cells, the monoclonal antibody 
did not stain any cells (c) while with the polyclonal antibody the staining was observed (d). No 
primary antibody control cells were used to test the specificity of the staining. There is no 
staining present in this case, which confirms the specificity (e) (f). 
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At this point it should be noted that despite obvious advantages, there are inherent 
disadvantages and bias within NGS techniques, and the interpretation of their output using 
bioinformatics (Shendure and Ji, 2008, Treangen and Salzberg, 2012). In view of these 
limitations it is essential for any findings produced using these techniques to also be 
experimentally validated using other techniques such as real-time PCR. 
Moreover, in our data analysis pipeline, closed chromatin ChIP samples were utilized as a 
non-specific binding events control against the CTCF ChIP samples. This strategy allowed us to 
focus on the open chromatin binding sites of CTCF, however an insight on the global binding 
pattern is needed especially since CTCF can reportedly bind to regions far away from the 
regulatory regions of known genes (Chen et al., 2012).  
Further computational analysis of our data which could not be completed within the time 
limits of this study will generate additional valuable information. A comparison analysis between 
our and other studies could highlight similarities between the datasets and potentially reveal 
novel binding sites and motifs. The integration of data from other assays, such as chromosome 
conformation capture (3C), investigating long range interactions could elucidate the potential 
role of CTCF180 in chromatin looping and architecture (Dekker et al., 2002, Naumova et al., 
2012, Merelli et al., 2015).   
Finally, although the 226LDM cell line model was of great value for our experimental 
design as it represents the closest a cell line can be to the normal healthy breast cells, nonetheless 
it cannot match the clinical relevance or the wealth of information and that could be mined from 
experimenting with tissues.  
In conclusion, we believe that this study constitutes an encouraging first step towards the 
exploration of CTCF180 binding and its potential as a regulator of gene expression.  
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 CTCF PARylation is involved in regulation of DNA damage response 7.3
pathways 
In the second part of our investigation we concentrated specifically on the DNA damage 
response (DDR) mechanism and explored the involvement of CTCF PARylation in DDR 
regulation.  
 Although the DDR pathways are not currently fully understood, it is known that 
PARylation and the PARPs play an important role in DDR regulation (Oliver et al., 1999, El-
Khamisy et al., 2003, Robert et al., 2013). In addition, studies have revealed links between 
CTCF and PARP1 (Zampieri et al., 2012, Caiafa and Zlatanova, 2009). These findings support 
the hypothesis that CTCF could be a part of the DDR in a PARylation-dependent manner.  
To address this hypothesis we conducted experiments on 226LDM cells. The closeness of 
this cell line to normal cells was one of the factors for selection of these cells.  Our results 
showed that controlled concentrations of a DNA damaging agent (H2O2) did not affect the 
expression ratio between the isoforms (figure 6.1), although the localization of the protein 
changed (figure 6.2). Following DNA damage, CTCF translocated into the nucleolus, where it 
co-localized extensively with PARP1 (figure 6.2). Interestingly, such a translocation event has 
been reported previously in the context of nucleolar transcription (Torrano et al., 2006, van de 
Nobelen et al., 2010). Whether the translocation observed in our experiments is related or not to 
nucleolar transcription remains unknown at the present time and further experiments would be 
needed to answer this question. 
Subsequently, we proved that general inhibition of PARylation, caused by exposure to the 
ABT-888 inhibitor, has a limiting effect on the cellular repair process both by 
immunohistochemistry (figure 6.12) and for the first time with the automated FADU assay 
(figure 6.15). The observed hindering in repair is in total agreement with previous research 
linking PARylation and DDR (Durkacz et al., 1981a, Chevanne et al., 2010). The effect of the 
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inhibition was a delayed repair rather than a lack of repair activity which is consistent with 
previous research (Allinson et al., 2003).  
Inhibition of CTCF PARylation on the other hand, did not appear to limit the speed of 
repair. On the contrary, FADU experiments showed that cells induced to express a mutant CTCF 
deficient for PARylation, recovered from damage faster as compared to the control population. A 
closer look inside these transfected cells however, revealed what seemed as a catastrophic effect 
on the nucleolus. Pending further experiments which could elucidate the implication of the 
discovered events further, we suggest that the DDR pathway involves the PARylation of CTCF 
but that it can be circumvent when this is not a possibility.  
In accordance with our findings that portray a link between CTCF, PARylation and DDR, 
Izhar et al. (2015) showed that over 30 transcription factors are recruited at DNA damage sites in 
a PARP1-related manner, including CTCF. According to this study, several proteins were 
observed to re-localize to the sites of damage caused by UV irradiation shortly after the damage 
occurs. This recruitment is on many occasions completely dependent on PARP1, while the role 
of PARP1 and the TFs at the location includes chromatin remodelling. One of the roles of 
PARP1 in damage sites is to render them it accessible for the repair apparatus (Parsons et al., 
2005, Izhar et al., 2015). Given the known capacity of CTCF to act as architectural protein (Ong 
and Corces, 2014, Xu et al., 2014) it is conceivable that CTCF could be recruited to assist with 
keeping chromatin accessible at the damage site.  
Closely linked with DDR and cell cycle progression is the study of cellular senescence 
(Lou and Chen, 2006, Cichowski and Hahn, 2008). Senescence is the state of permanent cell-
cycle arrest that cells are programmed to go into after a certain number of proliferation cycles or 
in response to accumulating stress (Campisi and d'Adda di Fagagna, 2007, Campisi, 2013). It is 
the field where PARylation holds a key role and there is potential for CTCF to be involved as 
well.   
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Initial experiments revealed that indeed, cells going into senescence can display a clear 
switch in the isoform expression (figure 7.). As it was the case with the DDR mechanism, CTCF 
PARylation appears to have a divergent significance in healthy compared to cancer cells. In cells 
resembling healthy tissues (226LDM) the expression ratio between CTCF130 and CTCF180 was 
decreasing with time, while in cancer cell lines (HeLa) the prevalence of CTCF130 did not 
appear to decrease in the time-course of our experiment. This finding implies that CTCF 
PARylation is important in the replicative senescence pathways and, given the links between the 
DDR and senescence, the argument that CTCF PARylation could play an active part in both 
pathways appears valid.  
To continue the above studies it will be important to employ a cell system in which 
senescence can be induced synchronously. In this system, based on human lung fibroblasts, the 
telomere function can be blocked triggering senescence(van Steensel et al., 1998). These cells 
(termed T19) have been obtained from Prof T. von Zglinicki and tested in our laboratory. They 
will be used in future experiments to study the role of CTCF and CTCF PARylation in the 
processes of ageing and DNA damage repair.  
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Figure 7.2 Expression profile of CTCF on aging 226LDM and HeLa cells 
226LDM and HeLa cells were grown in wells of a 12-well plate and allowed to grow for 
consecutive days without the addition of new nutrients. Each day the contents of a well were 
harvested and prepared for a western blot experiment. The CTCF polyclonal antibody was used 
in the experiment. Tubulin was used as a loading control and the signal was visualized with the 
UptiLight™ chemiluminescence substrate.  
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 Concluding Remarks 7.4
CTCF is a major regulator in a plethora of cellular processes and this has made it appealing 
and at the same time complex to study. The full range of the pathways that it is involved in 
remains realistically far from elucidated. But especially when it comes to its PARylated isoform 
the view is even more unclear.  
Our investigation into DNA damage response suggests that CTCF PARylation is involved 
in the paths that are activated as part of the cellular defence to damage, particularly for non-
cancer cells. Moreover, our genome-wide study provided novel insights into CTCF180 binding 
calling for further research that would highlight new areas of interest for this isoform. 
Our initial hypotheses were that differentially PARylated isoforms of CTCF control different 
groups of genes (Hypothesis 1) and different functions (Hypothesis 2) in different biological 
situations. Our experimental findings supports Hypothesis 1 since the overall binding of 
CTCF130 and CTCF180 was associated with differential gene expression. Our findings also 
support Hypothesis 2 because CTCF PARylation is involved in DNA damage response and 
important for nucleolar stability following DNA damage. 
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